"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","medianAltmetricScore","altmetric_score_mean_top25AltmScore","altmetric_score_min_top25AltmScore","altmetric_score_max_top25AltmScore","cited_by_accounts_count_mean_top25AltmScore","cited_by_accounts_count_min_top25AltmScore","cited_by_accounts_count_max_top25AltmScore","cited_by_fbwalls_count_mean_top25AltmScore","cited_by_fbwalls_count_min_top25AltmScore","cited_by_fbwalls_count_max_top25AltmScore","cited_by_feeds_count_mean_top25AltmScore","cited_by_feeds_count_min_top25AltmScore","cited_by_feeds_count_max_top25AltmScore","cited_by_gplus_count_mean_top25AltmScore","cited_by_gplus_count_min_top25AltmScore","cited_by_gplus_count_max_top25AltmScore","cited_by_msm_count_mean_top25AltmScore","cited_by_msm_count_min_top25AltmScore","cited_by_msm_count_max_top25AltmScore","cited_by_patents_count_mean_top25AltmScore","cited_by_patents_count_min_top25AltmScore","cited_by_patents_count_max_top25AltmScore","cited_by_peer_review_sites_count_mean_top25AltmScore","cited_by_peer_review_sites_count_min_top25AltmScore","cited_by_peer_review_sites_count_max_top25AltmScore","cited_by_policies_count_mean_top25AltmScore","cited_by_policies_count_min_top25AltmScore","cited_by_policies_count_max_top25AltmScore","cited_by_posts_count_mean_top25AltmScore","cited_by_posts_count_min_top25AltmScore","cited_by_posts_count_max_top25AltmScore","cited_by_rdts_count_mean_top25AltmScore","cited_by_rdts_count_min_top25AltmScore","cited_by_rdts_count_max_top25AltmScore","cited_by_rh_count_mean_top25AltmScore","cited_by_rh_count_min_top25AltmScore","cited_by_rh_count_max_top25AltmScore","cited_by_tweeters_count_mean_top25AltmScore","cited_by_tweeters_count_min_top25AltmScore","cited_by_tweeters_count_max_top25AltmScore","cited_by_videos_count_mean_top25AltmScore","cited_by_videos_count_min_top25AltmScore","cited_by_videos_count_max_top25AltmScore","cited_by_wikipedia_count_mean_top25AltmScore","cited_by_wikipedia_count_min_top25AltmScore","cited_by_wikipedia_count_max_top25AltmScore","cohorts.com_mean_top25AltmScore","cohorts.com_min_top25AltmScore","cohorts.com_max_top25AltmScore","cohorts.doc_mean_top25AltmScore","cohorts.doc_min_top25AltmScore","cohorts.doc_max_top25AltmScore","cohorts.pub_mean_top25AltmScore","cohorts.pub_min_top25AltmScore","cohorts.pub_max_top25AltmScore","cohorts.sci_mean_top25AltmScore","cohorts.sci_min_top25AltmScore","cohorts.sci_max_top25AltmScore","readers.citeulike_mean_top25AltmScore","readers.citeulike_min_top25AltmScore","readers.citeulike_max_top25AltmScore","readers.connotea_mean_top25AltmScore","readers.connotea_min_top25AltmScore","readers.connotea_max_top25AltmScore","readers.mendeley_mean_top25AltmScore","readers.mendeley_min_top25AltmScore","readers.mendeley_max_top25AltmScore","readers_count_mean_top25AltmScore","readers_count_min_top25AltmScore","readers_count_max_top25AltmScore","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internazionali","avg_ResultingPublications_per_grant","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","nClTrial_w_AltmScore","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n"
"IRCCS_CROB",2000,14,8.85714285714286,1.21428571428571,0.823529411764706,0.5,0,0,0,0,5,1,1,5,0.36,0.07,0.07,0.36,15.29,0.337202396418735,0.214285714285714,1,0,0.415866538646184,0.25,0,0,"GIOVANNI D’ARENA;SALVATORE PANICO;PELLEGRINO MUSTO;M CAROTENUTO;ROCCO GALASSO;VISCONTI GIRO;IGNAZIO CATALDO;PASQUALE DE NEGRI;C IOVINE;EGIDIO CELENTANO;POTITO ROSARIO SCALZULLI;GIANFRANCESCO GALLINO;FRANCO BERRINO;ADA MAFFETTONE;BÁRBARA CONTI;SAVERIO MANTUANO;PAOLA CIPRIANO;BORRELLI FELICE;GIORGIO IVANI;COSIMO LEQUAGLIE","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GIOVANNI D’ARENA;M CAROTENUTO;VISCONTI GIRO;PASQUALE DE NEGRI;BORRELLI FELICE;GIORGIO IVANI;NICOLA CASCAVILLA;MICHAEL J. KEATING;PELLEGRINO MUSTO;SALVATORE PANICO;ROCCO GALASSO;IGNAZIO CATALDO;GIANFRANCESCO GALLINO;BÁRBARA CONTI;COSIMO LEQUAGLIE;POTITO ROSARIO SCALZULLI;SAVERIO MANTUANO;C IOVINE;EGIDIO CELENTANO;FRANCO BERRINO","0.93;0.79;0.34;0.34;0.34;0.34;0.33;0.33;0.33;0.31;0.31;0.31;0.31;0.31;0.31;0.27;0.27;0.25;0.25;0.25","GIOVANNI D’ARENA;PELLEGRINO MUSTO;ROCCO GALASSO;PASQUALE DE NEGRI;COSIMO LEQUAGLIE;VALDEMAR VALENTE;GENNARO MANCINO;G. PLASTINO","4;3;3;2;2;1;1;1","GIOVANNI D’ARENA;PASQUALE DE NEGRI;PELLEGRINO MUSTO;ROCCO GALASSO;COSIMO LEQUAGLIE;GENNARO MANCINO;VALDEMAR VALENTE;G. PLASTINO","0.93;0.34;0.33;0.31;0.31;0.17;0.04;0.04","ROCCO GALASSO;SALVATORE PANICO;ALFREDO MORABIA;E E MCCRUM;JOHN YARNELL;LLUÍS RIBAS XIRGO;LLUÍS SERRA‐MAJEM;MARIA FENICIA VESCIO;MARY E. NORTHRIDGE;MS BERNSTEIN;OLGA VITEK;P PREZIOSI;PILAR GALÁN;SERGE HERÇBERG;SIGRID BEER‐BORST;SIMONA GIAMPAOLI;A. BOMBINI;ANDREW E. CAPUTO;BIAGIO DI IORIO;C. BAGNATO","141;141;119;119;119;119;119;119;119;119;119;119;119;119;119;119;23;23;23;23","ROCCO GALASSO;G. PLASTINO;VALDEMAR VALENTE;GENNARO MANCINO;PELLEGRINO MUSTO;COSIMO LEQUAGLIE;GIOVANNI D’ARENA;PASQUALE DE NEGRI","141;23;23;21;21;8;0;0","PELLEGRINO MUSTO;ROCCO GALASSO;COSIMO LEQUAGLIE;G. PLASTINO;GENNARO MANCINO;VALDEMAR VALENTE;GIOVANNI D’ARENA;PASQUALE DE NEGRI","3;3;2;1;1;1;0;0","MEDICINE;BIOLOGY;CHEMISTRY;GEOGRAPHY;PHYSICS;POLITICAL SCIENCE;SOCIOLOGY","12;4;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;RADIOLOGY;ANESTHESIA;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;FOOD SCIENCE;GENETICS;IMMUNOLOGY;PALEONTOLOGY;ACOUSTICS;DEMOGRAPHY;GASTROENTEROLOGY;GENERAL SURGERY;LAW;PATHOLOGY;UROLOGY","6;5;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;ANTIOXIDANT;FATTY ACID;LUNG;MEMBRANE;MULTIPLE MYELOMA;POPULATION;RED BLOOD CELL;ANEMIA;ASYMPTOMATIC;BASAL CELL;BONE MARROW;CARCINOMA;CATHETER;CELL;CLONIDINE;COMPLICATION;CONCOMITANT;CONCORDANCE;DIALYSIS;ENDOSCOPY;ERYTHROPOIETIN;ESOPHAGUS;FISTULA;HARMONIZATION;HEMODIALYSIS;KETAMINE;LAPAROTOMY;LEUKEMIA;LUNG CANCER;LYMPH;LYMPH NODE;LYMPHOMA;NODULE (GEOLOGY);PLATELET;POLITICS;RADIATION THERAPY;REGIMEN;ROPIVACAINE;SEDATION;STAGE (STRATIGRAPHY);STEM CELL;STOMACH;THROMBOSIS","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BUTYLATED HYDROXYTOLUENE;ERYTHROCYTE MEMBRANE;METASTASIS;POLYUNSATURATED FATTY ACID;AMIFOSTINE;BASAL CELL CARCINOMA;CANCER STAGING;CD34;CHRONIC LYMPHOCYTIC LEUKEMIA;CYCLOPHOSPHAMIDE;DEXMEDETOMIDINE;DIALYSIS CATHETER;ENDOSCOPIC ULTRASONOGRAPHY;ESOPHAGEAL CANCER;HEMODIALYSIS CATHETER;INTEGRIN;LYMPHOPROLIFERATIVE DISORDERS;MELPHALAN;MYELODYSPLASTIC SYNDROMES;MYELOFIBROSIS;NEUTROPENIA;PLATELET TRANSFUSION;PROMOTION (CHESS);RESPIRATORY DISEASE;VENOUS THROMBOSIS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABSOLUTE NEUTROPHIL COUNT;BRONCHUS;ESOPHAGECTOMY;FEBRILE NEUTROPENIA;LEUKAPHERESIS;METASTASECTOMY;RUXOLITINIB","1;1;1;1;1;1;1",";HUMANS;MIDDLE AGED;LUNG NEOPLASMS;MALE;ANTINEOPLASTIC AGENTS, ALKYLATING;CARCINOMA, BASAL CELL;CATHETERIZATION, CENTRAL VENOUS;FEMALE;MELPHALAN;RENAL DIALYSIS;STOMACH NEOPLASMS;AGED;ANTIGENS, CD34;CYCLOPHOSPHAMIDE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IMMUNOSUPPRESSIVE AGENTS;MULTIPLE MYELOMA;SKIN NEOPLASMS;BRONCHIAL FISTULA","7;7;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2","ADVANCES IN METABOLOMICS RESEARCH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER OF UNKNOWN PRIMARY SITE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ESOPHAGEAL INTERVENTION TECHNIQUES;GASTRIC CANCER RESEARCH AND TREATMENT;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;NEUROTOXIC EFFECTS OF ANESTHETIC AGENTS ON BRAIN DEVELOPMENT;ROLE OF ERYTHROPOIETIN IN DISEASE TREATMENT AND MANAGEMENT;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES","2;2;1;1;1;1;1;1;1;1;1;1","BUTYLATED HYDROXYTOLUENE;;ABSOLUTE NEUTROPHIL COUNT;AMIFOSTINE;B CELL ABNORMALITIES;BASAL CELL CARCINOMA;CANCER STAGING;CANCER TREATMENT;CENTRAL VENOUS CATHETERIZATION;CHRONIC LYMPHOCYTIC LEUKEMIA;CONCOMITANT;CONCORDANCE;DEXMEDETOMIDINE;DIALYSIS CATHETER;DIET QUALITY;DIETARY PATTERNS;ENDOSCOPIC ULTRASONOGRAPHY;ERYTHROCYTE;ERYTHROPOIESIS-STIMULATING AGENTS;ESOPHAGEAL PERFORATION","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACIDS EFFECTS;ERYTHROCYTE MEMBRANE;FATTY ACIDS;LOW TEMPERATURE;MEMBRANE FATTY;STORAGE TIME;ACCESS -MONTH;ASYMPTOMATIC MYELOMA;B-CELL CHRONIC;BASAL CELL;BELATED FISTULA;CAUDAL ADDITIVES;CELL CARCINOMA;CELL SUPPORT;CENTRAL VENOUS;CHRONIC LYMPHOCYTIC;CHRONIC LYMPHOPROLIFERATIVE;CLONIDINE ADDED;CM REGIMEN;COLLABORATIVE EUROPEAN;DATA HARMONIZATION;DIETARY PATTERNS;DOSE-INTENSIVE MELPHALAN;ELDERLY MYELOMA;ENDOSCOPIC ULTRASONOGRAPHY;ENHANCE POSTOPERATIVE;EPIDURAL INFUSION;ESOPHAGEAL TUMOR;EUROPEAN DATA;EUROPEAN POPULATIONS","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2001,12,7.66666666666667,2.66666666666667,0.375,0.333333333333333,0.333333333333333,0,0.0833333333333333,0,2,1,1,8,0.17,0.08,0.08,0.67,45.17,0.988493447018077,0.25,0.916666666666667,0,0.276103740700275,0.15,0,0,"GIOVANNI D’ARENA;IGNAZIO CATALDO;PASQUALE DE NEGRI;PELLEGRINO MUSTO;BÁRBARA CONTI;M CAROTENUTO;COSIMO LEQUAGLIE;GIANNI PERLA;PAOLA PARRELLA;MICHELE AIETA;ROBERTO SABBATINI;GIORGIO MANCINO;L. LAPADULA;ALDO CAMMAROTA;LUCIA SACCHETTI;CIRO VISCONTI;NICOLA DI RENZO;ANGELA DAMATO;PAOLA MAZZARELLI;SALVATORE PANICO","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","PASQUALE DE NEGRI;IGNAZIO CATALDO;BÁRBARA CONTI;COSIMO LEQUAGLIE;GIORGIO MANCINO;P. BIGNAMI;FEDERICO BOZZETTI;DARIO BARATTI;GIOVANNI D’ARENA;PELLEGRINO MUSTO;M CAROTENUTO;GIANNI PERLA;L. LAPADULA;CIRO VISCONTI;ANGELA DAMATO;VINCENZO FUSCO;V. VERILE;PER‐ARNE LÖNNQVIST;A CAVALLUZZO;B MACNANI","0.4;0.34;0.34;0.34;0.25;0.25;0.25;0.25;0.24;0.24;0.24;0.24;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","GIOVANNI D’ARENA;PASQUALE DE NEGRI;PELLEGRINO MUSTO;COSIMO LEQUAGLIE;MICHELE AIETA;GIORGIO MANCINO;L. LAPADULA;ALDO CAMMAROTA;LUCIA SACCHETTI;SALVATORE PANICO;EGIDIO CELENTANO;VINCENZO FUSCO;GENNARO MANCINO;FRANCESCO SALVATORE;PAOLO RUBBA;V. VERILE;ANNA MARIA BOCHICCHIO;GIUSEPPE COVETTI;M. GENE BOND;P. DI LEO","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PASQUALE DE NEGRI;COSIMO LEQUAGLIE;GIORGIO MANCINO;GIOVANNI D’ARENA;PELLEGRINO MUSTO;L. LAPADULA;VINCENZO FUSCO;V. VERILE;GIOVANNI CASTALDO;A. MONTAGNA;ALDO CAMMAROTA;GENNARO MANCINO;ANNA MARIA BOCHICCHIO;P. DI LEO;MARIAROSA COCCARO;A. CAPOBIANCO;MICHELE AIETA;LUCIA SACCHETTI;SALVATORE PANICO;EGIDIO CELENTANO","0.4;0.34;0.25;0.24;0.24;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.09;0.08;0.08;0.08","CARLA RABITTI;CARMELA CUOMO;DANIEL COHEN;DAVID SIDRANSKY;EDWARD GABRIELSON;MAKIKO FLISS;MONICA RINALDI;MONTSE SÁNCHEZ‐CÉSPEDES;MYLA SPENCER;PAOLA MAZZARELLI;PAOLA PARRELLA;SUNIL PANDIT;THERESA L. NICOL;VITO MICHELE FAZIO;YAN XIAO;GIANNI PERLA;GIOVANNI D’ARENA;M CAROTENUTO;PELLEGRINO MUSTO;PASQUALE DE NEGRI","243;243;243;243;243;243;243;243;243;243;243;243;243;243;243;112;112;112;112;95","CARMELA CUOMO;PASQUALE DE NEGRI;PELLEGRINO MUSTO;ANTONELLA PASTINESE;ARCANGELO IANNUZZI;EGIDIO CELENTANO;FRANCESCO SALVATORE;GIUSEPPE COVETTI;LUCIA SACCHETTI;M. GENE BOND;MARIA ANTONIETTA BELISARIO;MARIO MANCINI;PAOLO RUBBA;ROCCO GALASSO;SALVATORE PANICO;GIOVANNI D’ARENA;A. CAPOBIANCO;ALDO CAMMAROTA;ANNA MARIA BOCHICCHIO;GENNARO MANCINO","243;95;85;54;54;54;54;54;54;54;54;54;54;54;54;27;21;21;21;21","COSIMO LEQUAGLIE;PASQUALE DE NEGRI;A. CAPOBIANCO;ALDO CAMMAROTA;ANNA MARIA BOCHICCHIO;ANTONELLA PASTINESE;ARCANGELO IANNUZZI;CARMELA CUOMO;EGIDIO CELENTANO;FRANCESCO SALVATORE;GENNARO MANCINO;GIOVANNI D’ARENA;GIUSEPPE COVETTI;LUCIA SACCHETTI;M. GENE BOND;MARIA ANTONIETTA BELISARIO;MARIAROSA COCCARO;MARIO MANCINI;MICHELE AIETA;P. DI LEO","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;MATHEMATICS;PSYCHOLOGY","11;4;2;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ANESTHESIA;GENETICS;IMMUNOLOGY;ONCOLOGY;PALEONTOLOGY;PATHOLOGY;RADIOLOGY;CANCER RESEARCH;CARDIOLOGY;ELECTRICAL ENGINEERING;ENVIRONMENTAL HEALTH;GENERAL SURGERY;GEOMETRY;MECHANICAL ENGINEERING;MOLECULAR BIOLOGY;NEUROSCIENCE;PHARMACOLOGY","8;6;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;ANALGESIC;BONE MARROW;CHEMOTHERAPY;LOCAL ANESTHETIC;LUNG CANCER;LYMPH NODE;RADIATION THERAPY;RESECTION;ROPIVACAINE;STAGE (STRATIGRAPHY);ADVERSE EFFECT;ANEMIA;ANTIBODY;BIOPSY;BLOCK (PERMUTATION GROUP THEORY);BLOOD PRESSURE;BODY MASS INDEX;BRACHIAL PLEXUS;BUPIVACAINE;CARCINOMA;CAROTID ARTERIES;CATHETER;CENTRAL LINE;CLONIDINE;COHORT;DISSECTION (MEDICAL);DOSE;ERYTHROPOIETIN;FEMORAL NERVE;GENE;HILUM (ANATOMY);LEUKEMIA;LYMPHOCYTOSIS;LYMPHOMA;NERVE BLOCK;ODDS RATIO;PERIOPERATIVE;PERIPHERAL BLOOD;POPULATION;PORT (CIRCUIT THEORY);REGIMEN;SEDATION;SPINAL CORD;SPLEEN;STEM CELL;STROKE (ENGINE);THORACOSCOPY;THORACOTOMY;THROMBOSIS;TRISOMY;VEIN;VIDEO-ASSISTED THORACOSCOPIC SURGERY","5;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADENOCARCINOMA;BREAST CANCER;METASTASIS;BRACHIAL PLEXUS BLOCK;CD19;CD34;CD5;CHRONIC LYMPHOCYTIC LEUKEMIA;CODING REGION;COMMON CAROTID ARTERY;CYCLOPHOSPHAMIDE;DEEP VEIN;ERYTHROPOIESIS;GASTRECTOMY;GASTRIC CARCINOMA;GRANULOCYTE COLONY-STIMULATING FACTOR;IMMUNOGLOBULIN E;LEVOBUPIVACAINE;LYMPHADENECTOMY;MITOCHONDRIAL DNA;MITOXANTRONE;MUTATION;MYELODYSPLASTIC SYNDROMES;PNEUMONECTOMY;PULSE PRESSURE;RESECTION MARGIN;SOMATIC CELL;SPLENECTOMY;SUBCLAVIAN VEIN;WEDGE RESECTION","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;CD23;CD38;EPIRUBICIN;IGHV@;INFLAMMATORY BREAST CANCER;MEDIASTINAL LYMPH NODE;POINT MUTATION;PRIMARY TUMOR;SUPRACLAVICULAR LYMPH NODES;THIOTEPA","1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;ADULT;MALE;AGED;BREAST NEOPLASMS;GRANULOCYTE COLONY-STIMULATING FACTOR;LUNG NEOPLASMS;ANEMIA;BIOMARKERS;CAROTID ARTERY DISEASES;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;MYELODYSPLASTIC SYNDROMES;ADRENERGIC ALPHA-AGONISTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS, MALE;CARCINOMA, NON-SMALL-CELL LUNG;CLONIDINE;COLONY-STIMULATING FACTORS","11;8;8;7;7;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3","EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;ACUTE MYELOID LEUKEMIA;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CANCER OF UNKNOWN PRIMARY SITE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MANAGEMENT OF SPINAL METASTATIC TUMORS;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE","2;2;1;1;1;1;1;1;1;1","ROPIVACAINE;ATHEROSCLEROTIC PLAQUE;B-CELL RECEPTOR SIGNALING;BRACHIAL PLEXUS BLOCK;CANCER GENOMICS;CATHETER-RELATED BLOODSTREAM INFECTIONS;CD23;CD5;CENTRAL LINE;CENTRAL VENOUS CATHETERIZATION;CODING REGION;COLD-PCR;DOSE;EPIDURAL ANALGESIA;EPIRUBICIN;FEMORAL NERVE;GASTRIC CANCER;GASTRIC CARCINOMA;HILUM (ANATOMY);IGHV@","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADDING GROWTH;ADVERSE BIOLOGICAL;ATHEROSCLEROTIC PLAQUES;B-CELL CHRONIC;BIOLOGICAL FEATURES;BLOCKS PRELIMINARY;BLOOD PROGENITOR;BUPIVACAINE LEVOBUPIVACAINE;CANCER PATIENTS;CAROTID ARTERIES;CD EXPRESSION;CELL LUNG;CHRONIC LYMPHOCYTIC;CLINICAL OUTCOME;CLONIDINE ADDED;CONTINUOUS EPIDURAL;DNA MUTATIONS;DOSE CHEMOTHERAPY;DOSE-RESPONSE RELATIONSHIP;EPIDURAL INFUSION;EXPRESSION CORRELATES;FINE-NEEDLE ASPIRATES;GASTRIC CARCINOMA;GROWTH FACTORS;HOMOLATERAL NON-SMALL;II PILOT;INFLAMMATORY BREAST;INFUSIONAL SYSTEMS;LIMITED EFFECTS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COMMON CAROTID;ATHEROSCLEROTIC LESIONS;BLOOD PRESSURE;BODY MASS;CARDIOVASCULAR DISEASE;CAROTID BIFURCATIONS;CAROTID PLAQUES;CLINICALLY HEALTHY;HEALTHY MIDDLE-AGED;INTIMA-MEDIA THICKNESS;LDL CHOLESTEROL;MASS INDEX;MIDDLE-AGED WOMEN;ODDS RATIO;OXIDATION MARKERS;RATIO CI;SMOKING HABIT;SYSTOLIC BLOOD;ADJUSTMENT COMMON;AGE ADJUSTMENT;AGE LDL;AGE RANGE;ARTERIAL SEGMENTS;ASSESS INTIMA-MEDIA;ATHEROSCLEROTIC PLAQUES;B-MODE ULTRASOUND;BIFURCATIONEARLY ATHEROSCLEROTIC;BLOOD PRESSUREIN;CARDIOVASCULAR RISK;CAROTID ARTERIES","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2002,13,7.84615384615385,2.38461538461538,0.419354838709677,0.384615384615385,0.307692307692308,0.0769230769230769,0.0769230769230769,0,3,1,3,5,0.23,0.08,0.23,0.38,45.08,0.81707407432355,0.307692307692308,1,0,0.324480347008836,0.166666666666667,0.25,0,"PELLEGRINO MUSTO;BÁRBARA CONTI;B MAGNANI;COSIMO LEQUAGLIE;PIER PAOLO BREGA MASSONE;IGNAZIO CATALDO;PASQUALE DE NEGRI;LUIGI TERRACCIANO;LUIGI TORNILLO;ROCCO GALASSO;GIORGIO IVANI;SARA GALIMBERTI;GIOVANNI D’ARENA;ALESSANDRA BERTOLA;LUCIANO MASINI;ALESSANDRO SGAMBATO;LEONARDO BIANCHI;CHRISTIAN BAERISWYL;PAOLA OMEDÈ;E. MINÓLA","3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","PASQUALE DE NEGRI;GIORGIO IVANI;BÁRBARA CONTI;B MAGNANI;COSIMO LEQUAGLIE;PIER PAOLO BREGA MASSONE;IGNAZIO CATALDO;PELLEGRINO MUSTO;ROCCO GALASSO;LUIGI TERRACCIANO;LUIGI TORNILLO;TIZIANA TIRRI;IVANA CATALDO;ANNA NARDELLI;L. FAVULLO;B BORDI;EMILIO BORDI;ROBERTO GUARIGLIA;FRANCA FERRO;MARIA ROSARIA D’AMICO","0.7;0.7;0.57;0.57;0.57;0.57;0.37;0.25;0.24;0.24;0.24;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17","PELLEGRINO MUSTO;COSIMO LEQUAGLIE;PASQUALE DE NEGRI;LUIGI TORNILLO;ROCCO GALASSO;GIOVANNI D’ARENA;ALDO CAMMAROTA;LUCIA SACCHETTI;TIZIANA TIRRI;SALVATORE PANICO;EGIDIO CELENTANO;ROBERTO GUARIGLIA;ANNA NARDELLI;PAOLO RUBBA;FEDERICA ZARRILLI;ANNA MARIA BOCHICCHIO;M. GENE BOND;GIAMPIERO ROMANO;MARIAROSA COCCARO;L. FAVULLO","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PASQUALE DE NEGRI;COSIMO LEQUAGLIE;PELLEGRINO MUSTO;ROCCO GALASSO;LUIGI TORNILLO;TIZIANA TIRRI;ANNA NARDELLI;L. FAVULLO;ROBERTO GUARIGLIA;ALDO CAMMAROTA;ANNA MARIA BOCHICCHIO;GIAMPIERO ROMANO;MARIAROSA COCCARO;ALFREDO TARTARONE;GIOVANNI D’ARENA;LUCIA SACCHETTI;SALVATORE PANICO;EGIDIO CELENTANO;PAOLO RUBBA;FEDERICA ZARRILLI","0.7;0.57;0.25;0.24;0.24;0.2;0.2;0.2;0.17;0.14;0.14;0.14;0.14;0.14;0.1;0.1;0.1;0.1;0.1;0.1","ROCCO GALASSO;ANNA VITTORIA CIARDULLO;ARCANGELO IANNUZZI;EGIDIO CELENTANO;FEDERICA ZARRILLI;LUCIA SACCHETTI;M. GENE BOND;MARIO DE MICHELE;PAOLO RUBBA;SALVATORE PANICO;PELLEGRINO MUSTO;LUIGI TERRACCIANO;LUIGI TORNILLO;A LEDDA;ANGELO VACCA;CLAUDIA CELLINI;DELIA CANGINI;ELENA ZAMAGNI;F. LAURIA;FILIPPO BALLERINI","215;213;213;213;213;213;213;213;213;213;197;134;134;111;111;111;111;111;111;111","ROCCO GALASSO;ANNA VITTORIA CIARDULLO;ARCANGELO IANNUZZI;EGIDIO CELENTANO;FEDERICA ZARRILLI;LUCIA SACCHETTI;M. GENE BOND;MARIO DE MICHELE;PAOLO RUBBA;SALVATORE PANICO;PELLEGRINO MUSTO;LUIGI TORNILLO;COSIMO LEQUAGLIE;ANNA NARDELLI;L. FAVULLO;PASQUALE DE NEGRI;TIZIANA TIRRI;ROBERTO GUARIGLIA;GIOVANNI D’ARENA;ALDO CAMMAROTA","215;213;213;213;213;213;213;213;213;213;197;134;22;12;12;12;12;6;4;2","COSIMO LEQUAGLIE;PELLEGRINO MUSTO;LUIGI TORNILLO;PASQUALE DE NEGRI;ROCCO GALASSO;ALDO CAMMAROTA;ALFREDO TARTARONE;ANNA MARIA BOCHICCHIO;ANNA NARDELLI;ANNA VITTORIA CIARDULLO;ARCANGELO IANNUZZI;EGIDIO CELENTANO;FEDERICA ZARRILLI;GIAMPIERO ROMANO;GIOVANNI D’ARENA;L. FAVULLO;LUCIA SACCHETTI;M. GENE BOND;MARIAROSA COCCARO;MARIO DE MICHELE","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING","13;5;3;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;GENETICS;ANESTHESIA;IMMUNOLOGY;ONCOLOGY;PATHOLOGY;ACOUSTICS;ANATOMY;ASTROBIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;COMPUTER SECURITY;ENVIRONMENTAL ENGINEERING;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;OPTICS;PALEONTOLOGY;RADIOLOGY;UROLOGY","12;6;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;LUNG CANCER;MULTIPLE MYELOMA;STEM CELL;TRANSPLANTATION;ALTERNATIVE MEDICINE;ANEMIA;ANTIGEN;APOPTOSIS;BODY MASS INDEX;CARCINOMA;CARDIOTHORACIC SURGERY;CAROTID ARTERIES;COMPLICATION;CYTOKINE;FIBRIN GLUE;GENE;HELICOBACTER PYLORI;HEMANGIOPERICYTOMA;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);INFLAMMATION;LEAK;LESION;LEUKEMIA;LOUDSPEAKER;LUNG;MEDIASTINUM;MYELOID;MYELOID LEUKEMIA;NAUSEA;OBESITY;PAIN CONTROL;PATHOGENESIS;PERIOPERATIVE;PHARMACOTHERAPY;POPULATION;PROSPECTIVE COHORT STUDY;RASH;REFRACTORY (PLANETARY SCIENCE);REGIONAL ANESTHESIA;RETROSPECTIVE COHORT STUDY;RIB CAGE;SAFER;SARCOMA;STAGE (STRATIGRAPHY);THORAX (INSECT ANATOMY);TUMOR NECROSIS FACTOR ALPHA;VOMITING","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","METASTASIS;ADENOCARCINOMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARCINOGENESIS;CD34;CHROMOSOME;COMMON CAROTID ARTERY;CYCLOPHOSPHAMIDE;DIAPHRAGM (ACOUSTICS);DIAPHRAGMATIC BREATHING;ETOPOSIDE;GASTRITIS;INTERFERON GAMMA;INTIMA-MEDIA THICKNESS;LEUKOPENIA;LIVER TRANSPLANTATION;LYMPHOBLASTIC LEUKEMIA;MEDIASTINAL TUMOR;MELPHALAN;OVERWEIGHT;PNEUMONECTOMY;POSTOPERATIVE NAUSEA AND VOMITING;PROGENITOR CELL;PROGRAMMED CELL DEATH;PROINFLAMMATORY CYTOKINE;SALVAGE THERAPY;THALIDOMIDE;WAIST","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADENOSQUAMOUS CARCINOMA;COMPARATIVE GENOMIC HYBRIDIZATION;FAS LIGAND;IFOSFAMIDE;METASTASECTOMY","1;1;1;1;1","LUNG NEOPLASMS;HUMANS;FEMALE;ADULT;MIDDLE AGED;MULTIPLE MYELOMA;MALE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;CAROTID STENOSIS;GASTRITIS;HEMANGIOPERICYTOMA;OBESITY;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;PULMONARY BLASTOMA;T-LYMPHOCYTES;THROMBOPHILIA;ANTINEOPLASTIC AGENTS, ALKYLATING","13;12;9;8;8;8;7;6;5;5;5;4;4;4;4;4;4;4;4;3","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;MANAGEMENT OF HYPERBILIRUBINEMIA IN NEWBORN INFANTS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING","2;1;1;1;1;1;1;1;1;1;1;1","INTERNATIONAL MYELOMA WORKING GROUP;ADENOSQUAMOUS CARCINOMA;ANTIEMETIC THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BIOMARKER ANALYSIS;CARDIOTHORACIC SURGERY;CAROTID INTIMA-MEDIA THICKNESS;CHROMOSOME DUPLICATION;COMPARATIVE GENOMIC HYBRIDIZATION;CONGENITAL DIAPHRAGMATIC HERNIA;DIAPHRAGM (ACOUSTICS);ERYTHROCYTE;FAS LIGAND;HEMANGIOPERICYTOMA;INFLAMMATION;INTIMA-MEDIA THICKNESS;LEUKOPENIA;LOCAL ANESTHETICS;LUNG CANCER;LUNG NODULES","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MULTIPLE MYELOMA;ACUTE LYMPHOBLASTIC;ADEQUATE COLLECTION;ADULT ACUTE;ADVANCED RELAPSEDREFRACTORY;ANEMIA TYPE;ANTIGEN POSITIVE;APOPTOSIS INIHELICOBACTER;ARTERY WALL;BLOOD PROGENITOR;CAROTID ARTERY;CENTRAL FAT;CHROMOSOMAL ALTERATIONS;CLINICO-BIOLOGICAL TOOL;COMPARATIVE GENOMIC;CONGENITAL DYSERYTHROPOIETIC;CYTOKINE SECRETION;DIAGNOSIS HAMPERS;DIAPHRAGMATIC METASTASIS;DYSERYTHROPOIETIC ANEMIA;DYSPLASTIC NODULES;EFFECTIVE CLINICO-BIOLOGICAL;ELDERLY PATIENTS;FACTORS ANALYSIS;FAT DISTRIBUTION;FIBRIN GLUE;GENOMIC HYBRIDIZATION;GILBERTS SYNDROME;GLUE MODIFICATION;HAMPERS ADEQUATE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANEMIA TYPE;ANTITHROMBIN III;CDA-II GILBERTS;CONGENITAL DYSERYTHROPOIETIC;DYSERYTHROPOIETIC ANEMIA;GALLSTONE FORMATION;GILBERTS SYNDROME;GS CAUSED;HEMOLYTIC ANEMIAS;II CDA-II;INCREASED PRODUCTION;MALLEOLAR ULCERATION;MONOCONJUGATED BILIRUBIN;SYNDROME GS;THROMBOPHILIC TENDENCY;TROPHIC MALLEOLAR;TYPE II;UNDERGO CHOLECYSTECTOMY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2003,12,14.6666666666667,1.5,0.666666666666667,0,0.166666666666667,0,0.166666666666667,0,3,1,5,3,0.25,0.08,0.42,0.25,44.42,0.839191905000429,0.666666666666667,1,0,0.427401916941666,0,0.25,0,"­ROSARIO ­TUMINO;DOMENICO PALLI;ROCCO GALASSO;EGIDIO CELENTANO;GRAZIELLA FRASCA;CARLOTTA SACERDOTE;LAURA FIORINI;SIMONETTA SALVINI;FRANCO BERRINO;SABINA SIERI;GIOVANNA MASALA;VITTORIO KROGH;VALERIA PALA;SALVATORE PANICO;ANNA VITTORIA CIARDULLO;PAOLO VINEIS;MARIA CONCETTA GIURDANELLA;GIOVANNA TAGLIABUE;IGNAZIO CATALDO;ELISABETTA FUSCONI","6;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;2;2;2","IGNAZIO CATALDO;BREGA-MASSONE PP;BÁRBARA CONTI;COSIMO LEQUAGLIE;­ROSARIO ­TUMINO;DOMENICO PALLI;ROCCO GALASSO;EGIDIO CELENTANO;GRAZIELLA FRASCA;CARLOTTA SACERDOTE;LAURA FIORINI;FRANCA FERRO;GIOVANNA MASALA;SIMONETTA SALVINI;FRANCO BERRINO;SABINA SIERI;VITTORIO KROGH;LUIGI TERRACCIANO;LUIGI TORNILLO;GUIDO PETTINATO","0.45;0.45;0.45;0.45;0.35;0.35;0.35;0.27;0.27;0.26;0.26;0.2;0.19;0.19;0.19;0.19;0.19;0.18;0.18;0.18","ROCCO GALASSO;SALVATORE PANICO;LUIGI TORNILLO;COSIMO LEQUAGLIE;PASQUALE DE NEGRI;L. IADANZA;VINCENZO FUSCO;ANTONELLA CAIVANO;SABRINA BERTINETTI;SILVIA ZACCHI;GIUSEPPE CASCONE","6;3;2;2;1;1;1;1;1;1;1","COSIMO LEQUAGLIE;ROCCO GALASSO;LUIGI TORNILLO;L. IADANZA;VINCENZO FUSCO;SALVATORE PANICO;PASQUALE DE NEGRI;ANTONELLA CAIVANO;GIUSEPPE CASCONE;SABRINA BERTINETTI;SILVIA ZACCHI","0.45;0.35;0.18;0.11;0.11;0.11;0.1;0.1;0.08;0.02;0.02","DOMENICO PALLI;ROCCO GALASSO;­ROSARIO ­TUMINO;CARLOTTA SACERDOTE;EGIDIO CELENTANO;LAURA FIORINI;FRANCO BERRINO;GRAZIELLA FRASCA;SABINA SIERI;SIMONETTA SALVINI;VITTORIO KROGH;VALERIA PALA;MANUELA BELLEGOTTI;GIOVANNA MASALA;SALVATORE PANICO;PAOLO VINEIS;CALOGERO SAIEVA;ANNA VITTORIA CIARDULLO;MARIA CONCETTA GIURDANELLA;AMALIA MATTIELLO","523;523;523;516;516;516;509;494;487;487;487;480;345;306;299;277;270;171;171;164","ROCCO GALASSO;SABRINA BERTINETTI;SILVIA ZACCHI;PASQUALE DE NEGRI;LUIGI TORNILLO;ANTONELLA CAIVANO;SALVATORE PANICO;GIUSEPPE CASCONE;L. IADANZA;VINCENZO FUSCO;COSIMO LEQUAGLIE","523;135;135;66;41;29;29;7;5;5;4","ROCCO GALASSO;COSIMO LEQUAGLIE;LUIGI TORNILLO;ANTONELLA CAIVANO;GIUSEPPE CASCONE;L. IADANZA;PASQUALE DE NEGRI;SABRINA BERTINETTI;SALVATORE PANICO;SILVIA ZACCHI;VINCENZO FUSCO","6;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;SOCIOLOGY;ART;PHYSICS;MATHEMATICS;GEOGRAPHY;MATERIALS SCIENCE","11;5;5;4;4;3;1;1","INTERNAL MEDICINE;DEMOGRAPHY;ENVIRONMENTAL HEALTH;LITERATURE;OPTICS;PATHOLOGY;COMBINATORICS;GENETICS;GERONTOLOGY;PALEONTOLOGY;SURGERY;ANESTHESIA;BIOCHEMISTRY;CLASSICAL MECHANICS;COMPUTATIONAL PHYSICS;ENDOCRINOLOGY;FOOD SCIENCE;GASTROENTEROLOGY;MATHEMATICAL ANALYSIS;MICROBIOLOGY;NUCLEAR MEDICINE;PARTICLE PHYSICS;QUANTUM MECHANICS;SOCIAL SCIENCE;STATISTICS;VIROLOGY","9;5;4;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;EPIC;COHORT;POPULATION;GENE;INCIDENCE (GEOMETRY);STAGE (STRATIGRAPHY);ANALGESIC;ANTHROPOMETRY;ANTIBODY;ANTIGEN;BLOCK (PERMUTATION GROUP THEORY);CALIBRATION;CARCINOMA;CHEMOTHERAPY;CLINICAL NUTRITION;COHORT STUDY;COMPARABILITY;CONSUMPTION (SOCIOLOGY);DETECTION LIMIT;DOSIMETRY;ENZYME;EPIDEMIOLOGY;ESOPHAGUS;EXTRAPOLATION;FOOD FREQUENCY QUESTIONNAIRE;FOOD GROUP;HELICOBACTER PYLORI;HEPATOBLASTOMA;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;ION;LIFE STYLE;LUNG;LYMPHOMA;MALIGNANCY;MENOPAUSE;MONTE CARLO METHOD;MOTION (PHYSICS);ORANGE (COLOUR);PARITY (PHYSICS);POLYNOMIAL;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;STOMACH;TRISOMY","5;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;BREAST CANCER;ADENOCARCINOMA;BRACHYTHERAPY;CALIBRATION CURVE;CANCER REGISTRY;CERVICAL CANCER;CHROMOSOME;COLORECTAL CANCER;DIET AND CANCER;EPITOPE;ESCHERICHIA COLI;ESOPHAGEAL CANCER;FERTILITY;FOOD COMPOSITION DATA;GASTRIC LYMPHOMA;INTERPOLATION (COMPUTER GRAPHICS);IONIZATION;KERMA;LEVOBUPIVACAINE;LINEAR INTERPOLATION;MALT LYMPHOMA;PHAGE DISPLAY;PNEUMONECTOMY;PULMONARY BLASTOMA;PYRUVATE DEHYDROGENASE COMPLEX;RECOMBINANT DNA;RESEARCH METHODOLOGY","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY;ANEUPLOIDY;BACTERIOPHAGE;COMPARATIVE GENOMIC HYBRIDIZATION;CYTOGENETICS;DIHYDROLIPOAMIDE DEHYDROGENASE;ESOPHAGECTOMY;FAMILIAL ADENOMATOUS POLYPOSIS;FAMILY PLANNING;FLUORESCENCE IN SITU HYBRIDIZATION;FUSION PROTEIN;IONIZATION CHAMBER","1;1;1;1;1;1;1;1;1;1;1;1","NEOPLASMS;HUMANS;ITALY;FEMALE;MALE;MIDDLE AGED;SMOKING;STOMACH NEOPLASMS;LUNG NEOPLASMS;PROSPECTIVE STUDIES;ADULT;AIDS VACCINES;ALCOHOL DRINKING;BRACHYTHERAPY;LYMPHOMA, B-CELL;LYMPHOMA, B-CELL, MARGINAL ZONE;RADIOMETRY;SEX DISTRIBUTION;VACCINES, SYNTHETIC;ACETYLTRANSFERASES","16;11;11;9;9;7;6;6;5;5;4;4;4;4;4;4;4;4;4;3","ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;EFFECTS OF HORMONES ON MENOPAUSAL WOMEN'S HEALTH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;IMPACT OF SOCIAL FACTORS ON HEALTH OUTCOMES;LYMPHOID NEOPLASMS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;THERAPEUTIC ANTIBODIES: DEVELOPMENT, ENGINEERING, AND APPLICATIONS","2;1;1;1;1;1;1;1;1;1;1","HEALTHY EATING INDEX;ADJUVANT CHEMOTHERAPY;ANTIBODY ENGINEERING;BRACHYTHERAPY DOSE CALCULATION;CANCER INCIDENCE;CANCER REGISTRY DATA;CANCER SURVIVORSHIP;CHROMOSOME DUPLICATION;CLINICAL NUTRITION;COHORT STUDY;COMPARABILITY;COMPARATIVE GENOMIC HYBRIDIZATION;CONSUMPTION (SOCIOLOGY);DIET AND CANCER;DIHYDROLIPOAMIDE DEHYDROGENASE;EPIDURAL ANALGESIA;ESOPHAGECTOMY;FOOD COMPOSITION DATA;FOOD FREQUENCY QUESTIONNAIRE;FOOD GROUP","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIGENS DEVELOPMENT;BASELINE CHARACTERISTICS;BIPHASIC BLASTOMA;BRACHYTHERAPY SOURCE;CANCER INCIDENCE;CAUDAL BLOCK;COHORTS PRESENTATION;COMPARATIVE GENOMIC;CORRECTION FACTOR;DISPLAY SYSTEMS;EPIC COHORTS;EPIC-ITALY COHORTS;EPIC-ITALY PROSPECTIVE;EPIDEMIOLOGY PROJECT;ESOPHAGEAL MICROCYTOMA;FUSION PROTEINS;GASTRIC MALT;GENOMIC HYBRIDIZATION;HEPATOBLASTOMA REVEALS;HIV- ANTIGENS;HIV- INFECTION;HYBRIDIZATION ANALYSIS;IMMUNOHISTOCHEMICAL STUDY;IONIZATION CHAMBER;ITALIAN EPIC;LIFE-STYLE CHARACTERISTICS;LONG-TERM PROGNOSIS;LUNG REPORT;MALT LYMPHOMA;METHODOLOGICAL ISSUES","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HG TUMORS;LG TUMORS;ASSESSED HG;ASSESSED LG;MOTOR BLOCKADE;POSTOPERATIVE ANALGESIA;CAUDAL BLOCKADE;HP INFECTION;POSTOPERATIVE MOTOR;CLINICAL OUTCOME;KI EXPRESSION;MALT LYMPHOMA;MIN MIN;SHORTER DURATION;YR NA;ANALGESIA BASED;ANALGESIA COMPARED;ANALGESIA MIN;ANALYSIS INCLUDING;BCELL MALT;BCL PROTEIN;BLOCKADE MLKG;CLINICAL OPTION;COMPLETE FOLLOWUP;DOSE-RESPONSE RELATIONSHIP;GASTRIC MALT;HELICOBACTER PYLORI;HG LYMPHOMA;HIGHGRADE HG;HIGHLY EXPRESSED","6;5;4;4;4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.08,9,9,9,9,5,5,5,0,0,0,0,0,0,0,0,0,0,0,0,5,5,5,0,0,0,0,0,0,5,5,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12,12,12,12,12,12,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2004,11,7.63636363636364,4.18181818181818,0.239130434782609,0.454545454545455,0.636363636363636,0.272727272727273,0,0,5,3,1,0,0.45,0.27,0.09,0,36.09,0.767016744278212,0.0909090909090909,0.818181818181818,0,0.279013880256888,0.380952380952381,0.25,0,"ALFREDO TARTARONE;NICOLA DI RENZO;GIOVANNI IODICE;ROSELLA MATERA;MARIAROSA COCCARO;PIER P. BREGA-MASSONE;G. LELLI;GIANPIERO ROMANO;B MAGNANI;MARIA LUIGIA VIGLIOTTI;ANNA MARIA BOCHICCHIO;GIAMPIERO ROMANO;P. DI LEO;RAFFAELE ARDITO;COSIMO LEQUAGLIE;FRANCA FERRO;A. CAPOBIANCO;LUKAS BUBENDORF;SARA GALIMBERTI;GIOVANNI D’ARENA","5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","ALFREDO TARTARONE;NICOLA DI RENZO;GIOVANNI IODICE;PIER P. BREGA-MASSONE;B MAGNANI;COSIMO LEQUAGLIE;FRANCA FERRO;ROSELLA MATERA;GIAMPIERO ROMANO;MARIAROSA COCCARO;RAFFAELE ARDITO;MARIA LUIGIA VIGLIOTTI;LUKAS BUBENDORF;IGNAZIO CATALDO;GIUSEPPE MORGIA;LUIGI TERRACCIANO;G. LELLI;LUIGI TORNILLO;BÁRBARA CONTI;GIANPIERO ROMANO","0.65;0.45;0.45;0.4;0.4;0.4;0.4;0.31;0.31;0.31;0.31;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","ALFREDO TARTARONE;NICOLA DI RENZO;GIOVANNI IODICE;ROSELLA MATERA;MARIAROSA COCCARO;G. LELLI;GIANPIERO ROMANO;MARIA LUIGIA VIGLIOTTI;ANNA MARIA BOCHICCHIO;GIAMPIERO ROMANO;P. DI LEO;RAFFAELE ARDITO;COSIMO LEQUAGLIE;A. CAPOBIANCO;LUKAS BUBENDORF;ALESSANDRO SGAMBATO;LUIGI TERRACCIANO;GIULIA VITA;GIUSEPPINA GALLUCCI;LUIGI TORNILLO","5;4;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","ALFREDO TARTARONE;NICOLA DI RENZO;GIOVANNI IODICE;COSIMO LEQUAGLIE;ROSELLA MATERA;GIAMPIERO ROMANO;MARIAROSA COCCARO;RAFFAELE ARDITO;MARIA LUIGIA VIGLIOTTI;LUKAS BUBENDORF;LUIGI TERRACCIANO;G. LELLI;LUIGI TORNILLO;GIANPIERO ROMANO;ANNA MARIA BOCHICCHIO;P. DI LEO;MARIO FALSAPERLA;A. CAPOBIANCO;M. OBERHOLZER;GIULIA VITA","0.65;0.45;0.45;0.4;0.31;0.31;0.31;0.31;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.14","RAFFAELE ARDITO;ALESSANDRA BERTOLA;ANTONIO PALUMBO;FEDERICA CAVALLO;GIOVANNINO CICCONE;LUISA GIACCONE;MARIO BOCCADORO;PATRIZIA FALCO;PATRIZIA PREGNO;PELLEGRINO MUSTO;ROSALBA ROSATO;SARA GALIMBERTI;TOMMASO CARAVITA;ALFREDO TARTARONE;GIAMPIERO ROMANO;GIUSEPPE MORGIA;MARIO FALSAPERLA;ACHILLE CITTADINI;ALESSANDRO SGAMBATO;ALMA BONINSEGNA","168;138;138;138;138;138;138;138;138;138;138;138;138;136;126;109;109;59;59;59","PELLEGRINO MUSTO;ALFREDO TARTARONE;GIAMPIERO ROMANO;MARIO FALSAPERLA;RAFFAELE ARDITO;ACHILLE CITTADINI;ALESSANDRO SGAMBATO;GABRIELLA BIANCHINO;LUIGI TERRACCIANO;LUIGI TORNILLO;LUKAS BUBENDORF;M. OBERHOLZER;COSIMO LEQUAGLIE;MARIA LUIGIA VIGLIOTTI;GIOVANNI IODICE;GIUSEPPE MELE;GIUSEPPINA GALLUCCI;MARIAROSA COCCARO;NICOLA DI RENZO;ROSELLA MATERA","138;126;126;109;109;59;59;59;37;37;37;37;27;27;17;17;17;17;17;17","ALFREDO TARTARONE;GIOVANNI IODICE;MARIAROSA COCCARO;NICOLA DI RENZO;ROSELLA MATERA;COSIMO LEQUAGLIE;GIAMPIERO ROMANO;MARIA LUIGIA VIGLIOTTI;ACHILLE CITTADINI;ALESSANDRO SGAMBATO;GABRIELLA BIANCHINO;GIAMPIERO VOLPE;GIUSEPPE MELE;GIUSEPPINA GALLUCCI;LUIGI TERRACCIANO;LUIGI TORNILLO;LUKAS BUBENDORF;M. OBERHOLZER;MARIO FALSAPERLA;PELLEGRINO MUSTO","4;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;MATERIALS SCIENCE","11;3;2;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ANESTHESIA;BIOCHEMISTRY;CANCER RESEARCH;ONCOLOGY;ASTROBIOLOGY;ASTRONOMY;COMPOSITE MATERIAL;DERMATOLOGY;ENDOCRINOLOGY;GENETICS;IMMUNOLOGY;MICROBIOLOGY;PATHOLOGY;PHARMACOLOGY;UROLOGY","9;5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CHEMOTHERAPY;CANCER;CRYOTHERAPY;PLEURAL EFFUSION;THORACOSCOPY;TOXICITY;ADENOMA;ADVERSE EFFECT;ANTIBIOTICS;ANTIOXIDANT;BACTERIA;BLOOD PRESSURE;CARCINOMA;CELL GROWTH;DEXAMETHASONE;IMMUNOHISTOCHEMISTRY;INSUFFLATION;INTUBATION;JAUNDICE;LEUKEMIA;LYMPH NODE;MALIGNANCY;MELANOMA;MULTIPLE MYELOMA;PRIMARY (ASTRONOMY);RECEPTOR;REFRACTORY (PLANETARY SCIENCE);REGIMEN;TALC;THERAPEUTIC EFFECT;THORACOTOMY;THYROID","5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MALIGNANT PLEURAL EFFUSION;MELPHALAN;MUCOSITIS;PLEURODESIS;PROSTATE CANCER;ANAPLASTIC CARCINOMA;CELL CYCLE;CHEMOTHERAPY REGIMEN;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;CYCLOPHOSPHAMIDE;CYTOKERATIN;EPIDERMAL GROWTH FACTOR;EPIDERMAL GROWTH FACTOR RECEPTOR;GROWTH INHIBITION;HEART RATE;NEUTROPENIA;POLYPHENOL;PSAMMOMA BODY;SALVAGE THERAPY;STAPHYLOCOCCUS AUREUS;THALIDOMIDE;THYROID CARCINOMA","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANDROGEN RECEPTOR;BRADYCARDIA;CYCLIN D1;ELLAGIC ACID;FLUDARABINE;LNCAP;PROSTATE DISEASE;VANCOMYCIN;VINORELBINE","1;1;1;1;1;1;1;1;1","HUMANS;MIDDLE AGED;PLEURAL EFFUSION, MALIGNANT;MALE;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;PLEURODESIS;SCLEROSING SOLUTIONS;;CARCINOMA, PAPILLARY;CELL LINE, TUMOR;CYCLOPHOSPHAMIDE;ERBB RECEPTORS;JAUNDICE;MULTIPLE MYELOMA;NEOPLASM RECURRENCE, LOCAL;PROSTATIC NEOPLASMS","8;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;PATHOBIOLOGY AND MANAGEMENT OF MUCOSITIS IN CANCER THERAPY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HER2 SIGNALING IN BREAST CANCER TREATMENT;MELANOMA;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;ROLE OF GALECTINS IN IMMUNITY AND DISEASE","2;2;1;1;1;1;1;1;1","TREATMENT;CRYOTHERAPY;MALIGNANT PLEURAL EFFUSION;MELPHALAN;MUCOSITIS;PARAPNEUMONIC EFFUSIONS;PLEURAL EFFUSION;PLEURODESIS;THORACOSCOPY;ANAPLASTIC CARCINOMA;CANCER THERAPY;CANCER TREATMENT;CHEMOTHERAPY REGIMEN;CLINICOPATHOLOGIC ANALYSIS;DIFFERENTIATED THYROID CANCER;DU145;EGFR;ELLAGIC ACID;ESTRAMUSTINE;FLUTAMIDE","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","DOSE MELPHALAN-INDUCED;MELPHALAN-INDUCED MUCOSITIS;PROSTATE CANCER;TRANSPLANTED PATIENTS;ACID THERAPY;B-CELL CHRONIC;CANCER CELLS;CANCER HRPC;CELLCYCLE ARREST;CHEMICAL PLEURODESIS;CHRONIC LYMPHOCYTIC;COMPLICATING MOBILIZATION;DIAGNOSTIC ASSESSMENT;DOUBLE ULCER;ELLAGIC ACID;EPIDERMAL GROWTH;ESTRAMUSTINE PHOSPHATE;FACTOR RECEPTORTYROSINE;GASTRIC MELANOMA;GROWTH FACTOR;GUILLAIN-BARRÉ SYNDROME;HISTOLOGIC CYTOLOGIC;HORMONE REFRACTORY;IMMUNOHISTOCHEMICAL STUDY;IMPROVE PATIENTS;INDUCES CELLCYCLE;INHIBITS PROLIFERATION;INVASIVE THORACIC;IRESSA INDUCES;LINEZOLID-INDUCED BRADYCARDIA","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",2,0.18,3.5,4,4,4,4,4,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,4,4,4,0,0,0,0,0,0,1,1,1,0,0,0,3,3,3,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,70,70,70,70,70,70,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2005,14,8.14285714285714,2.71428571428571,0.368421052631579,0.714285714285714,0.571428571428571,0.214285714285714,0.142857142857143,0,5,2,3,4,0.36,0.14,0.21,0.29,16.79,0.31704820794443,0.214285714285714,0.571428571428571,0,0.411270915387882,0.152380952380952,0.3125,0,"NICOLA DI RENZO;MARIA LUIGIA VIGLIOTTI;COSIMO LEQUAGLIE;PASQUALE DE NEGRI;NICOLETTA URBANO;GIANPIERO ROMANO;MARIAROSA COCCARO;SERGIO MODONI;RAFFAELE ARDITO;ALFREDO TARTARONE;GIORGIO IVANI;GABRIELLA GIUDICE;F. SCAGLIONE;KIM OVERVAD;GIOVANNI D’ARENA;ELISABET WIRFÄLT;FRANCA ROSSO;PAOLA DELLA CIOPPA;ANTONIO TRAFICANTE;MARIA CRISTINA LERARIO","4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","COSIMO LEQUAGLIE;GABRIELLA GIUDICE;NICOLA DI RENZO;MARIA LUIGIA VIGLIOTTI;NICOLETTA URBANO;SERGIO MODONI;PASQUALE DE NEGRI;GIORGIO IVANI;GIUSEPPINA GALLUCCI;GIANPIERO ROMANO;MARIAROSA COCCARO;RAFFAELE ARDITO;ALFREDO TARTARONE;F. SCAGLIONE;ANTONIO TRAFICANTE;TIZIANA TIRRI;MARÍA SOTO;MASSIMO TORLONTANO;G. DEMARTINI;ANNA CLAUDIA DEL PIANO","1.25;1;0.89;0.68;0.5;0.5;0.39;0.39;0.33;0.31;0.31;0.31;0.31;0.25;0.25;0.25;0.25;0.25;0.25;0.25","NICOLA DI RENZO;MARIA LUIGIA VIGLIOTTI;COSIMO LEQUAGLIE;PASQUALE DE NEGRI;GIANPIERO ROMANO;MARIAROSA COCCARO;SERGIO MODONI;RAFFAELE ARDITO;ALFREDO TARTARONE;GIORGIO IVANI;GABRIELLA GIUDICE;F. SCAGLIONE;GIOVANNI D’ARENA;ANTONIO TRAFICANTE;TIZIANA TIRRI;GIUSEPPINA GALLUCCI;GIOVANNI LODICE;G. DEMARTINI;ANNA MARIA BOCHICCHIO;ANNA CLAUDIA DEL PIANO","4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","COSIMO LEQUAGLIE;GABRIELLA GIUDICE;NICOLA DI RENZO;MARIA LUIGIA VIGLIOTTI;SERGIO MODONI;PASQUALE DE NEGRI;GIORGIO IVANI;GIUSEPPINA GALLUCCI;GIANPIERO ROMANO;MARIAROSA COCCARO;RAFFAELE ARDITO;ALFREDO TARTARONE;F. SCAGLIONE;ANTONIO TRAFICANTE;TIZIANA TIRRI;G. DEMARTINI;ANNA CLAUDIA DEL PIANO;F. FRASCHINI;GIOVANNI LODICE;ANNA MARIA BOCHICCHIO","1.25;1;0.89;0.68;0.5;0.39;0.39;0.33;0.31;0.31;0.31;0.31;0.25;0.25;0.25;0.25;0.25;0.25;0.11;0.11","GIORGIO IVANI;PASQUALE DE NEGRI;ANJA OLSEN;ANNE TJØNNELAND;ANNEKATRIN LUKANOVA;ANTONIA TRICHOPOULOU;CARLA H. VAN GILS;CARLOS A. GONZÁLEZ;CARMEN MARTÍNEZ GARCIA;DIMITRIOS TRICHOPOULOS;DOMENICO PALLI;EILIV LUND;ELIO RÍBOLI;ELISABET WIRFÄLT;EVA ARDANÁZ;EVA LUNDIN;FRANÇOISE CLAVEL‐CHAPELON;FREDERIKE L. BÜCHNER;GURI SKEIE;GÖRAN BERGLUND","76;76;69;69;69;69;69;69;69;69;69;69;69;69;69;69;69;69;69;69","PASQUALE DE NEGRI;ROCCO GALASSO;GIOVANNI STORTO;ANNA CLAUDIA DEL PIANO;GIORGIO IVANI;TIZIANA TIRRI;SERGIO MODONI;ALFREDO TARTARONE;GIANPIERO ROMANO;MARIAROSA COCCARO;NICOLA DI RENZO;RAFFAELE ARDITO;A. CAPOBIANCO;ANNA MARIA BOCHICCHIO;GIOVANNI LODICE;P. DI LEO;ANTONIO TRAFICANTE;COSIMO LEQUAGLIE;F. FRASCHINI;F. SCAGLIONE","76;69;68;21;21;21;12;10;10;10;10;10;8;8;8;8;0;0;0;0","NICOLA DI RENZO;ALFREDO TARTARONE;GIANPIERO ROMANO;MARIAROSA COCCARO;PASQUALE DE NEGRI;RAFFAELE ARDITO;SERGIO MODONI;A. CAPOBIANCO;ANNA CLAUDIA DEL PIANO;ANNA MARIA BOCHICCHIO;GIORGIO IVANI;GIOVANNI LODICE;GIOVANNI STORTO;P. DI LEO;ROCCO GALASSO;TIZIANA TIRRI;ANTONIO TRAFICANTE;COSIMO LEQUAGLIE;F. FRASCHINI;F. SCAGLIONE","4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;0;0;0;0","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;MATHEMATICS","13;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ANESTHESIA;CARDIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;ORGANIC CHEMISTRY;VIROLOGY;BIOCHEMISTRY;CHROMATOGRAPHY;DERMATOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENERAL SURGERY;GENETICS;GEOMETRY;IMMUNOLOGY;MICROBIOLOGY;OPERATIONS RESEARCH;OPTICS;PATHOLOGY;PHARMACOLOGY;QUANTUM MECHANICS;RADIOCHEMISTRY;RADIOLOGY;UROLOGY","9;5;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;LUNG;CHEMOTHERAPY;LUNG CANCER;LYMPHOMA;ADVERSE EFFECT;ANESTHETIC;ANTIBIOTICS;ANTIFUNGAL;ARTERY;BLOCK (PERMUTATION GROUP THEORY);BLOOD FLOW;BLOOD PRESSURE;BUPIVACAINE;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;CYSTIC FIBROSIS;DIPYRIDAMOLE;EDEMA;ELUTION;HAEMOLYSIS;INCIDENCE (GEOMETRY);IODINE;LIPOSOME;LOCAL ANESTHETIC;NAUSEA;OXIDIZING AGENT;PENETRATION (WARFARE);PERIPHERAL;POWER (PHYSICS);PROSPECTIVE COHORT STUDY;PULMONARY INFECTION;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REGIMEN;RESECTION;ROPIVACAINE;STEM CELL;THYROID;TOXICITY;ULTRASOUND;VIRUS;VOMITING","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DOCETAXEL;AMPHOTERICIN B;BLOCKADE;BRACHIAL ARTERY;BURKITT'S LYMPHOMA;CHICKENPOX;CISPLATIN;CORONARY FLOW RESERVE;GENERATOR (CIRCUIT THEORY);HAZARD RATIO;HUMAN LUNG;LEVOBUPIVACAINE;MOTOR BLOCK;NEUTROPENIA;OVARIAN CANCER;PERFORMANCE STATUS;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;QUINOLONE;THYROID CARCINOMA;TOLERABILITY","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PAPILLARY CARCINOMA;PROSTATE DISEASE","1;1",";TAXOIDS;HUMANS;AGED;CARCINOMA, PAPILLARY;FEMALE;MIDDLE AGED;PROSTATIC NEOPLASMS;THYROID NEOPLASMS;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CARCINOMA, NON-SMALL-CELL LUNG;CISPLATIN;ESTRAMUSTINE;MALE;OVARIAN NEOPLASMS;PAIN, POSTOPERATIVE;VASCULAR DISEASES;BRACHIAL ARTERY;BUPIVACAINE","8;7;6;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2","MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HERPESVIRUSES: EPIDEMIOLOGY, PATHOGENESIS, AND MANAGEMENT;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;PREVENTION AND MANAGEMENT OF SURGICAL SITE INFECTIONS;PULMONARY DRUG DELIVERY TECHNIQUES","2;1;1;1;1;1;1;1;1;1;1;1;1","REGIONAL ANESTHESIA;ANAL CANCER;BIOMARKER ANALYSIS;BRACHIAL ARTERY;BRACHIAL ARTERY ASSESSMENT;BURKITT'S LYMPHOMA;CARDIAC IMAGING;CHICKENPOX;CORONARY FLOW RESERVE;DIPYRIDAMOLE;ESTRAMUSTINE;HAEMOLYSIS;HERPES ZOSTER;HUMAN LUNG;LEUKEMIA STEM CELLS;LEVOBUPIVACAINE;LUNG REGENERATION;LUNG STEM CELLS;METASTATIC PROSTATE CANCER;MOTOR BLOCK","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LUNG CANCER;WEEKLY DOCETAXEL;ABNORMAL LUNG;ACUTE HAEMOLYSIS;ADVANCED NON-SMALL;AGGRESSIVE NON-HODGKINS;ARTERY DISEASE;ARTERY FLOW-MEDIATED;ATRIO-VENTRICULAR BLOCK;BRACHIAL ARTERY;BURKITT-LIKE LYMPHOMA;CARDIAC LOCALIZATION;CAUDAL ANESTHESIA;CELL APHAERESIS;CELL LUNG;CHOICE THERAPY;COMPLETE ATRIO-VENTRICULAR;CORONARY FLOW;CYSTIC FIBROSIS;DOSE-FINDING STUDY;EPITHELIAL OVARIAN;EUROPEAN PROSPECTIVE;FIRST-LINE THERAPY;FLOW RESERVE;FLOW-MEDIATED DILATION;HORMONE-REFRACTORY METASTATIC;HUMAN LUNG;II STUDY;IODINE- UPTAKE;LIPOSOMAL AMPHOTERICIN","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OVARIAN CANCER;HISTOLOGIC SUBTYPE;GARLICONION VEGETABLES;ACCRUED CONSUMPTION;BENEFICIAL EFFECT;BORDERLINE SIGNIFICANT;CANCER GARLICONION;CANCER INCIDENCE;CANCER RESECTED;CANCER RISKOVERALL;DEVELOP OVARIAN;DIETARY QUESTIONNAIRES;DIFFERENTIAL EFFECTS;DONETOTAL INTAKE;EPITHELIAL OVARIAN;EUROPEAN PROSPECTIVE;FRUITING ROOT;HAZARD REGRESSION;INVASIVE EPITHELIAL;IV ADMINISTRATION;LEAFY VEGETABLES;LIPOSOMAL AMPHOTERICIN;LUNG CANCER;MODELS HISTOLOGIC;MULTIVARIABLE HAZARD;NUTRITION STUDY;PERSON-YEARS VERIFIED;PRIMARY INVASIVE;PROSPECTIVE INVESTIGATION;REDUCED RISK","7;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.07,14.088,14.09,14.088,14.088,3,3,3,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,3,3,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,55,55,55,55,55,55,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2006,19,14.2631578947368,1.63157894736842,0.612903225806452,0.368421052631579,0.0526315789473684,0.473684210526316,0.105263157894737,0,7,4,0,6,0.37,0.21,0,0.32,24.79,0.485323879842647,0.0526315789473684,0.947368421052632,0,0.299423853558551,0.314285714285714,0,0.0888888888888889,"PELLEGRINO MUSTO;NICOLA DI RENZO;STEFANO LUMINARI;MARIO BOCCADORO;ANTONIETTA FALCONE;STEFANO SACCHI;MARIA LUIGIA VIGLIOTTI;ELISA FEUDALE;ALESSANDRO PULSONI;GIOVANNI D’ARENA;SAMANTHA POZZI;EMILIO IANNITTO;GIUSEPPE LEONE;FABRIZIO MARCUCCI;GIUSEPPE PIETRANTUONO;FIORELLA D′AURIA;FRANCESCA GAY;ANTONIO PINTO;MASSIMO FEDERICO;ROBERTO GUARIGLIA","6;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ELISA FEUDALE;PELLEGRINO MUSTO;MARIA LUIGIA VIGLIOTTI;PASQUALE CIANCI;CLEMENTE VERRUSIO;GIUSEPPE LA TORRE;NICOLA DI RENZO;STEFANO LUMINARI;STEFANO SACCHI;MARIO BOCCADORO;ANTONIETTA FALCONE;MASSIMO FEDERICO;MAURA BRUGIATELLI;ANTONELLA MONTANINI;GIOVANNI D’ARENA;ANTONIO PINTO;GIANPAOLO MARCACCI;ALESSANDRO PULSONI;CARLO BARONE;MAURO CIGNARELLI","0.32;0.32;0.27;0.25;0.25;0.25;0.25;0.21;0.18;0.18;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14","PELLEGRINO MUSTO;NICOLA DI RENZO;MARIA LUIGIA VIGLIOTTI;ELISA FEUDALE;GIOVANNI D’ARENA;GIUSEPPE PIETRANTUONO;FIORELLA D′AURIA;ROBERTO GUARIGLIA;MARIALUCIA BARONE;GIUSEPPE LA TORRE;ALESSANDRO SGAMBATO;ALDO CAMMAROTA;POTITO ROSARIO SCALZULLI;GIOVANNA MANSUETO;ANNA MARIA BOCHICCHIO;SERGIO MODONI;ACHILLE CITTADINI;ROCCO GALASSO;G. MARINO","6;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ELISA FEUDALE;PELLEGRINO MUSTO;MARIA LUIGIA VIGLIOTTI;GIUSEPPE LA TORRE;NICOLA DI RENZO;GIOVANNI D’ARENA;SERGIO MODONI;ALDO CAMMAROTA;GIUSEPPE PIETRANTUONO;FIORELLA D′AURIA;ROBERTO GUARIGLIA;MARIALUCIA BARONE;ALESSANDRO SGAMBATO;ACHILLE CITTADINI;G. MARINO;GIOVANNA MANSUETO;POTITO ROSARIO SCALZULLI;ANNA MARIA BOCHICCHIO;ROCCO GALASSO","0.32;0.32;0.27;0.25;0.25;0.17;0.14;0.12;0.11;0.11;0.11;0.11;0.1;0.1;0.1;0.09;0.07;0.05;0.05","PELLEGRINO MUSTO;ALESSANDRO PULSONI;ALFONSO MELE;AMALIA DE RENZO;ANGELA CANDIDO;ANNA MARIA BARBUI;BRUNO MARTINO;ELISABETTA MADONNA;ELVIRA BIANCO;EMILIO IANNITTO;ENEA SPADA;FABRIZIO MARCUCCI;LIVIO PAGANO;MARCO MONTANARO;MARIA RAPICETTA;PAOLA CHIONNE;RODOLFO COTICHINI;SYLVAIN DORÉ;VINCENZO LISO;NICOLA DI RENZO","160;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;130","PELLEGRINO MUSTO;NICOLA DI RENZO;ROCCO GALASSO;ELISA FEUDALE;POTITO ROSARIO SCALZULLI;ACHILLE CITTADINI;ALESSANDRO SGAMBATO;G. MARINO;MARIA LUIGIA VIGLIOTTI;SERGIO MODONI;GIOVANNA MANSUETO;ANNA MARIA BOCHICCHIO;ALDO CAMMAROTA;FIORELLA D′AURIA;GIUSEPPE LA TORRE;GIUSEPPE PIETRANTUONO;MARIALUCIA BARONE;ROBERTO GUARIGLIA;GIOVANNI D’ARENA","160;130;75;23;23;22;22;19;16;16;13;12;1;1;1;1;1;1;0","PELLEGRINO MUSTO;NICOLA DI RENZO;FIORELLA D′AURIA;GIUSEPPE LA TORRE;GIUSEPPE PIETRANTUONO;MARIALUCIA BARONE;ROBERTO GUARIGLIA;ACHILLE CITTADINI;ALDO CAMMAROTA;ALESSANDRO SGAMBATO;ANNA MARIA BOCHICCHIO;ELISA FEUDALE;G. MARINO;GIOVANNA MANSUETO;MARIA LUIGIA VIGLIOTTI;POTITO ROSARIO SCALZULLI;ROCCO GALASSO;SERGIO MODONI;GIOVANNI D’ARENA","6;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE","19;3;2;1","INTERNAL MEDICINE;GASTROENTEROLOGY;SURGERY;PATHOLOGY;ONCOLOGY;CANCER RESEARCH;IMMUNOLOGY;RADIOLOGY;CELL BIOLOGY;GENERAL SURGERY;ASTROBIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;FOOD SCIENCE;QUANTUM MECHANICS;VIROLOGY;WORLD WIDE WEB","18;10;7;6;5;3;3;3;2;2;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;LYMPHOMA;MULTIPLE MYELOMA;REGIMEN;BONE MARROW;COHORT;CONFIDENCE INTERVAL;DEXAMETHASONE;IMMUNOHISTOCHEMISTRY;PREDNISONE;THYROID;TRANSPLANTATION;VIRUS;ANEMIA;ANTHROPOMETRY;BIOPSY;BODY MASS INDEX;CARCINOID TUMORS;CONCOMITANT;CYST;DAIRY FOODS;DISEASE;DUODENUM;EPITHELIUM;EXTRACELLULAR MATRIX;FOLLICULAR PHASE;FOOD GROUP;GENE;HEAD AND NECK;HEMATOLOGY;HEPATITIS B;INDEX (TYPOGRAPHY);KINASE;LEUKEMIA;LICHEN SCLEROSUS;LYMPH NODE;LYMPHANGIOMA;LYMPHOCYTOSIS;MEDIASTINUM;MEDITERRANEAN DIET;MITOMYCIN C;MYELOID LEUKEMIA;ODDS RATIO;RADIATION THERAPY;RED MEAT;REFRACTORY (PLANETARY SCIENCE);RETROSPECTIVE COHORT STUDY;TERM (TIME);TOXICITY;WHITE MEAT;WHOLE GRAINS","6;6;5;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RITUXIMAB;THALIDOMIDE;BORTEZOMIB;CISPLATIN;CYCLOPHOSPHAMIDE;HEPATITIS C VIRUS;MELPHALAN;NEUTROPENIA;AUTOIMMUNE HEMOLYTIC ANEMIA;BREAST CANCER;CARCINOGENESIS;CD20;CERVICAL CANCER;CERVIX;CHROMOGRANIN A;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;CUMULATIVE INCIDENCE;DIFFUSE LARGE B-CELL LYMPHOMA;DOCETAXEL;DUODENAL BULB;EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION;FINE-NEEDLE ASPIRATION;FLUOROURACIL;FOLLICULAR LYMPHOMA;GASTRECTOMY;GEMCITABINE;GENE EXPRESSION;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS B VIRUS;HODGKIN LYMPHOMA;IMATINIB;LAMININ;LENALIDOMIDE;METASTASIS;NON-HODGKIN'S LYMPHOMA;OVARIAN CANCER;PERINEURAL INVASION;PLASMA CELL LEUKEMIA;PROSTATE;PROSTATE CANCER;REFINED GRAINS;SALVAGE THERAPY;SYNAPTOPHYSIN;SYSTEMIC MASTOCYTOSIS;THYROID NODULES","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BILLROTH I;CERVICAL LYMPH NODES;DEBULKING;DNA METHYLATION;DYSTROGLYCAN;FEBRILE NEUTROPENIA;FLUDARABINE;HBSAG;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC INDEX;IRINOTECAN;LNCAP;NEUROENDOCRINE DIFFERENTIATION;VINCRISTINE;VINORELBINE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MALE;MIDDLE AGED;ADENOCARCINOMA;LYMPHOMA, NON-HODGKIN;THYROID GLAND;THYROID NEOPLASMS;TREATMENT OUTCOME;;ADULT;LYMPHOMA, B-CELL;MULTIPLE MYELOMA;AGED, 80 AND OVER;ANEMIA, HEMOLYTIC, AUTOIMMUNE;BIOMARKERS, TUMOR;CAMPTOTHECIN;CARCINOMA, PAPILLARY","14;11;8;8;8;8;7;7;7;6;6;5;5;5;5;4;4;4;4;4","LYMPHOID NEOPLASMS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GASTRIC CANCER RESEARCH AND TREATMENT;HEPATITIS B INFECTION AND TREATMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;STRUCTURE AND FUNCTION OF G PROTEIN-COUPLED RECEPTORS","4;3;2;2;1;1;1;1;1;1;1;1","REGIMEN;INTERNATIONAL MYELOMA WORKING GROUP;MANTLE CELL LYMPHOMA;MELPHALAN;THYROID NODULES;B-CELL RECEPTOR SIGNALING;BILLROTH I;CANCER;CARCINOID TUMORS;CERVICAL LYMPH NODES;CHROMOGRANIN A;CONCOMITANT;CUMULATIVE INCIDENCE;DAIRY FOODS;DEBULKING;DIETARY PATTERNS;DIFFERENTIATED THYROID CANCER;DNA METHYLATION;DU145;DUODENAL BULB","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BONE MARROW;NON-HODGKINS LYMPHOMA;ABERRANT EXPRESSION;AGGRESSIVE NON-HODGKINS;AGGRESSIVE NONHODGKINS;ANTIVIRAL TREATMENTS;ASPIRATION BIOPSY;AUTOIMMUNE HEMOLYTIC;B-CELL LYMPHOCYTOSIS;B-CELL LYMPHOMAS;B-CELL NON-HODGKINS;BIOPSY FNAB;BREAST CANCER;CELL DIFFERENTIATION;CELL LEUKEMIA;CELL SUPPORT;CHRONIC LYMPHOCYTIC;CLINICAL OUTCOME;CYSTIC LYMPHANGIOMA;DAP-KINASE HYPERMETHYLATION;DEI LINFOMII;DIAGNOSING THYROID;DIETARY PATTERN;DIFFERENTIATED THYROID;DIFFERENTIATION COMPREHENSION;DUODENAL CARCINOIDS;ELDERLY MYELOMA;ELDERLY PARTICIPANTS;EPIC-ITALY COHORT;FINE NEEDLE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL LINES;CHROMOGRANIN-A SYNAPTOPHYSIN;ANTI-CD MONOCLONAL;CLL-ASSOCIATED AIHA;HUMAN PROSTATE;MICROSCOPIC PERINEURAL;MONOCLONAL ANTIBODY;NEUROD EXPRESSION;NEUROENDOCRINE DIFFERENTIATION;PATIENTS RECEIVED;PERINEURAL INVASION;PROSTATE CELL;ABSOLUTE LYMPHOCYTE;ACTIVELY EXPRESSED;ALTERNATIVE TREATMENT;AMINO TRANSFERASES;ANALYSIS NEUROD;ANEMIA AIHA;ANTIBODY RITUXIMAB;ANTIGLOBULIN TEST;AUTOIMMUNE HEMOLYTIC;AUTOIMMUNE THROMBOCYTOPENIA;BASELINE PROSTATE;CAMP EXPOSURE;CAMP-TREATED EPN;CANCER PCA;CARDIAC FAILURE;CD ANTIBODIES;CD STAINING;CELL TRANSFUSIONS","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",2,0.11,2,3,3,3,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,39,39,39,39,39,39,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2007,23,10.5217391304348,2.8695652173913,0.348484848484849,0.695652173913043,0.391304347826087,0.782608695652174,0.217391304347826,0,12,3,4,3,0.52,0.13,0.17,0.13,24,0.454752238139791,0.130434782608696,0.521739130434783,0,0.506117088836787,0.431818181818182,0.397515527950311,0.397993311036789,"PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;ROBERTO GUARIGLIA;ORESTE VILLANI;FIORELLA D′AURIA;NICOLETTA URBANO;SERGIO MODONI;MARIA CARMEN MARTORELLI;GIOVANNI D’ARENA;FELICETTO FERRARA;TOMMASINA GUGLIELMELLI;ANTONIETTA FALCONE;GRAZIA SANPAOLO;ANTONIO PINTO;PASQUALE CIANCI;FAUSTO ROSSINI;ALFREDO TARTARONE;COSIMO LEQUAGLIE;ANIELLO DELLA MORTE;GIUSEPPE LA TORRE","9;6;6;6;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2","NICOLETTA URBANO;SERGIO MODONI;PASQUALE CIANCI;GIUSEPPE LA TORRE;PELLEGRINO MUSTO;COSIMO LEQUAGLIE;ANIELLO DELLA MORTE;GABRIELLA GIUDICE;ROBERTO GUARIGLIA;GIUSEPPE PIETRANTUONO;ORESTE VILLANI;FIORELLA D′AURIA;MARIA CARMEN MARTORELLI;G GUARINO;PASQUALINA MODANO;TIZIANA TIRRI;PASQUALE DE NEGRI;GIANLUCA PATERNOSTER;VINCENZO SURIANO;MATTEO ZINGRILLO","1.39;1.39;0.83;0.83;0.79;0.58;0.58;0.58;0.56;0.54;0.54;0.46;0.39;0.33;0.25;0.25;0.25;0.25;0.25;0.25","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;ROBERTO GUARIGLIA;ORESTE VILLANI;FIORELLA D′AURIA;NICOLETTA URBANO;SERGIO MODONI;MARIA CARMEN MARTORELLI;ALFREDO TARTARONE;COSIMO LEQUAGLIE;ANIELLO DELLA MORTE;GIUSEPPE LA TORRE;GABRIELLA GIUDICE;ALESSANDRO SGAMBATO;PASQUALINA MODANO;TIZIANA TIRRI;PASQUALE DE NEGRI;L. IADANZA;A. CAPOBLANCO;VINCENZO FUSCO","9;6;6;6;5;4;4;4;2;2;2;2;2;1;1;1;1;1;1;1","NICOLETTA URBANO;SERGIO MODONI;GIUSEPPE LA TORRE;PELLEGRINO MUSTO;COSIMO LEQUAGLIE;ANIELLO DELLA MORTE;GABRIELLA GIUDICE;ROBERTO GUARIGLIA;GIUSEPPE PIETRANTUONO;ORESTE VILLANI;FIORELLA D′AURIA;MARIA CARMEN MARTORELLI;PASQUALINA MODANO;TIZIANA TIRRI;PASQUALE DE NEGRI;GIANLUCA PATERNOSTER;VINCENZO SURIANO;MATTEO ZINGRILLO;ALFREDO TARTARONE;A. CAPOBLANCO","1.39;1.39;0.83;0.79;0.58;0.58;0.58;0.56;0.54;0.54;0.46;0.39;0.25;0.25;0.25;0.25;0.25;0.25;0.2;0.12","PELLEGRINO MUSTO;GIOVANNI D’ARENA;FELICETTO FERRARA;ROBERTO GUARIGLIA;FAUSTO ROSSINI;GIANLUCA PATERNOSTER;PASQUALE DE NEGRI;PASQUALINA MODANO;TIZIANA TIRRI;GIUSEPPE PIETRANTUONO;ORESTE VILLANI;ANTONIO PALUMBO;TOMMASINA GUGLIELMELLI;FRANCESCA GAY;NUNZIO FILARDI;VINCENZO PITINI;ANDREAS REITER;ANDREW CLARK;CLAIRE CURTIS;FRANCIS GRAND","253;156;152;104;96;94;94;94;94;91;91;87;87;82;82;82;80;80;80;80","PELLEGRINO MUSTO;ROBERTO GUARIGLIA;GIANLUCA PATERNOSTER;PASQUALE DE NEGRI;PASQUALINA MODANO;TIZIANA TIRRI;GIUSEPPE PIETRANTUONO;ALFREDO TARTARONE;ACHILLE CITTADINI;ALESSANDRO SGAMBATO;ANTONI MARGALIDA;L. IADANZA;S. ZUCCA;VINCENZO FUSCO;NICOLETTA URBANO;SERGIO MODONI;ROCCO GALASSO;FIORELLA D′AURIA;ORESTE VILLANI;MATTEO ZINGRILLO","251;102;94;94;94;94;89;69;49;49;47;45;45;45;37;37;27;20;20;12","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;NICOLETTA URBANO;ROBERTO GUARIGLIA;SERGIO MODONI;FIORELLA D′AURIA;ORESTE VILLANI;ALFREDO TARTARONE;MARIA CARMEN MARTORELLI;ACHILLE CITTADINI;ALESSANDRA BENVENUTO;ALESSANDRO SGAMBATO;ANTONI MARGALIDA;CARLA PAPA;ELISA FEUDALE;GIANLUCA PATERNOSTER;L. IADANZA;LUIGINA DIGIOVANNANTONIO;MATTEO ZINGRILLO;PASQUALE DE NEGRI","7;4;4;4;4;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATERIALS SCIENCE;SOCIOLOGY;CHEMISTRY;ECONOMICS;HISTORY;PSYCHOLOGY","22;4;4;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY;NUCLEAR MEDICINE;CANCER RESEARCH;IMMUNOLOGY;RADIOLOGY;GENETICS;OPTICS;ANIMAL SCIENCE;ARCHAEOLOGY;ARTIFICIAL INTELLIGENCE;ASTROBIOLOGY;BIOCHEMISTRY;CELL BIOLOGY;CHROMATOGRAPHY;DEMOGRAPHY;ECOLOGY;ENVIRONMENTAL HEALTH;FINANCE;GENERAL SURGERY;MEDICAL PHYSICS;METALLURGY;NUCLEAR PHYSICS;NURSING;PROGRAMMING LANGUAGE;PSYCHOTHERAPIST;QUANTUM MECHANICS;SOCIAL SCIENCE;UROLOGY;VIROLOGY;ZOOLOGY","17;10;7;6;5;4;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;MULTIPLE MYELOMA;CHEMOTHERAPY;ADVERSE EFFECT;ANTIBODY;LYMPHOMA;ALTERNATIVE MEDICINE;ANEMIA;BONE MARROW;DOSIMETRY;GENE;RECEPTOR;SCANNER;THORACOTOMY;THYROID;TRANSPLANTATION;ABDOMEN;ADJUVANT;ANALYSER;ASSOCIATION (PSYCHOLOGY);ASYMPTOMATIC;BEAM (STRUCTURE);BOLUS (DIGESTION);BROOD;CEMENT;CHRONIC MYELOID LEUKAEMIA;COMPUTED TOMOGRAPHY;CONSUMPTION (SOCIOLOGY);DETECTOR;DIARRHEA;DISEASE;DISSECTION (MEDICAL);ERYTHROPOIETIN;EXTRACELLULAR MATRIX;HATCHING;HEMOLYSIS;HEMOLYTIC ANEMIA;HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;IMAGING PHANTOM;INCIDENCE (GEOMETRY);INCUBATION;IODINE;ION;LIQUID SCINTILLATION COUNTING;LUNG;LUNG CANCER;LYMPH NODE;MAGNETIC RESONANCE IMAGING;MESOTHELIOMA;MONITOR UNIT;MYELOID LEUKEMIA;NAUSEA;NEST (PROTEIN STRUCTURAL MOTIF);OSTEOPOROSIS;PEG RATIO;PERCUTANEOUS;POPULATION;PREDNISOLONE;QUALITY OF LIFE (HEALTHCARE);RADIONUCLIDE;RADIONUCLIDE THERAPY;REFRACTORY (PLANETARY SCIENCE);REPRODUCTION;RESECTION;SARCOMA;SIGNAL (PROGRAMMING LANGUAGE);SPLEEN;STROMAL CELL;TOXICITY;VERTEBRAL BODY;VISUAL ANALOGUE SCALE","5;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AUTOLOGOUS STEM-CELL TRANSPLANTATION;BORTEZOMIB;CD20;LENALIDOMIDE;NEUTROPENIA;PLASMA CELL LEUKEMIA;RITUXIMAB;THALIDOMIDE;THYROID CANCER;AUTOANTIBODY;AUTOIMMUNE HEMOLYTIC ANEMIA;AVIAN CLUTCH SIZE;AZATHIOPRINE;B CELL;BONE CEMENT;BREAST CANCER;BULLA (SEAL);CANCER THERAPY;CARCINOGENESIS;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;CYCLOPHOSPHAMIDE;DARBEPOETIN ALFA;DIAPHRAGMATIC BREATHING;DOSE PROFILE;DOSIMETER;ERYTHROPOIESIS;FLEDGE;FLUOROURACIL;FUSION GENE;GENOTYPE;GIST;GOITER;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HOUNSFIELD SCALE;IMATINIB;IONIZATION;ISOCENTER;LAMININ;LOW BACK PAIN;LYMPHADENECTOMY;LYMPHOPROLIFERATIVE DISORDERS;MANTLE CELL LYMPHOMA;MONOCLONAL ANTIBODY;MUCOSITIS;MYELODYSPLASTIC SYNDROMES;OVARIAN CANCER;PEPTIDE RECEPTOR;PERCUTANEOUS VERTEBROPLASTY;PLASMACYTOMA;PNEUMONECTOMY;POLYMERASE CHAIN REACTION;PROSTATE;PROSTATE CANCER;PROTEASOME INHIBITOR;SPLENECTOMY;THYROGLOBULIN;THYROID CARCINOMA;TOLERABILITY;TYROSINE KINASE;VERTEBRAL COMPRESSION FRACTURE;WEDGE RESECTION","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABL;BREAKPOINT;DYSTROGLYCAN;FEBRILE NEUTROPENIA;FILGRASTIM;FLUORESCENCE IN SITU HYBRIDIZATION;IMATINIB MESYLATE;IONIZATION CHAMBER;LNCAP;METASTATIC BREAST CANCER;OSWESTRY DISABILITY INDEX;PAPILLARY THYROID CANCER;PDGFRA;RADIOIMMUNOTHERAPY","1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;RADIOMETRY;AGED;FEMALE;MALE;MIDDLE AGED;GOITER, NODULAR;HISTIOCYTOMA, MALIGNANT FIBROUS;PROSTATIC NEOPLASMS;RETROPERITONEAL NEOPLASMS;ANTINEOPLASTIC AGENTS;IODINE RADIOISOTOPES;THYROID NEOPLASMS;ADULT;AGED, 80 AND OVER;ANTIBODIES, MONOCLONAL;DYSTROGLYCANS;FRACTURES, COMPRESSION;GRANULOCYTE COLONY-STIMULATING FACTOR","13;9;8;7;7;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DISEASES RELATED TO BLOOD GROUP VARIANTS;ECOLOGICAL IMPACT OF INVASIVE SPECIES ON ISLANDS;GASTRIC CANCER RESEARCH AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;HYPEREOSINOPHILIC SYNDROME AND RELATED DISORDERS;LYMPHOID NEOPLASMS;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ROLE OF ERYTHROPOIETIN IN DISEASE TREATMENT AND MANAGEMENT;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;SARCOMA RESEARCH AND TREATMENT;SPINE SURGERY TECHNIQUES AND TECHNOLOGIES;THE P53 SIGNALING NETWORK IN CANCER RESEARCH","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AUTOLOGOUS STEM-CELL TRANSPLANTATION;CANCER THERAPY;PLASMA CELL LEUKEMIA;THORACOTOMY;ABL;ALPHA PARTICLE THERAPY;ANALYSER;ASSOCIATION (PSYCHOLOGY);AVIAN CLUTCH SIZE;AVIAN ECOLOGY;BIOMARKER ANALYSIS;BISPHOSPHONATES;BOLUS (DIGESTION);BONE CEMENT;BREAKPOINT;BULLA (SEAL);CANCER TREATMENT;CHRONIC MYELOID LEUKAEMIA;CLINICAL IMPLEMENTATION;CLINICAL PRACTICE GUIDELINES","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CELL LEUKEMIA;PLASMA CELL;ADJUVANT SETTING;ADULT PATIENTS;ADVANCED MANTLE;ANIMAL FOODS;APPROXIMATION DOSIMETRY;AQUILA ADALBERTI;ASYMPTOMATIC MYELOMA;AUGMENTATION PROCEDURES;AUTOIMMUNE HEMOLYTIC;AUTOLOGOUS STEM;BETA-COUNTING SYSTEMS;BREAST CANCER;BREEDING BIOLOGY;CANCER CELLS;CANCER PRELIMINARY;CANCER RESECTION;CANCER THERAPY;CASE-CONTROL STUDY;CELL COMPARTMENTALISATION;CELL DIFFERENTIATION;CELL LYMPOMA;CELL TRANPLANTATION;CHRONIC EOSINOPHILIC;CMF ADMINISTRATION;COMPARING ZOLEDRONATE;COMPRESSION FRACTURES;CYCLOPHOSPHAMIDE RBC;DARBEPOETIN MCG","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMAN PROSTATE;PROSTATE CANCER;DG EXPRESSION;RESPONSES DEFINED;CANCER CELLS;COMPLETE RESPONSES;EPP SUBMITTED;FDG-PETTC SCAN;FREQUENTLY REDUCED;HOSPITAL STAY;LOW SUV;PARTIAL RESPONSES;PATIENTS UNDERWENT;PERITONEAL METASTASES;RECEIVED BORTEZOMIB;RESECTABLE LUNG;SUBMITTED PATIENTS;ABLATION THERAPY;ABSTRACT PROSTATE;ACCURATELY PREDICT;ACHIEVED CYTOGENETIC;ADHESION MOLECULE;ADVANCED MM;ADVERSE CLINICAL;ADVERSE EVENTS;AGGRESSIVE VARIANT;AMERICAN CANCER;ANALYSIS CORRELATION;ANALYSIS REVEALED;ANDROGEN ABLATION","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1",3,0.13,3,6,6,6,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,2,2,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,46,46,46,46,46,46,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2008,32,12.21875,1.9375,0.516129032258065,0.3125,0.28125,0.125,0.21875,1,19,4,2,5,0.59,0.12,0.06,0.16,34.91,0.636141060298525,0.09375,0.84375,0,0.43507539291012,0.466666666666667,0.557971014492754,0.491228070175439,"PELLEGRINO MUSTO;MARIO BOCCADORO;ANTONIO PALUMBO;ANTONIETTA FALCONE;MARIA TERESA PETRUCCI;SARA GALIMBERTI;VINCENZO CALLEA;FORTUNATO MORABITO;TOMMASO CARAVITA;LUCA BALDINI;GIUSEPPE PIETRANTUONO;VINCENZO FUSCO;FRANCESCA GAY;FRANCESCO DI RAIMONDO;VINCENZO METTIVIER;LUCA PEZZULLO;ORESTE VILLANI;SARA BRINGHEN;MICHÈLE CAVO;COSIMO LEQUAGLIE","15;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","PELLEGRINO MUSTO;ANTONI MARGALIDA;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;MAURO HERNÁNDEZ;ANTONI MARGALIDA;A. CAPOBIANCO;VINCENZO FUSCO;MARGHERITA GARRAMONE;DANIELA RITA MARASCO;MARIO BOCCADORO;ANTONIO PALUMBO;ANGELA VENETUCCI;GIUSEPPINA GALLUCCI;MARIAROSA COCCARO;VINCENZO SURIANO;MARIA TERESA PETRUCCI;VINCENZO METTIVIER;LUCA PEZZULLO;ANTONIETTA FALCONE","1.05;1;0.64;0.64;0.5;0.5;0.43;0.4;0.39;0.39;0.35;0.35;0.33;0.33;0.33;0.33;0.3;0.28;0.28;0.28","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;VINCENZO FUSCO;ORESTE VILLANI;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;A. CAPOBIANCO;ANTONIO TRAFICANTE;ANGELA VENETUCCI;MARGHERITA GARRAMONE;GIUSEPPINA GALLUCCI;DANIELA RITA MARASCO;ROBERTO GUARIGLIA;MARIAROSA COCCARO;VINCENZO SURIANO;PASQUALINA MODANO;TIZIANA TIRRI;PASQUALE DE NEGRI;ANTONIA ZONNO;FIORELLA D′AURIA","15;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1","PELLEGRINO MUSTO;ANTONI MARGALIDA;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;ANTONI MARGALIDA;A. CAPOBIANCO;VINCENZO FUSCO;MARGHERITA GARRAMONE;DANIELA RITA MARASCO;ANGELA VENETUCCI;GIUSEPPINA GALLUCCI;MARIAROSA COCCARO;VINCENZO SURIANO;T. FABRIZIO;ANTONIO TRAFICANTE;GIUSEPPE PIETRANTUONO;ORESTE VILLANI;ROBERTO GUARIGLIA;PASQUALINA MODANO;TIZIANA TIRRI","1.05;1;0.64;0.64;0.5;0.43;0.4;0.39;0.39;0.33;0.33;0.33;0.33;0.25;0.22;0.21;0.18;0.14;0.14;0.14","PELLEGRINO MUSTO;ANTONIO PALUMBO;MARIO BOCCADORO;TOMMASO CARAVITA;ANTONIETTA FALCONE;FRANCESCA GAY;VINCENZO CALLEA;SARA BRINGHEN;MICHÈLE CAVO;PATRIZIA FALCO;ANNA MARINA LIBERATI;ANTONIO CAPALDI;DANIELE DERUDAS;FEDERICA CAVALLO;GIOVANNINO CICCONE;GIULIA BENEVOLO;MARCO MONTANARO;RENATO ZAMBELLO;ROBERTO RIA;SYLVAIN DORÉ","779;691;690;682;510;489;485;484;382;366;360;360;360;360;360;360;360;360;360;360","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;ANTONI MARGALIDA;GIUSEPPINA IMPROTA;GIOVANNI STORTO;VINCENZO FUSCO;A. CAPOBIANCO;ANGELA VENETUCCI;GIUSEPPINA GALLUCCI;MARIAROSA COCCARO;VINCENZO SURIANO;ROCCO GALASSO;ORESTE VILLANI;T. FABRIZIO;ANTONIA ZONNO;BEATRICE TEDESCO;FIORELLA D′AURIA;MARIA CARMEN MARTORELLI;ROBERTO GUARIGLIA;ROSA LEROSE","779;180;159;91;35;33;20;19;19;19;19;13;4;2;1;1;1;1;1;1","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;ORESTE VILLANI;VINCENZO FUSCO;A. CAPOBIANCO;ANGELA VENETUCCI;ANTONI MARGALIDA;GIUSEPPINA GALLUCCI;MARIAROSA COCCARO;ROBERTO GUARIGLIA;VINCENZO SURIANO;ANTONIA ZONNO;BEATRICE TEDESCO;FIORELLA D′AURIA;GIOVANNI STORTO;GIUSEPPINA IMPROTA;MARIA CARMEN MARTORELLI;ROCCO GALASSO;ROSA LEROSE;T. FABRIZIO","15;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;MATERIALS SCIENCE;ECONOMICS;ENGINEERING;ENVIRONMENTAL SCIENCE;MATHEMATICS","30;7;4;2;1;1;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;SURGERY;ONCOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;RADIOLOGY;ECOLOGY;GENETICS;ASTROBIOLOGY;CARDIOLOGY;GENERAL SURGERY;NURSING;ANATOMY;CANCER RESEARCH;COMPOSITE MATERIAL;ELECTRONIC ENGINEERING;ENDOCRINOLOGY;ENVIRONMENTAL ENGINEERING;GEOMETRY;INTENSIVE CARE MEDICINE;MACROECONOMICS;METEOROLOGY;NUCLEAR MEDICINE;NUCLEAR PHYSICS;PATHOLOGY;PEDIATRICS;PHYSICAL THERAPY;PHYSIOLOGY;PSYCHIATRY;TOXICOLOGY;UROLOGY;ZOOLOGY","26;16;15;9;5;5;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CHEMOTHERAPY;MULTIPLE MYELOMA;CANCER;LYMPHOMA;POPULATION;TRANSPLANTATION;ASYMPTOMATIC;CLINICAL TRIAL;REGIMEN;ADVERSE EFFECT;ANEMIA;ANTIBODY;BONE MARROW;COHORT;GENE;LUNG CANCER;PERFUSION;PREDATION;PREDNISONE;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REFRACTORY (PLANETARY SCIENCE);VULTURE","14;11;7;5;5;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BORTEZOMIB;NEUTROPENIA;BREAST CANCER;LENALIDOMIDE;RITUXIMAB;AUTOLOGOUS STEM-CELL TRANSPLANTATION;MELPHALAN;THALIDOMIDE;CARDIOTOXICITY;DIFFUSE LARGE B-CELL LYMPHOMA;FOLLICULAR LYMPHOMA;MAINTENANCE THERAPY;MONOCLONAL ANTIBODY;MYELODYSPLASTIC SYNDROMES;A549 CELL;ACCIPITRIDAE;ADENOCARCINOMA;ALLELE;BLEOMYCIN;CD20;CHEMOTHERAPY REGIMEN;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;CYTOPENIA;DNA REPAIR;DOXORUBICIN;ENDANGERED SPECIES;EPIDERMAL GROWTH FACTOR RECEPTOR;FLUORODEOXYGLUCOSE;FLUOROURACIL;GENE EXPRESSION;GENOTYPE;GRANULOCYTE COLONY-STIMULATING FACTOR;HAZARD RATIO;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;IMATINIB;IMMUNOGLOBULIN G;INSULIN RESISTANCE;MALIGNANT PLEURAL EFFUSION;MANTLE CELL LYMPHOMA;MEDIAN FOLLOW-UP;MENSTRUAL CYCLE;METABOLIC SYNDROME;METASTASIS;MULTICENTER STUDY;NEUTRON CAPTURE;NEUTRON DETECTION;NEUTRON FLUX;NEUTRON SOURCE;NEUTRON TEMPERATURE;NON-HODGKIN'S LYMPHOMA;PESTICIDE RESIDUE;PHASES OF CLINICAL RESEARCH;PLANT NUTRITION;PLASMA CELL;PLASMA CELL LEUKEMIA;PLEURODESIS;PROGRESSION-FREE SURVIVAL;RETINOIC ACID;SALVAGE THERAPY;SYSTEMIC MASTOCYTOSIS;THYROGLOBULIN;THYROID CANCER;THYROID CARCINOMA;THYROIDECTOMY;VALPROIC ACID","5;5;4;4;4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;ABSOLUTE NEUTROPHIL COUNT;FEBRILE NEUTROPENIA;BENDAMUSTINE;DNA METHYLATION;ELECTROCHEMOTHERAPY;EPIRUBICIN;ERLOTINIB;FILGRASTIM;FLUDARABINE;FOLINIC ACID;IMMUNOGLOBULIN A;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MONOCLONAL;MONOGASTRIC;MULTICENTER TRIAL;NEUTRON CROSS SECTION;NON-SMALL CELL LUNG CANCER (NSCLC);RADIOIMMUNOTHERAPY;RADIOIODINE THERAPY;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;TRETINOIN","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;MULTIPLE MYELOMA;AGED;MIDDLE AGED;FEMALE;ADULT;MALE;ADENOCARCINOMA;BONE NEOPLASMS;MASTOCYTOSIS;ADENOCARCINOMA, FOLLICULAR;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;CARCINOMA, PAPILLARY;DIPHOSPHONATES;IMIDAZOLES;PANCREATIC NEOPLASMS;THYROID NEOPLASMS","20;11;10;9;9;8;7;7;6;6;5;4;4;4;4;4;4;4;4;4","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;CARDIOTOXICITY OF CANCER TREATMENTS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;AVIAN ECOLOGY AND CLIMATE CHANGE IMPACTS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER OF UNKNOWN PRIMARY SITE;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME;GASTRIC CANCER RESEARCH AND TREATMENT;MALARIA PARASITES IN BIRDS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;MOLECULAR MECHANISMS OF DNA DAMAGE RESPONSE;NEUTRON IMAGING AND ANALYSIS TECHNIQUES;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE","8;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","INTERNATIONAL MYELOMA WORKING GROUP;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CANCER THERAPY;MELPHALAN;REGIMEN;TREATMENT OUTCOMES;ABSOLUTE NEUTROPHIL COUNT;CARDIOTOXICITY;FOLLICULAR LYMPHOMA;MAINTENANCE THERAPY;REFRACTORY (PLANETARY SCIENCE);VULTURE;ACCIPITRIDAE;ADAPTIVE EVOLUTION;ADJUVANT THERAPY;ALPHA PARTICLE THERAPY;ANIMAL ECOLOGY;ANTIVIRAL THERAPY;AZACITIDINE;BENDAMUSTINE","7;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MULTIPLE MYELOMA;ANTHRACYCLINE CHEMOTHERAPY;BREAST CANCER;CASE-CONTROL STUDY;ITALIAN MULTICENTER;LEFT BREAST;MELPHALAN PREDNISONE;MICROVASCULAR DAMAGE;MM PATIENTS;MULTICENTER STUDY;MYELOMA MM;MYOCARDIAL PERFUSION;ORAL MELPHALAN;PERFUSION DEFECTS;RADIATION THERAPY;STEM CELL;ACCESS VIDEO-ASSISTED-THORACOSCOPY;ACID VERSUS;ADVANCED GASTRIC;ADVANCED MAST;ADVANCED MULTIPLE;ADVANCED STAGE;AEGYPIUS MONACHUS;AIR LEAK;AIR LEAKS;ALL-TRANS RETINOIC;ANTIVIRAL TREATMENT;ASYMPTOMATIC MYELOMA;AUTOLOGOUS STEM;AZACYTIDINE VALPROIC","7;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ZOLEDRONIC ACID;INCIDENCE RATIO;PARTIAL RESPONSE;B-CELL LYMPHOMA;CHARACTERISTICS LABORATORY;LABORATORY PARAMETERS;MEDIAN FOLLOW-UP;MGM DAYS;NEWLY DIAGNOSED;NON-HODGKINS LYMPHOMA;RECEIVE ZOLEDRONIC;RENAL FAILURE;SALVAGE REGIMENS;SURVIVAL ADVANTAGE;SYMPTOMATIC MYELOMA;TIME FREE;UPDATED ANALYSIS;ZOLEDRONIC ACIDTREATED;ACID VERSUS;ACTIVE SALVAGE;ADVERSE EVENTS;AGE RELATED;AGE SERUM;AIR LEAKAGE;ALKYLATING DRUG;AMERICAN CANCER;ANALYSIS EFFICACY;ANEMIA GASTROINTESTINAL;ANEMIA RENAL;ANTINEOPLASTIC ACTIVITY","7;5;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1",6,0.19,4,6.62,6,7.25,3.5,3,4,0,0,0,0,0,0,0,0,0,0,0,0,3,3,3,0,0,0,2,2,2,3.5,3,4,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0.5,0,1,0.5,0,1,85.5,45,126,86.5,45,128,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2009,50,13.9,2.26,0.442477876106195,0.3,0.22,0.24,0.26,0,27,6,11,6,0.54,0.12,0.22,0.12,31.84,0.688324946254638,0.2,0.96,0,0.458853753337831,0.55,0.496951219512195,0.45959595959596,"PELLEGRINO MUSTO;VINCENZO CALLEA;FRANCESCO DI RAIMONDO;AGOSTINO CORTELEZZI;VALERIA SANTINI;ANTONINO NERI;LUCA BALDINI;ALESSANDRO SGAMBATO;NICOLA DI RENZO;MARIO BOCCADORO;ANTONIETTA FALCONE;FORTUNATO MORABITO;FIORELLA D′AURIA;MARIA TERESA PETRUCCI;GABRIELLA BIANCHINO;ACHILLE CITTADINI;ANTONIO PALUMBO;MICHELE AIETA;MARCO GOBBI;GIULIANA ALIMENA","22;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3","PELLEGRINO MUSTO;ANTONI MARGALIDA;GIOVANNI STORTO;MAURO HERNÁNDEZ;JOAN BERTRAN;ALESSANDRO SGAMBATO;ACHILLE CITTADINI;GIOVANNI MARTINELLI;V. LAPENNA;MARCO MUCCIARELLI;G. COLANGELO;GABRIELLA BIANCHINO;VALERIA SANTINI;EMANUELE NICOLAI;MICHELANGELO VESTITA;MARCO SALVATORE;NICOLETTA CASSANO;AGOSTINO CORTELEZZI;GAETANO DE ROSA;TERESA PELLEGRINO","1.29;1;0.62;0.5;0.5;0.46;0.46;0.4;0.4;0.4;0.4;0.39;0.35;0.33;0.33;0.33;0.33;0.33;0.32;0.29","PELLEGRINO MUSTO;AGOSTINO CORTELEZZI;VALERIA SANTINI;ALESSANDRO SGAMBATO;FIORELLA D′AURIA;GABRIELLA BIANCHINO;ACHILLE CITTADINI;MICHELE AIETA;GIULIANA ALIMENA;GIUSEPPE LEONE;GIUSEPPE PIETRANTUONO;GAETANO DE ROSA;VINCENZO FUSCO;ORESTE VILLANI;GIOVANNI STORTO;VINCENZO LISO;FRANCESCO BUCCISANO;MICHELANGELO VESTITA;PAOLA FAZI;ANTONIA ZONNO","22;6;6;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","PELLEGRINO MUSTO;ANTONI MARGALIDA;GIOVANNI STORTO;JOAN BERTRAN;ALESSANDRO SGAMBATO;ACHILLE CITTADINI;G. COLANGELO;GABRIELLA BIANCHINO;VALERIA SANTINI;MICHELANGELO VESTITA;AGOSTINO CORTELEZZI;GAETANO DE ROSA;MICHELE AIETA;FIORELLA D′AURIA;VINCENZO FUSCO;ORESTE VILLANI;GIUSEPPE PIETRANTUONO;VITINA GRIECO;GIUSEPPE LEONE;MARIASSUNTA PIANTANIDA","1.29;1;0.62;0.5;0.46;0.46;0.4;0.39;0.35;0.33;0.33;0.32;0.26;0.25;0.24;0.2;0.2;0.17;0.17;0.17","PELLEGRINO MUSTO;MICHELE AIETA;VINCENZO FUSCO;A. GONNELLA;ANTONIO GIORDANO;CARMELA ROMANO;CORRADO FICORELLA;COSIMO DE NUNZIO;ENRICO RICEVUTO;GIACOMO CARTENÌ;GIANNI BRUNI;GIUSEPPE DI LORENZO;MARIANNA TUDINI;MARIO GIULIANO;MICHAEL S. EWER;MIMMA RIZZO;RICCARDO AUTORINO;SABINO DE PLACIDO;VINCENZO MONTESARCHIO;ANNA SANTACATERINA","585;225;222;193;193;193;193;193;193;193;193;193;193;193;193;193;193;193;193;187","PELLEGRINO MUSTO;VINCENZO FUSCO;CARMELA ROMANO;MICHELE AIETA;FIORELLA D′AURIA;ANTONI MARGALIDA;GAETANO DE ROSA;AGOSTINO CORTELEZZI;ALFONSO PICIOCCHI;ANNA DI TUCCI;CARLO FINELLI;EMANUELE ANGELUCCI;EMILIANO FABIANI;ENRICO POGLIANI;FRANCESCO BUCCISANO;GINA ZINI;GIOVANNI MARTINELLI;GIULIANA ALIMENA;GIUSEPPE FIORITONI;GIUSEPPE LEONE","585;222;193;193;137;136;116;102;102;102;102;102;102;102;102;102;102;102;102;102","PELLEGRINO MUSTO;FIORELLA D′AURIA;GAETANO DE ROSA;GIOVANNI STORTO;ACHILLE CITTADINI;ALESSANDRO SGAMBATO;GABRIELLA BIANCHINO;GIUSEPPE PIETRANTUONO;ORESTE VILLANI;VINCENZO FUSCO;ANNA SPARANO;ANTONI MARGALIDA;ANTONIA ZONNO;ELISA FEUDALE;G. COLANGELO;M. COZZOLINO;MARIA CARMEN MARTORELLI;MICHELANGELO VESTITA;MICHELE AIETA;ROSA LEROSE","22;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;GEOGRAPHY;GEOLOGY;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY","44;12;7;4;2;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;GASTROENTEROLOGY;SURGERY;ONCOLOGY;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;GENETICS;NUCLEAR MEDICINE;RADIOLOGY;CANCER RESEARCH;DERMATOLOGY;ASTROBIOLOGY;CARDIOLOGY;ORGANIC CHEMISTRY;PHARMACOLOGY;PSYCHIATRY;ECOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;MEDICAL PHYSICS;NURSING;OPTICS;PALEONTOLOGY;PURE MATHEMATICS;SEISMOLOGY","36;16;16;14;10;9;9;5;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CHEMOTHERAPY;GENE;BONE MARROW;MULTIPLE MYELOMA;TRANSPLANTATION;ANTIBODY;CANCER;REGIMEN;LYMPHOMA;RADIATION THERAPY;TOXICITY;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;IMMUNOHISTOCHEMISTRY;LEUKEMIA;POSITRON EMISSION TOMOGRAPHY;REFRACTORY (PLANETARY SCIENCE);RETROSPECTIVE COHORT STUDY;BLOOD PRESSURE;CLINICAL SIGNIFICANCE;DERMATOPATHOLOGY;DEXAMETHASONE;DIALYSIS;DISEASE;DOSIMETRY;EPILEPSY;HEART FAILURE;IMAGING PHANTOM;INDETERMINATE;KAPPA;MEDICAL DIAGNOSIS;POPULATION;PREDNISONE;QUALITY OF LIFE (HEALTHCARE);RENAL CELL CARCINOMA;STAGE (STRATIGRAPHY);VULTURE","10;10;9;9;6;5;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MYELODYSPLASTIC SYNDROMES;CYCLOPHOSPHAMIDE;BORTEZOMIB;GENE EXPRESSION;CHRONIC LYMPHOCYTIC LEUKEMIA;MELPHALAN;MONOCLONAL ANTIBODY;NEUTROPENIA;RITUXIMAB;ALEMTUZUMAB;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BLADDER CANCER;CELL CYCLE;CHROMOSOME;EJECTION FRACTION;FLUORODEOXYGLUCOSE;FOLLICULAR LYMPHOMA;GENOTYPE;GRANULOCYTE COLONY-STIMULATING FACTOR;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ISOCENTER;LENALIDOMIDE;MUCOSITIS;PHASES OF CLINICAL RESEARCH;PLASMA CELL LEUKEMIA;PROSTATE;PROSTATE CANCER;RADIATION TREATMENT PLANNING;REGULATION OF GENE EXPRESSION;SALVAGE THERAPY;SUNITINIB;VALPROIC ACID","6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DNA METHYLATION;FLUDARABINE;BENDAMUSTINE;FLUORESCENCE IN SITU HYBRIDIZATION;MONOCLONAL;ABSOLUTE NEUTROPHIL COUNT;AL AMYLOIDOSIS;ALPHA (FINANCE);BUSULFAN;CATECHOL-O-METHYL TRANSFERASE;CD38;CELL CYCLE CHECKPOINT;CHRONIC MYELOMONOCYTIC LEUKEMIA;CRITICAL LIMB ISCHEMIA;DASATINIB;DESMOGLEIN;DESMOGLEIN 1;DESMOGLEIN 3;DIHYDROTESTOSTERONE;FEBRILE NEUTROPENIA;FILGRASTIM;GENE REGULATORY NETWORK;GLUTATHIONE S-TRANSFERASE;GSTP1;HISTONE DEACETYLASE;IDARUBICIN;IMATINIB MESYLATE;IMMUNOGLOBULIN A;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;METHYLENETETRAHYDROFOLATE REDUCTASE;METHYLTRANSFERASE;NILOTINIB;NITROGEN MUSTARD;PARANEOPLASTIC PEMPHIGUS;PEMPHIGOID;PROMOTER;RADIOIMMUNOTHERAPY;RETINOBLASTOMA PROTEIN;TAMOXIFEN;TRANSCRIPTIONAL REGULATION;TRANSITIONAL CELL CARCINOMA;TRANSMETHYLATION;VINCRISTINE","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;AGED;MIDDLE AGED;MULTIPLE MYELOMA;;FEMALE;MALE;ADULT;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;ANTIBODIES, MONOCLONAL;ANTINEOPLASTIC AGENTS;MYELODYSPLASTIC SYNDROMES;RETROSPECTIVE STUDIES;TOMOGRAPHY, X-RAY COMPUTED;BORONIC ACIDS;PROSTATIC NEOPLASMS;PYRAZINES;TREATMENT OUTCOME","27;21;21;21;20;20;20;11;11;10;8;7;7;7;7;7;6;6;6;6","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;MELANOMA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;RENAL CELL CARCINOMA;STUDY OF EARTHQUAKE PRECURSOR PHENOMENA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANALYSIS OF GENE INTERACTION NETWORKS;AVIAN ECOLOGY AND CLIMATE CHANGE IMPACTS;DENTAL RESTORATIVE MATERIALS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;EVOLUTIONARY ECOLOGY OF ANIMAL BEHAVIOR AND TRAITS;GENOTOXICITY AND CARCINOGENESIS MECHANISMS;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;MANAGEMENT OF SPINAL METASTATIC TUMORS","7;5;5;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","REGIMEN;INTERNATIONAL MYELOMA WORKING GROUP;MELPHALAN;NONMELANOMA SKIN CANCER;REFRACTORY (PLANETARY SCIENCE);AUTOLOGOUS STEM-CELL TRANSPLANTATION;AZACITIDINE;BENDAMUSTINE;BONE MARROW MICROENVIRONMENT;CLINICAL SIGNIFICANCE;DERMATOPATHOLOGY;DERMOSCOPY;FLUORODEOXYGLUCOSE;FOLLICULAR LYMPHOMA;IMAGE-GUIDED RADIOTHERAPY;INDETERMINATE;ISOCENTER;KAPPA;MELANOMA;MUCOSITIS","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE MYELOMA;MYELODYSPLASTIC SYNDROMES;MYELOMA PATIENTS;NEWLY DIAGNOSED;RISK MYELODYSPLASTIC;BONE MARROW;CARDIOVASCULAR TOXICITY;CASE-CONTROL STUDY;CELL CARCINOMA;CELL LEUKEMIA;CHRONIC LYMPHOCYTIC;CLINICAL INFORMATION;FINAL RESULTS;HISTOPATHOLOGIC DIAGNOSIS;IIN VITROI;LUNG TUMORS;MELANOCYTIC SKIN;MELPHALAN MGM;METASTATIC RENAL;MULTICENTER ANALYSIS;PEMPHIGUS VULGARIS;PLASMA CELL;PLASMA LEVELS;PRIMARY PLASMA;RENAL CELL;RETROSPECTIVE STUDY;SKIN NEOPLASMS;SOUTHERN ITALY;SUNITINIB THERAPY;THERAPEUTIC PLASMA","6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","UNIVERSITÀ DI;DI SCIENZE;MULTIPLE MYELOMA;DI PADOVA;CLINICAL INFORMATION;CTMO FONDAZIONE;DI MILANO;EMATOLOGIA CTMO;FONDAZIONE IRCCS;HISTOPATHOLOGIC DIAGNOSIS;HISTOPATHOLOGIC EVALUATION;IRCCS OSPEDALE;MEDICHE UNIVERSITÀ;MILANO EMATOLOGIA;MILANO ITALY;OSPEDALE POLICLINICO;PADOVA ITALY;RESPONSE RATE;SCIENZE MEDICHE;SFORZA MILANO;UNANIMOUS DIAGNOSIS;AMYLOID DEPOSITS;BIOLOGIA UNIVERSITÀ;BONE MARROW;DI BIOLOGIA;DIAGNOSTIC CERTAINTY;INTERNATIONAL PROGNOSTIC;LVEF DYSFUNCTION;MM PATIENTS;MONTHS RANGE","11;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3",11,0.22,3,6.33,6,7,2.33,1,4,0,0,0,0,0,0,0,0,0,1,1,1,3,3,3,0,0,0,1.5,1,2,2.67,1,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,46.67,16,104,46.67,16,104,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2010,39,14.3076923076923,1.8974358974359,0.527027027027027,0.205128205128205,0.128205128205128,0.384615384615385,0.333333333333333,1,26,4,6,2,0.67,0.1,0.15,0.05,62.36,1.37991049373369,0.17948717948718,0.974358974358974,0,0.492397884702052,0.595238095238095,0.222222222222222,0.601449275362319,"PELLEGRINO MUSTO;ANTONELLA GOZZINI;VINCENZO CALLEA;ANTONINO NERI;PATRIZIA PREGNO;MASSIMO BRECCIA;VALERIA SANTINI;MICHELE AIETA;ROBERTO LATAGLIATA;ROBIN FOÀ;NICOLA DI RENZO;DAVIDE ROSSI;STEFANO LUMINARI;MARIO TIRIBELLI;FORTUNATO MORABITO;FRANCESCO CAVAZZINI;MARIO ANNUNZIATA;FRANCESCO DI RAIMONDO;CLOTILDE CANGIALOSI;STEFANO SACCHI","17;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ANTONI MARGALIDA;PELLEGRINO MUSTO;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;GIOVANNI STORTO;ANNAMARIA PISCAZZI;MATTEO LANDRISCINA;FRANCESCA MADDALENA;GIANFRANCO ORLANDINO;MARGHERITA GARRAMONE;JURI TASSINARI;LUCA CALABRESE;RITA MARASCO;TOMMASO FABRIZIO;VALERIA SANTINI;LORENZO LO MUZIO;VINCENZO FUSCO;MARIA LUIGIA DE BONIS;ANTONELLA GOZZINI;MASSIMO BRECCIA","1;0.97;0.75;0.75;0.36;0.26;0.26;0.26;0.25;0.25;0.25;0.25;0.25;0.25;0.24;0.24;0.23;0.23;0.22;0.22","PELLEGRINO MUSTO;MICHELE AIETA;GIOVANNI STORTO;VINCENZO FUSCO;FIORELLA D′AURIA;FRANCESCA MADDALENA;LORENZO LO MUZIO;MARIA LUIGIA DE BONIS;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;GIANFRANCO ORLANDINO;MICHELANGELO VESTITA;L. LAPADULA;ALDO CAMMAROTA;SALVATORE PUCCIARELLI;CRISTINA GHIOTTO;GIUSEPPE PIETRANTUONO;MARGHERITA GARRAMONE;GAETANO DE ROSA;TEODORO SAVA","17;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","ANTONI MARGALIDA;PELLEGRINO MUSTO;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;GIOVANNI STORTO;FRANCESCA MADDALENA;GIANFRANCO ORLANDINO;MARGHERITA GARRAMONE;JURI TASSINARI;RITA MARASCO;TOMMASO FABRIZIO;LORENZO LO MUZIO;VINCENZO FUSCO;MARIA LUIGIA DE BONIS;MICHELE AIETA;MICHELANGELO VESTITA;GAETANO DE ROSA;CARMEN LOSASSO;FIORELLA D′AURIA;STEFANIA CLEMENTE","1;0.97;0.75;0.75;0.36;0.26;0.25;0.25;0.25;0.25;0.25;0.24;0.23;0.23;0.22;0.17;0.17;0.17;0.15;0.14","ANTONIO PALUMBO;PELLEGRINO MUSTO;CLOTILDE CANGIALOSI;ANNA MARINA LIBERATI;LUCA DE ROSA;MARIELLA GRASSO;MARIO BOCCADORO;TOMMASINA GUGLIELMELLI;VINCENZO CALLEA;ALBERTO ROCCI;CARLO M. CROCE;CRAIG HOFMAINSTER;CRISTIAN TACCIOLI;DANILO PERROTTI;DON M. BENSON;FLAVIA PICHIORRI;GIANPIERO DI LEVA;HANSJÜERG ALDER;HUEY-JEN LIN;LUCIANA DE LUCA","1049;886;661;639;639;639;639;639;639;410;410;410;410;410;410;410;410;410;410;410","PELLEGRINO MUSTO;LUCIANA DE LUCA;MARIA LUIGIA DE BONIS;MARCO MAZZOTTA;MICHELE AIETA;FRANCESCA MADDALENA;ALBERTO AMADORI;ANTONIO JIRILLO;CARMEN BARILE;CRISTINA GHIOTTO;CRISTINA MAGRO;ELISABETTA ROSSI;FRANCESCA ZILIO;GIORGIO BONCIARELLI;RITA ZAMARCHI;ROMINA CELADIN;SALVATORE PUCCIARELLI;SALVATORE TUMOLO;STEFANO INDRACCOLO;TEODORO SAVA","886;410;262;231;190;150;123;123;123;123;123;123;123;123;123;123;123;123;123;123","PELLEGRINO MUSTO;GIOVANNI STORTO;MICHELE AIETA;FIORELLA D′AURIA;FRANCESCA MADDALENA;MARIA LUIGIA DE BONIS;VINCENZO FUSCO;A. CAPOBIANCO;ALBERTO AMADORI;ALDO CAMMAROTA;ALFREDO TARTARONE;ANNARITA NAPPI;ANTONI MARGALIDA;ANTONIO JIRILLO;CARMEN BARILE;CARMEN LOSASSO;CRISTINA GHIOTTO;CRISTINA MAGRO;ELISABETTA ROSSI;FRANCESCA ZILIO","17;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","32;15;7;4;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GASTROENTEROLOGY;SURGERY;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;PATHOLOGY;IMMUNOLOGY;RADIOLOGY;ECOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;ANESTHESIA;CARDIOLOGY;CELL BIOLOGY;OPTICS;ORGANIC CHEMISTRY;PEDIATRICS;PSYCHIATRY","27;15;11;10;8;7;6;6;5;4;3;3;3;2;2;2;2;2;2;2","GENE;CANCER;MULTIPLE MYELOMA;CHEMOTHERAPY;BONE MARROW;REGIMEN;APOPTOSIS;LYMPHOMA;MYELOID LEUKEMIA;PROSPECTIVE COHORT STUDY;BASAL CELL;CORONARY ARTERY DISEASE;DEXAMETHASONE;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);LUNG;POPULATION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;THALASSEMIA;TOXICITY","11;9;8;6;5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","GENE EXPRESSION;MYELODYSPLASTIC SYNDROMES;BORTEZOMIB;BREAST CANCER;IMATINIB;LENALIDOMIDE;CHROMOSOME;CYCLOPHOSPHAMIDE;DEFERASIROX;METASTASIS;MICRORNA;NEUTROPENIA;PLASMA CELL LEUKEMIA;RITUXIMAB;TYROSINE-KINASE INHIBITOR;ANTIEMETIC;BASAL CELL CARCINOMA;BREAKPOINT CLUSTER REGION;CANCER CELL;CARDIOTOXICITY;CD34;CHELATION THERAPY;CHEMOTHERAPY REGIMEN;CHROMATIN;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;COLORECTAL CANCER;CORONARY ARTERIES;CYTOKERATIN;CYTOPROTECTION;DEFERIPRONE;DNA REPAIR;DOTA;DOWNREGULATION AND UPREGULATION;EJECTION FRACTION;ENDANGERED SPECIES;EPIDERMAL GROWTH FACTOR RECEPTOR;EPIGENETICS;FACTOR XI;FOLLICULAR LYMPHOMA;GENOTYPE;GLUTAMINE;GRANULOCYTE COLONY-STIMULATING FACTOR;H&E STAIN;HEAD AND NECK CANCER;HEART RATE;HISTONE;HOMOLOGOUS RECOMBINATION;IMMUNOGLOBULIN HEAVY CHAIN;IMMUNOGLOBULIN LIGHT CHAIN;IMMUNOSTAINING;KAWASAKI DISEASE;KERATOCYST;MAGIC ANGLE SPINNING;MDM2;METHYLATION;MUTATION;MYOCARDIAL PERFUSION IMAGING;MYOMETRIUM;NEURORADIOLOGY;NEUROTROPHIC FACTORS;PI3K/AKT/MTOR PATHWAY;PLASMA CELL;POLYMERASE CHAIN REACTION;PROGRESSIVE DISEASE;PROHIBITIN;PROTEIN SUBUNIT;RADIATION TREATMENT PLANNING;REAL-TIME POLYMERASE CHAIN REACTION;REGULATOR;REPRODUCTIVE SUCCESS;SACCHAROMYCES CEREVISIAE;SORAFENIB;SPECIFIC ACTIVITY;SUNITINIB;TAURINE;TELOMERASE;TELOMERE;THALIDOMIDE;THREATENED SPECIES;THYROID CANCER;THYROID CARCINOMA;TOMOTHERAPY;TRANSCRIPTION FACTOR;TUMOR PROGRESSION;UTERINE LEIOMYOMA;VARICELLA ZOSTER VIRUS;WHITE MATTER;YTTRIUM","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;DASATINIB;DNA METHYLATION;IMATINIB MESYLATE;ANAPLASTIC THYROID CANCER;BRAIN-DERIVED NEUROTROPHIC FACTOR;CAPTIVE BREEDING;CARFILZOMIB;CD38;CETUXIMAB;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CIRCULATING TUMOR CELL;COLD PRESSOR TEST;COMPARATIVE GENOMIC HYBRIDIZATION;COMPLEMENTARITY DETERMINING REGION;COMPOUND HETEROZYGOSITY;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA-BINDING PROTEIN;ERLOTINIB;FEBRILE NEUTROPENIA;FILGRASTIM;FLUORESCENCE IN SITU HYBRIDIZATION;GENE DOSAGE;GENE EXPRESSION PROFILING;IGHV@;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;KRAS;MISSENSE MUTATION;NEVOID BASAL-CELL CARCINOMA SYNDROME;NILOTINIB;PALONOSETRON;PINNACLE;PROMOTER;PROTEIN QUATERNARY STRUCTURE;SUBTELOMERE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MIDDLE AGED;MULTIPLE MYELOMA;AGED;MALE;ADULT;MYELODYSPLASTIC SYNDROMES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BORONIC ACIDS;PYRAZINES;THALIDOMIDE;APOPTOSIS;ANTINEOPLASTIC AGENTS;TREATMENT OUTCOME;ANTHRACYCLINES;CARCINOMA, RENAL CELL;CARCINOMA, SQUAMOUS CELL;DEXAMETHASONE","22;15;15;15;13;11;11;10;10;8;8;8;8;7;6;6;5;5;5;5","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATITIS C INFECTION AND TREATMENT;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;AVIAN ECOLOGY AND CLIMATE CHANGE IMPACTS;CANCER STEM CELLS AND TUMOR METASTASIS;CARDIOTOXICITY OF CANCER TREATMENTS;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;HEREDITARY ANGIOEDEMA: MOLECULAR MECHANISMS AND CLINICAL MANAGEMENT;HERPESVIRUSES: EPIDEMIOLOGY, PATHOGENESIS, AND MANAGEMENT;INVERTEBRATE IMMUNITY AND HOST DEFENSE MECHANISMS;LYMPHOID NEOPLASMS","5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTERNATIONAL MYELOMA WORKING GROUP;REGIMEN;IMATINIB;TREATMENT;DASATINIB;DEFERASIROX;IMATINIB MESYLATE;PLASMA CELL LEUKEMIA;TREATMENT OUTCOMES;ABNORMALITY;ANAPLASTIC THYROID CANCER;ARTHROPOD;AZACITIDINE;B CELL ABNORMALITIES;B-CELL RECEPTOR SIGNALING;BDNF;BISULFITE SEQUENCING;BREAKPOINT CLUSTER REGION;BTK INHIBITORS;CANCER BIOMARKERS","5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MULTIPLE MYELOMA;ITALIAN STUDY;MULTICENTER ITALIAN;MYELODYSPLASTIC SYNDROMES;AGGRESSIVE NON-HODGKINS;CELL LEUKEMIA;MYELOMA PATIENTS;NON-HODGKINS LYMPHOMAS;PLASMA CELL;PREDICT SURVIVAL;PROGNOSTIC MODELS;VIRUS INFECTION;AESTUARII SQUILLA;AIR LEAKS;ANTIBLASTIC AGENTS;APOPTOSIS INDUCED;ARC THERAPY;ASYMPTOMATIC ITALIAN;AUGMENTS GLOBAL;AUTOGRAFTED MYELOMA;AUTOREGULATORY LOOP;BDNF VALMET;BEARDED VULTURE;BINDING PROTEIN;BINET STAGE;BORTEZOMIB THALIDOMIDE;BRAIN VOLUMES;BREAST CANCER;BREEDING SUCCESS;CALCIUM BINDING","4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MULTIPLE MYELOMA;BREAST CANCER;STROMAL TISSUE;AUTOREGULATORY LOOP;CARCINOMA CELLS;COMPLETE RESPONSES;FEBRILE EPISODES;FULL-TEXT PDF;LEFT BREAST;M-POSITIVE CTC;MD UNIT;MEC REGIMENS;MMP EXPRESSION;MYELOMA DEVELOPMENTPICHIORRI;MYOCARDIAL PERFUSION;P-INDUCIBLE MICRORNAS;PMDM AUTOREGULATORY;PRIMARY ENDPOINT;RISK MDS;SPORADIC OCKS;SUBMENTAL FLAP;ADMINISTERED DEXAMETHASONE;ADVERSE EVENTS;ALCANCER CELLOCTOBER;APOPTOTIC CTC;ARTICLE WITHDRAWAL;BASAL CELL;BRIEFCANCER CELL;CANCER RES;CELL CANCER","5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2",5,0.13,5,22.14,10,34.29,29,3,55,0,0,0,1,1,1,0,0,0,1.5,1,2,24,2,46,1,1,1,0,0,0,40.5,3,78,0,0,0,0,0,0,3,3,3,0,0,0,2,2,2,0,0,0,1,1,1,2,2,2,0,0,0,0.5,0,1,0,0,0,159,101,217,159.5,101,218,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2011,74,16.3648648648649,2.28378378378378,0.437869822485207,0.310810810810811,0.189189189189189,0.283783783783784,0.391891891891892,1,44,9,17,4,0.59,0.12,0.23,0.05,46.49,1.09291796780745,0.297297297297297,0.972972972972973,0,0.56354038929472,0.538095238095238,0.523076923076923,0.551948051948052,"PELLEGRINO MUSTO;FORTUNATO MORABITO;NICOLA CASCAVILLA;VINCENZO FUSCO;FRANCESCO DI RAIMONDO;GIOVANNI D’ARENA;NICOLA DI RENZO;MARIO BOCCADORO;FRANCESCO CAVAZZINI;FIORELLA D′AURIA;LORENZO LO MUZIO;ANTONIO PALUMBO;ROBERTO LATAGLIATA;ANTONELLA GOZZINI;C. CHIUMENTO;ANGELO MICHELE CARELLA;DARIO FERRERO;MARIO TIRIBELLI;GIUSEPPE VISANI;P. SANPAOLO","33;11;8;8;8;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5","PELLEGRINO MUSTO;VINCENZO FUSCO;P. SANPAOLO;V. BARBIERI;DOMENICO GENOVESI;C. CHIUMENTO;GIANPIETRO SUMMA;ALBA FIORENTINO;LORENZO LO MUZIO;M. COZZOLINO;NICOLA CASCAVILLA;GIOVANNI D’ARENA;GIOVANNI CASTALDO;FORTUNATO MORABITO;GIULIA VITA;RITA MARASCO;COSIMO LEQUAGLIE;ANIELLO DELLA MORTE;GABRIELLA GIUDICE;MICHELE BISCEGLIA","1.93;1.57;1.45;1.45;1.2;1.04;1;0.64;0.56;0.54;0.52;0.51;0.5;0.5;0.48;0.45;0.45;0.45;0.45;0.42","PELLEGRINO MUSTO;VINCENZO FUSCO;GIOVANNI D’ARENA;FIORELLA D′AURIA;LORENZO LO MUZIO;C. CHIUMENTO;P. SANPAOLO;V. BARBIERI;ANNAMARIA PISCAZZI;GIUSEPPE PIETRANTUONO;ROBERTO GUARIGLIA;GIOVANNA MANSUETO;MATTEO LANDRISCINA;MARCO MAZZOTTA;ALBA FIORENTINO;GIULIA VITA;ORESTE VILLANI;PANTALEO BUFO;ROCCO GALASSO;M. COZZOLINO","33;8;7;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3","PELLEGRINO MUSTO;VINCENZO FUSCO;P. SANPAOLO;V. BARBIERI;C. CHIUMENTO;GIANPIETRO SUMMA;ALBA FIORENTINO;LORENZO LO MUZIO;M. COZZOLINO;GIOVANNI D’ARENA;GIOVANNI CASTALDO;GIULIA VITA;COSIMO LEQUAGLIE;STEFANIA CLEMENTE;ANTONIETTA MONTAGNA;P. PEDICINI;MARCO MAZZOTTA;ANNAMARIA PISCAZZI;MATTEO LANDRISCINA;FIORELLA D′AURIA","1.93;1.57;1.45;1.45;1.04;1;0.64;0.56;0.54;0.51;0.5;0.48;0.45;0.4;0.4;0.39;0.39;0.35;0.35;0.34","PELLEGRINO MUSTO;ALESSANDRO PULSONI;GIANPIETRO SEMENZATO;FRANCESCO DI RAIMONDO;ROBIN FOÀ;ACHILLE AMBROSETTI;FRANCESCO FORCONI;LUCA ARCAINI;ALESSANDRA PUCCIARINI;ANTONY B. HOLMES;ARCANGELO LISO;BARBARA BIGERNA;BRUNANGELO FALINI;CATERINA PATTI;CLAUDIA HAFERLACH;ENRICO TIACCI;GIANLUCA SCHIAVONI;GIORGIO INGHIRAMI;GIOVANNI PIZZOLO;LAURA PASQUALUCCI","1978;1069;1048;1041;1038;1021;1021;976;971;971;971;971;971;971;971;971;971;971;971;971","PELLEGRINO MUSTO;ROCCO GALASSO;GIOVANNI D’ARENA;ANNA MARIA BOCHICCHIO;MATTEO LANDRISCINA;ROBERTO GUARIGLIA;GIUSEPPE PIETRANTUONO;GIOVANNA MANSUETO;ORESTE VILLANI;FRANCESCA MADDALENA;ANNAMARIA PISCAZZI;LORENZO LO MUZIO;GABRIELLA CAUZILLO;MARCO MAZZOTTA;MARIA CARMEN MARTORELLI;P. SANPAOLO;V. BARBIERI;FIORELLA D′AURIA;AGNESE SECONDO;ALBERTO FERSINI","1978;283;257;204;187;187;184;183;182;168;153;137;126;110;105;88;88;83;79;79","PELLEGRINO MUSTO;VINCENZO FUSCO;FIORELLA D′AURIA;GIOVANNI D’ARENA;P. SANPAOLO;V. BARBIERI;C. CHIUMENTO;GIOVANNA MANSUETO;GIUSEPPE PIETRANTUONO;ROBERTO GUARIGLIA;LORENZO LO MUZIO;ORESTE VILLANI;M. COZZOLINO;MARCO MAZZOTTA;ROCCO GALASSO;GIULIA VITA;MATTEO LANDRISCINA;ALBA FIORENTINO;ANGELA ZUPA;ANNA MARIA BOCHICCHIO","33;8;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;ART;COMPUTER SCIENCE;ENGINEERING;GEOLOGY;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","66;24;8;4;2;1;1;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;CANCER RESEARCH;IMMUNOLOGY;PATHOLOGY;RADIOLOGY;BIOCHEMISTRY;PALEONTOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;CELL BIOLOGY;ASTROBIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;OPTICS;PEDIATRICS;UROLOGY","58;29;23;17;14;13;10;10;8;7;7;6;6;5;3;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;MULTIPLE MYELOMA;LEUKEMIA;GENE;RETROSPECTIVE COHORT STUDY;LYMPHOMA;RADIATION THERAPY;TRANSPLANTATION;MYELOID LEUKEMIA;PROPORTIONAL HAZARDS MODEL;STAGE (STRATIGRAPHY);BONE MARROW;CONFIDENCE INTERVAL;MULTIVARIATE ANALYSIS;BIOPSY;HEMATOLOGY;PROSPECTIVE COHORT STUDY;RECEPTOR;STEM CELL","31;14;14;11;10;10;8;8;8;7;7;7;5;5;5;4;4;4;4;4","BREAST CANCER;LENALIDOMIDE;BORTEZOMIB;CHRONIC LYMPHOCYTIC LEUKEMIA;IMATINIB;PLASMA CELL LEUKEMIA;THALIDOMIDE;UNIVARIATE ANALYSIS;CYCLOPHOSPHAMIDE;HAZARD RATIO;METASTASIS;PROSTATE CANCER;ADENOCARCINOMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CLINICAL ENDPOINT;COLORECTAL CANCER;MELPHALAN;MONOCLONAL ANTIBODY;OVARIAN CANCER;RITUXIMAB;THYROID CARCINOMA","11;6;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","IMATINIB MESYLATE;ANDROGEN DEPRIVATION THERAPY;DASATINIB;ESTROGEN RECEPTOR;FLUDARABINE;MONOCLONAL;PROSTATE BRACHYTHERAPY;SANGER SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;AGGRESSIVE LYMPHOMA;AMPLICON;ANDROGEN RECEPTOR;BARRETT'S ESOPHAGUS;BENDAMUSTINE;BRAIN METASTASIS;CALNEXIN;CETUXIMAB;CHROMOSOME 13;CHROMOSOME INSTABILITY;COMPARATIVE GENOMIC HYBRIDIZATION;CXCR4;CYTOGENETICS;DEOXYCYTIDINE;DNA METHYLATION;ENDOPLASMIC-RETICULUM-ASSOCIATED PROTEIN DEGRADATION;EXOME SEQUENCING;FEBRILE NEUTROPENIA;FLUORESCENCE IN SITU HYBRIDIZATION;GENOTYPING;GROUNDWATER RECHARGE;HPV INFECTION;IFOSFAMIDE;IL-2 RECEPTOR;JUNB;KARYOTYPE;LUNG CANCER STAGING;MAMMARY GLAND;MASTECTOMY;MEK INHIBITOR;MISSENSE MUTATION;NEOADJUVANT THERAPY;NEUROENDOCRINE DIFFERENTIATION;OLIGOMYCIN;OSTEOCALCIN;OSTEONECROSIS OF THE JAW;OXALIPLATIN;PLEURAL DISEASE;RADIOIMMUNOTHERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;TRIPLE-NEGATIVE BREAST CANCER;UNDIFFERENTIATED PLEOMORPHIC SARCOMA;V600E;VENETOCLAX;VINCRISTINE","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MIDDLE AGED;FEMALE;AGED;MALE;ADULT;BREAST NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ANTINEOPLASTIC AGENTS;MULTIPLE MYELOMA;;NEOPLASM RECURRENCE, LOCAL;TREATMENT OUTCOME;MOUTH NEOPLASMS;RETROSPECTIVE STUDIES;ADENOCARCINOMA;CARCINOMA;CARCINOMA, SQUAMOUS CELL;THALIDOMIDE","54;42;40;37;36;30;28;24;23;22;22;19;19;17;16;15;14;14;14;13","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;LYMPHOID NEOPLASMS;MOLECULAR RESEARCH ON BREAST CANCER;ACUTE MYELOID LEUKEMIA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;CANCER OF UNKNOWN PRIMARY SITE;COLORECTAL CANCER RESEARCH AND TREATMENT;ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;ORAL MUCOSAL DISORDERS AND MALIGNANT TRANSFORMATION RISK;PROSTATE CANCER RESEARCH AND TREATMENT;14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATION;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CUTANEOUS MANIFESTATIONS OF COVID-19: A COMPREHENSIVE REVIEW;DIAGNOSIS AND TREATMENT OF LUNG CANCER;DIAGNOSIS AND TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA","10;8;5;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1","BREAST CANCER;PLASMA CELL LEUKEMIA;UNIVARIATE ANALYSIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;HEMATOLOGY;IMATINIB MESYLATE;INTERNATIONAL MYELOMA WORKING GROUP;ACUTE MYELOID LEUKEMIA;CANCER;CLINICAL ENDPOINT;CONCOMITANT;IMATINIB;MELPHALAN;NOVEL THERAPIES;PET IMAGING;REFRACTORY (PLANETARY SCIENCE);SURVIVAL ANALYSIS;AML;BARRETT'S ESOPHAGUS;BONE MARROW MICROENVIRONMENT","5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","BREAST CANCER;MULTIPLE MYELOMA;MYELOID LEUKEMIA;RETROSPECTIVE STUDY;CELL LEUKEMIA;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;PLASMA CELL;PRIMARY PLASMA;RETROSPECTIVE ANALYSIS;STEM CELL;OVARIAN CANCER;ACUTE MYELOID;AUTOLOGOUS STEM;CASE-CONTROL STUDY;CELL CARCINOMA;CML PATIENTS;COLORECTAL CANCER;DIAGNOSED MULTIPLE;DOSIMETRIC RESULTS;EARLY-STAGE BREAST;ELDERLY GT;EUROPEAN PROSPECTIVE;FINAL RESULTS;FONDAZIONE ITALIANA;II STUDY;IMPLANT CLINICAL;INDUCTION THERAPY;ITALIAN RETROSPECTIVE;ITALIANA LINFOMI","8;8;5;5;4;4;4;4;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","INDOLENT NHL;BREAST CANCER;ER STRESS;HR CI;MULTIVARIATE ANALYSIS;OVARIAN CANCER;RESPONSE RATE;SURVIVAL OS;BRAIN METASTASES;GROWTH FACTOR;LOW-DOSE ALEMTUZUMAB;MGM INTRAVENOUSLY;PARTIAL RESPONSE;SEVERE RI;TN PATIENTS;ANTIVIRAL THERAPY;COMPLETE RESPONSE;CONSECUTIVE PATIENTS;CRC CELLS;EGFR MLMIN;HCV NHL;HEPATIC TOXICITY;KDA ISOFORM;LOWER RISK;LRFS RATES;MODERATE RI;NEURAL NETWORKS;NON-TN PATIENTS;ODN IL;ORAL CONTRACEPTIVES","8;6;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",20,0.27,3,20.36,6,64.99,10.83,1,38,2,1,3,3,2,4,0,0,0,1.5,1,2,6.5,2,11,0,0,0,1.25,1,2,12.5,1,44,0,0,0,1,1,1,8,6,11,0,0,0,9,9,9,0,0,0,1,1,1,7,4,11,2,2,2,0.83,0,4,0,0,0,134.17,27,390,135,27,394,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2012,78,14.7564102564103,2.76923076923077,0.361111111111111,0.307692307692308,0.243589743589744,0.769230769230769,0.41025641025641,0,52,6,15,2,0.67,0.08,0.19,0.03,35.88,0.859134450382426,0.256410256410256,1,5.65968586387435,0.502024758367449,0.52660406885759,0.56043956043956,0.412538226299694,"PELLEGRINO MUSTO;GIOVANNI D’ARENA;GIORGINA SPECCHIA;MICHELE AIETA;MARIO BOCCADORO;ALBA FIORENTINO;VINCENZO FUSCO;GIANLUCA GAÏDANO;MONIA LUNGHI;ROBERTO LATAGLIATA;DAVIDE ROSSI;ANTONIETTA FALCONE;DANIELA CILLONI;FIORELLA D′AURIA;GIUSEPPE VISANI;LUCIANA DE LUCA;ORESTE VILLANI;MASSIMO BRECCIA;MARIA CARMEN MARTORELLI;ROCCHINA CAIVANO","25;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5","PELLEGRINO MUSTO;VINCENZO FUSCO;ALBA FIORENTINO;RITA MARASCO;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;ROCCHINA CAIVANO;GIOVANNI D’ARENA;MICHELE AIETA;C. CHIUMENTO;GIULIA VITA;GIANLUCA GAÏDANO;DAVIDE ROSSI;ANNALISA PASCARIELLO;PAOLA IOVINO;F. TREMOLATERRA;CAROLINA CIACCI;VITALBA RUGGIERI;P. PEDICINI;ROSA LEROSE","1.4;1.38;1.27;1.03;1.03;1.03;0.79;0.66;0.64;0.61;0.58;0.48;0.42;0.4;0.4;0.4;0.4;0.38;0.38;0.36","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;ALBA FIORENTINO;VINCENZO FUSCO;FIORELLA D′AURIA;LUCIANA DE LUCA;ORESTE VILLANI;MARIA CARMEN MARTORELLI;ROCCHINA CAIVANO;TEODORA STATUTO;GIUSEPPE PIETRANTUONO;GIULIA VITA;GIOVANNA MANSUETO;P. PEDICINI;GABRIELLA BIANCHINO;RITA MARASCO;COSIMO LEQUAGLIE;VITINA GRIECO;GABRIELLA GIUDICE","25;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","PELLEGRINO MUSTO;VINCENZO FUSCO;ALBA FIORENTINO;RITA MARASCO;COSIMO LEQUAGLIE;GABRIELLA GIUDICE;ROCCHINA CAIVANO;GIOVANNI D’ARENA;MICHELE AIETA;C. CHIUMENTO;GIULIA VITA;F. TREMOLATERRA;VITALBA RUGGIERI;P. PEDICINI;ROSA LEROSE;ALFREDO TARTARONE;CLÁUDIA PICCOLI;FRANCESCA AGRIESTI;LUCIANA DE LUCA;ORESTE VILLANI","1.4;1.38;1.27;1.03;1.03;1.03;0.79;0.66;0.64;0.61;0.58;0.4;0.38;0.38;0.36;0.33;0.3;0.3;0.29;0.29","PELLEGRINO MUSTO;MONIA LUNGHI;VALERIO DE STEFANO;ANTONIO SPADEA;GIUSEPPE VISANI;ROBERTO LATAGLIATA;ALESSANDRA IURLO;GIORGINA SPECCHIA;GIOVANNI QUARTA;ALESSIA TIEGHI;ARIANNA MASCIULLI;CATERINA MUSOLINO;DANIELA CILLONI;DAVIDE RAPEZZI;ELENA MARIA ELLI;ELISA RUMI;FRANCESCA LUNGHI;GUIDO FINAZZI;MARCO RUGGERI;MARIA LUIGIA RANDI","1705;1058;1018;1004;824;788;776;767;715;713;713;713;713;713;713;713;713;713;713;713","PELLEGRINO MUSTO;MICHELE AIETA;ROCCO GALASSO;ALBA FIORENTINO;P. PEDICINI;GABRIELLA BIANCHINO;VITINA GRIECO;FIORELLA D′AURIA;TEODORA STATUTO;PASQUALE DE NEGRI;RICCARDO AMODIO;VINCENZO FUSCO;F. TREMOLATERRA;CARMELA MAZZOCCOLI;LUCIANA DE LUCA;MICHELANGELO VESTITA;T. TATARANNI;G. CALIFANO;LAURA TROIANI;MICHELE BISCEGLIA","1704;181;139;117;88;86;86;80;80;79;79;70;68;66;66;63;59;58;56;56","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;ALBA FIORENTINO;VINCENZO FUSCO;LUCIANA DE LUCA;ORESTE VILLANI;FIORELLA D′AURIA;ROCCHINA CAIVANO;MARIA CARMEN MARTORELLI;COSIMO LEQUAGLIE;GABRIELLA BIANCHINO;GABRIELLA GIUDICE;GIOVANNA MANSUETO;GIULIA VITA;GIUSEPPE PIETRANTUONO;P. PEDICINI;RITA MARASCO;VITINA GRIECO;TEODORA STATUTO","24;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;MATHEMATICS","69;25;5;5;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CANCER RESEARCH;IMMUNOLOGY;GASTROENTEROLOGY;GENETICS;BIOCHEMISTRY;PATHOLOGY;CELL BIOLOGY;RADIOLOGY;ANESTHESIA;NUCLEAR MEDICINE;MOLECULAR BIOLOGY;DERMATOLOGY;ENDOCRINOLOGY;OPTICS;UROLOGY;BIOINFORMATICS;GYNECOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;PALEONTOLOGY;PHYSICAL THERAPY","57;28;26;20;15;14;13;10;10;9;7;5;5;4;3;3;3;3;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;GENE;LEUKEMIA;MULTIPLE MYELOMA;MYELOID LEUKEMIA;TRANSPLANTATION;LYMPHOMA;RADIATION THERAPY;BONE MARROW;DEXAMETHASONE;REGIMEN;STEM CELL;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;ANTIBODY;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;DISEASE;HEMATOLOGY","22;14;12;11;11;8;8;7;7;6;6;6;6;5;5;4;4;4;4;4;4","BREAST CANCER;LENALIDOMIDE;GENE EXPRESSION;CHRONIC LYMPHOCYTIC LEUKEMIA;BORTEZOMIB;CLINICAL ENDPOINT;COLORECTAL CANCER;HAEMATOPOIESIS;IMATINIB;RITUXIMAB;SUNITINIB;ADENOCARCINOMA;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CD34;CUMULATIVE INCIDENCE;FLUOROURACIL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MELPHALAN;PHASES OF CLINICAL RESEARCH;PLASMA CELL LEUKEMIA","8;8;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","DASATINIB;ADJUVANT CHEMOTHERAPY;BENDAMUSTINE;DNA METHYLATION;IRINOTECAN;CD38;FOLINIC ACID;GENE EXPRESSION PROFILING;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;NILOTINIB;BASE EXCISION REPAIR;C-MET;CARFILZOMIB;CIRCULATING TUMOR CELL;COLONIC DISEASE;CONTACT ALLERGY;CXCR4;CYCLIN;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA GLYCOSYLASE;DNA MISMATCH REPAIR;EGFR INHIBITORS;EPITHELIAL OVARIAN CANCER;ERBB3;ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR (EPH) RECEPTOR;EXTERNAL BEAM RADIOTHERAPY;GENOME INSTABILITY;IGHV@;IMATINIB MESYLATE;INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR;JURKAT CELLS;METASTATIC BREAST CANCER;MUTAGENESIS;NICOTINAMIDE ADENINE DINUCLEOTIDE;NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;ONCOGENE;P22PHOX;PLASMA CELL DYSCRASIA;PLEURAL DISEASE;PROPIDIUM IODIDE;PROSTATE-SPECIFIC ANTIGEN;PULMONARY ADENOCARCINOMA;RECTAL EXAMINATION;TRANSCRIPTOME;V600E","4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;PYRIMIDINES;SKIN NEOPLASMS;THIAZOLES;BRAIN NEOPLASMS;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;BONE NEOPLASMS;BREAST NEOPLASMS;NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL;PROTEIN KINASE INHIBITORS","44;33;33;32;31;27;21;17;16;16;13;12;12;12;11;11;10;10;10;10","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;ACUTE MYELOID LEUKEMIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SARCOMA RESEARCH AND TREATMENT;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF PLEURAL DISEASES;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GASTRIC CANCER RESEARCH AND TREATMENT;GLIOMAS;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;ROLE OF NEUTROPHIL EXTRACELLULAR TRAPS IN IMMUNITY;14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATION;ATOPIC DERMATITIS AND SKIN MICROBIOME;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CANCER STEM CELLS AND TUMOR METASTASIS;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA","8;5;4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","REGIMEN;CLINICAL ENDPOINT;EWING'S SARCOMA;HEMATOLOGY;ADJUVANT CHEMOTHERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BENDAMUSTINE;CUMULATIVE INCIDENCE;IMAGE-GUIDED RADIOTHERAPY;INTENSITY-MODULATED RADIOTHERAPY;INTERNATIONAL MYELOMA WORKING GROUP;MELPHALAN;PLASMA CELL LEUKEMIA;POLYCYTHEMIA VERA;TREATMENT;ADJUVANT RADIOTHERAPY;ADJUVANT THERAPY;AZACITIDINE;BLOATING;BRACHYTHERAPY DOSE CALCULATION","6;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MULTIPLE MYELOMA;MYELOID LEUKEMIA;ELDERLY PATIENTS;NEWLY DIAGNOSED;BREAST CANCER;CHRONIC LYMPHOCYTIC;CHRONIC MYELOID;LYMPHOCYTIC LEUKEMIA;PLASMA CELL;PRIMARY PLASMA;CELL LEUKEMIA;PHASE II;POLYCYTHEMIA VERA;STEM CELL;ACID LV;ACUTE MYELOID;ADJUVANT CHEMOTHERAPY;CARDIOVASCULAR EVENTS;CELL LINES;CELL TRANSPLANTATION;CISPLATIN VERSUS;CYTO-PV TRIAL;DIAGNOSED MULTIPLE;EUROPEAN PROSPECTIVE;EWING SARCOMA;FLUOROURACIL -FUFOLINIC;FUFOLINIC ACID;FULV REGIMEN;GASTRIC CANCER;HISTOLOGICAL FEATURES","6;6;5;5;4;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GROWTH FACTOR;AIR LEAKS;FACTOR RECEPTOR;RETROANGULAR FLAP;ONCOGENE HOMOLOG;VIRAL ONCOGENE;EPIDERMAL GROWTH;CLL CELLS;ERYTHROBLASTIC LEUKEMIA;HOMOLOG ERBB;LEUKEMIA VIRAL;PROTEIN SIGNALING;ACUTE LYMPHOID;CELL CARCINOMA;CLL PATIENTS;CRC SURGERY;CWI ANALGESIA;LYMPHOID LEUKEMIALYMPHOMA-TYPE;MONTHS RANGE;OVARIAN CANCER;PATHWAY ACTIVATION;SYMBIOTIC MIXTURE;TYROSINE KINASE;ACTIVATED PROTEIN;ACTIVATION MAPPING;ACUTE MYELOID;CONTINUOUS INFUSION;ERBB V-ERB-B;FRONTAL SINUS;LUNG RESECTION","15;9;9;9;8;8;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4",25,0.32,3,25.17,6,115.37,19.71,2,103,6.5,2,11,2.5,2,3,0,0,0,4,4,4,4.5,2,9,0,0,0,1.4,1,2,21.71,2,112,0,0,0,1,1,1,21.75,2,79,0,0,0,1,1,1,2,1,3,4.33,1,11,14.75,1,55,5.5,1,10,0.14,0,1,0,0,0,153.57,45,478,121.43,45,253,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2013,95,12.8526315789474,2.63157894736842,0.38,0.368421052631579,0.2,0.242105263157895,0.4,3,44,22,17,5,0.46,0.23,0.18,0.05,23.2,0.664898100950932,0.294736842105263,0.978947368421053,6.03162055335968,0.57636795755326,0.442225998300765,0.517171717171717,0.497344278126509,"PELLEGRINO MUSTO;ALBA FIORENTINO;VINCENZO FUSCO;GIOVANNI D’ARENA;C. CHIUMENTO;GIANLUCA GAÏDANO;P. PEDICINI;DAVIDE ROSSI;STEFANIA CLEMENTE;M. COZZOLINO;ROCCHINA CAIVANO;MICHELE AIETA;FRANCESCO DI RAIMONDO;VITTORIO SIMEON;GIUSEPPINA IMPROTA;SILVIA DEAGLIO;ILARIA LAURENZANA;MARTA COSCIA;LUCA BALDINI;FILIPPO FRAGGETTA","24;16;13;12;10;9;9;8;8;8;8;7;6;6;6;6;5;5;5;5","C. CHIUMENTO;ALBA FIORENTINO;VINCENZO FUSCO;PELLEGRINO MUSTO;P. PEDICINI;TOMMASO FABRIZIO;STEFANIA CLEMENTE;M. COZZOLINO;GIOVANNI D’ARENA;ROCCHINA CAIVANO;ALBA FIORENTINO COSTANZA CHIUMENTO;GIUSEPPINA IMPROTA;LIDIA STRIGARI;FILIPPO FRAGGETTA;GIOVANNI STORTO;GIANLUCA GAÏDANO;DAVIDE ROSSI;VALENTINA CONDELLI;G. CALIFANO;VITTORIO SIMEON","2.42;2.25;1.85;1.83;1.57;1.14;1.09;1.09;1.03;1.01;1;0.86;0.79;0.69;0.64;0.59;0.54;0.49;0.49;0.47","PELLEGRINO MUSTO;ALBA FIORENTINO;VINCENZO FUSCO;GIOVANNI D’ARENA;C. CHIUMENTO;P. PEDICINI;STEFANIA CLEMENTE;M. COZZOLINO;ROCCHINA CAIVANO;MICHELE AIETA;VITTORIO SIMEON;GIUSEPPINA IMPROTA;ILARIA LAURENZANA;GIOVANNI STORTO;GIUSEPPE PIETRANTUONO;FIORELLA D′AURIA;LUCIANA DE LUCA;G. CALIFANO;TEODORA STATUTO;GIULIA VITA","24;16;13;12;10;9;8;8;8;7;6;6;5;5;4;4;4;4;3;3","C. CHIUMENTO;ALBA FIORENTINO;VINCENZO FUSCO;PELLEGRINO MUSTO;P. PEDICINI;TOMMASO FABRIZIO;STEFANIA CLEMENTE;M. COZZOLINO;GIOVANNI D’ARENA;ROCCHINA CAIVANO;ALBA FIORENTINO COSTANZA CHIUMENTO;GIUSEPPINA IMPROTA;GIOVANNI STORTO;VALENTINA CONDELLI;G. CALIFANO;VITTORIO SIMEON;MICHELE AIETA;ILARIA LAURENZANA;GIUSEPPE PIETRANTUONO;ANTONIO NAPPI","2.42;2.25;1.85;1.83;1.57;1.14;1.09;1.09;1.03;1.01;1;0.86;0.64;0.49;0.49;0.47;0.41;0.41;0.37;0.36","GIANLUCA GAÏDANO;PELLEGRINO MUSTO;GIOVANNI D’ARENA;DAVIDE ROSSI;LUCA LAURENTI;MARTA COSCIA;SILVIA DEAGLIO;GIORGIO INGHIRAMI;OZREN JAKŠIĆ;SARA SERRA;FRANCESCO DI RAIMONDO;DAVIDE BRUSA;FABIO MALAVASI;ANDREA GALLAMINI;CAROLA BOCCOMINI;ALBA FIORENTINO;GIORGIO FEDELE;ALFONSO MARIA D’ARCO;C. RUSCONI;LUCA ARCAINI","545;530;519;491;378;378;378;313;306;306;290;247;247;223;223;215;200;198;198;198","GIOVANNI D’ARENA;PELLEGRINO MUSTO;ALBA FIORENTINO;FRANCESCA MADDALENA;LORENZA SISINNI;LUCIANA DE LUCA;VINCENZO FUSCO;ILARIA LAURENZANA;VITTORIO SIMEON;MICHELE AIETA;GIACOMO LETTINI;GIUSEPPE PIETRANTUONO;VALENTINA CONDELLI;C. CHIUMENTO;P. PEDICINI;ROCCHINA CAIVANO;GIUSEPPINA IMPROTA;GIUSEPPE LA TORRE;GIOVANNI STORTO;DANIELA CAPACCHIONE","494;481;166;160;160;148;141;119;114;110;107;106;100;90;87;78;74;70;62;59","PELLEGRINO MUSTO;ALBA FIORENTINO;VINCENZO FUSCO;GIOVANNI D’ARENA;C. CHIUMENTO;MICHELE AIETA;P. PEDICINI;M. COZZOLINO;STEFANIA CLEMENTE;ROCCHINA CAIVANO;VITTORIO SIMEON;GIUSEPPINA IMPROTA;ILARIA LAURENZANA;LUCIANA DE LUCA;GIOVANNI STORTO;GIUSEPPE PIETRANTUONO;FIORELLA D′AURIA;G. CALIFANO;ANTONIO NAPPI;CATERINA OLIVIERO","22;12;11;11;9;7;7;6;6;6;5;5;5;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ENGINEERING;PHILOSOPHY;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;BUSINESS;HISTORY;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE","80;41;14;8;3;3;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;SURGERY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;RADIOLOGY;NUCLEAR MEDICINE;PATHOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;OPTICS;MOLECULAR BIOLOGY;ENVIRONMENTAL HEALTH;MEDICAL PHYSICS;PHARMACOLOGY;DERMATOLOGY;UROLOGY;VIROLOGY","61;27;27;24;21;20;19;15;13;13;11;11;7;6;5;5;5;4;4;4","CANCER;GENE;RADIATION THERAPY;LEUKEMIA;MULTIPLE MYELOMA;CHEMOTHERAPY;BONE MARROW;LYMPHOMA;LUNG CANCER;APOPTOSIS;DISEASE;IMMUNE SYSTEM;IN VITRO;POPULATION;ADVERSE EFFECT;IN VIVO;MYELOID LEUKEMIA;PROSPECTIVE COHORT STUDY;REGIMEN;SIGNAL TRANSDUCTION;STEM CELL;TOXICITY;VIRUS","30;25;17;14;11;10;8;8;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","PROSTATE CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;PROSTATE;LENALIDOMIDE;MUTATION;RITUXIMAB;BORTEZOMIB;HEAD AND NECK CANCER;BREAST CANCER;CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;HAEMATOPOIESIS;MYELODYSPLASTIC SYNDROMES;BRACHYTHERAPY;GENE EXPRESSION;IMAGE-GUIDED RADIATION THERAPY;POLYMERASE;RNA;T CELL;THALIDOMIDE;UNFOLDED PROTEIN RESPONSE","13;12;8;7;7;7;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3","DNA METHYLATION;BENDAMUSTINE;CHRONIC MYELOMONOCYTIC LEUKEMIA;ERLOTINIB;GERMLINE MUTATION;INTERNATIONAL PROGNOSTIC INDEX;NUCLEOLIN;ALTERNATIVE SPLICING;ANDROGEN DEPRIVATION THERAPY;APREPITANT;ATF4;CASPASE;CD3;CHLORAMBUCIL;CUCUMBER MOSAIC VIRUS;CYP2C9;CYTOGENETICS;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;DOSE-VOLUME HISTOGRAM;ELTROMBOPAG;EXOME SEQUENCING;EXTERNAL BEAM RADIOTHERAPY;FLUDARABINE;FLUORESCENCE IN SITU HYBRIDIZATION;FOURNIER GANGRENE;FRAMESHIFT MUTATION;FUSION PROTEIN;FUSION TRANSCRIPT;GENE MUTATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HES1;HISTONE DEACETYLASE;HLA-G;HSP70;HSP90;IGHV@;IL-2 RECEPTOR;IMATINIB MESYLATE;INTENSITY MODULATION;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IONIZATION CHAMBER;KARYOTYPE;KRAS;LYMPHOPOIESIS;MOLECULAR MEDICINE;MONOCLONAL;MULTILEAF COLLIMATOR;MYELOPROLIFERATIVE NEOPLASM;NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;NON-CODING RNA;ONCOGENE;PALONOSETRON;PCA3;PHARMACOGENETICS;POINT MUTATION;POLY ADP RIBOSE POLYMERASE;PROSTATE BIOPSY;PROSTATE CARCINOMA;PROSTATE-SPECIFIC ANTIGEN;PTEN;RECOMBINATION-ACTIVATING GENE;REPOPULATION;RNA INTERFERENCE;RNA POLYMERASE;RNA SPLICING;ROS1;SMALL INTERFERING RNA;STAT;T-CELL RECEPTOR;THYMOCYTE;TRANSLATION (BIOLOGY)","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;PROSTATIC NEOPLASMS;;AGED;MIDDLE AGED;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;ADULT;AGED, 80 AND OVER;HEAD AND NECK NEOPLASMS;MULTIPLE MYELOMA;RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;ITALY;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CELL PROLIFERATION;RETROSPECTIVE STUDIES;BORONIC ACIDS;COLORECTAL NEOPLASMS","63;39;35;33;31;31;27;25;20;20;19;16;16;15;14;13;13;13;12;12","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ACUTE MYELOID LEUKEMIA;LYMPHOID NEOPLASMS;ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE;PROSTATE CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EFFICACY AND RESISTANCE IN CML TREATMENT;GLIOMAS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;INFLUENZA VIRUS RESEARCH AND EPIDEMIOLOGY;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CANCER IMMUNOTHERAPY;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;COLORECTAL CANCER RESEARCH AND TREATMENT;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS","9;9;8;7;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1","INTENSITY-MODULATED RADIOTHERAPY;RADIOTHERAPY;IMAGE-GUIDED RADIOTHERAPY;CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;REGIMEN;ACUTE MYELOID LEUKEMIA;B-CELL RECEPTOR SIGNALING;CANCER IMAGING;IMAGE-GUIDED RADIATION THERAPY;INTERNATIONAL MYELOMA WORKING GROUP;PROSTATE CANCER;TUMOR STAGING;ADJUVANT RADIOTHERAPY;AZACITIDINE;BENDAMUSTINE;BRACHYTHERAPY DOSE CALCULATION;CELL STRESS;CHRONIC MYELOMONOCYTIC LEUKEMIA;DOCKING (ANIMAL)","8;6;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PROSTATE CANCER;ELDERLY PATIENTS;MULTIPLE MYELOMA;BREAST CANCER;CANCER PATIENTS;CELL LUNG;CHEMOTHERAPY CT;III STUDY;LUNG CANCER;MYELOID LEUKEMIA;NEWLY DIAGNOSED;PATIENTS TREATED;PHASE III;RADIATION THERAPY;ACUTE MYELOID;ADJUVANT RADIOTHERAPY;AFFECTS BREAST;BIOLOGICAL EVALUATION;BONE MARROW;BREAST CARCINOMA;CANCER AGGRESSIVENESS;CANCER BURDEN;CANCER PROSE;CARCINOMA CELLS;CELL CANCER;CELL CARCINOMA;CHRONIC MYELOMONOCYTIC;COLORECTAL CANCER","12;11;8;7;5;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;ER STRESS;PROSTATE CANCER;VHL GENE;CLL PATIENTS;TB-CT SCAN;CLL CELLS;LEUKEMIA CLL;CDD EXPRESSION;COMPUTED TOMOGRAPHY;DRUG RESISTANCE;HIF-Α PROTEIN;MPS OBTAINED;MULTIPLE MYELOMA;MULTIVARIATE ANALYSIS;MUTATIONAL STATUS;NOTCH PATHWAY;PROGRESSION-FREE SURVIVAL;QUALITY CONTROL;SOLUBLE HLA-G;WEGENERS GRANULOMATOSIS;APOPTOSIS INDUCED;BASE PAIR;BC CELLS;BREAST CANCER;DELETION MUTANT;DOSE VARIABILITY;ENDOPLASMIC RETICULUM;ENDOTHELIAL CELLS","15;15;13;8;8;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3",25,0.26,1.75,11.04,3.55,28.5,5.71,1,12,0,0,0,1,1,1,0,0,0,1.25,1,2,12,12,12,1,1,1,1,1,1,7.57,1,17,0,0,0,0,0,0,3.8,1,5,0,0,0,0,0,0,0,0,0,1,1,1,3.2,1,5,2,2,2,0,0,0,0,0,0,100.71,64,183,100.71,64,183,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2014,70,16.1571428571429,2.38571428571429,0.419161676646707,0.242857142857143,0.171428571428571,0.214285714285714,0.457142857142857,0,44,14,5,6,0.63,0.2,0.07,0.09,42.01,1.1117331191994,0.271428571428571,1,5.67961165048543,0.45580412727569,0.3125,0.472303206997085,0.403980099502488,"PELLEGRINO MUSTO;MICHELE AIETA;GIOVANNI D’ARENA;FRANCESCO DI RAIMONDO;VITTORIO SIMEON;PAOLA OMEDÈ;DAVIDE ROSSI;MARIO BOCCADORO;GIANLUCA GAÏDANO;CLÁUDIA PICCOLI;P. PEDICINI;GIOVANNI STORTO;ALDO CAMMAROTA;ALBA FIORENTINO;VINCENZO FUSCO;NAZZARENO CAPITANIO;MATTEO LANDRISCINA;GIUSEPPE DI LORENZO;GAETANO FACCHINI;R. CAIVANO","21;12;7;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","PELLEGRINO MUSTO;GIOVANNI D’ARENA;ALDO CAMMAROTA;MICHELE AIETA;P. PEDICINI;ALBA FIORENTINO;R. CAIVANO;VITTORIO SIMEON;GIULIA VITA;GIOVANNI STORTO;CLÁUDIA PICCOLI;NAZZARENO CAPITANIO;GIAMPAOLO FERRAIOLI;VITO PASCAZIO;FABIO BASELICE;ROCCHINA CAIVANO;DOMENICO GENOVESI;C. CHIUMENTO;ROSELLA SCRIMA;MATTEO LANDRISCINA","2.15;1.41;0.83;0.72;0.69;0.6;0.57;0.54;0.51;0.48;0.47;0.41;0.4;0.4;0.4;0.4;0.4;0.35;0.34;0.34","PELLEGRINO MUSTO;MICHELE AIETA;GIOVANNI D’ARENA;VITTORIO SIMEON;CLÁUDIA PICCOLI;P. PEDICINI;GIOVANNI STORTO;ALDO CAMMAROTA;ALBA FIORENTINO;VINCENZO FUSCO;R. CAIVANO;C. CHIUMENTO;ILARIA LAURENZANA;KATIA TODOERTI;GIULIA VITA;STEFANIA TRINO;CARMELA MAZZOCCOLI;ANTONELLA CAIVANO;SILVIA LEPORE;ROCCO GALASSO","21;12;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","PELLEGRINO MUSTO;GIOVANNI D’ARENA;ALDO CAMMAROTA;MICHELE AIETA;P. PEDICINI;ALBA FIORENTINO;R. CAIVANO;VITTORIO SIMEON;GIULIA VITA;GIOVANNI STORTO;CLÁUDIA PICCOLI;ROCCHINA CAIVANO;C. CHIUMENTO;P. SANPAOLO;V. BARBIERI;VINCENZO FUSCO;MICHELE BISCEGLIA;CARLOS GALLIANI;ILARIA LAURENZANA;VITALBA RUGGIERI","2.15;1.41;0.83;0.72;0.69;0.6;0.57;0.54;0.51;0.48;0.47;0.4;0.35;0.33;0.33;0.32;0.31;0.31;0.27;0.25","PELLEGRINO MUSTO;ANTONIO PALUMBO;MARIO BOCCADORO;PAOLA OMEDÈ;MARIA TERESA PETRUCCI;MASSIMO OFFIDANI;FRANCESCO DI RAIMONDO;FRANCESCA PATRIARCA;MICHÈLE CAVO;GIOVANNINO CICCONE;MARIELLA GENUARDI;TOMMASO CARAVITA;FRANCESCA GAY;FEDERICA CAVALLO;LUCIO CATALANO;ANDREA EVANGELISTA;ANGELO MICHELE CARELLA;ANNA MARIA CAFRO;ARNON NAGLER;CHIARA CERRATO","1571;1100;1100;1100;1057;1057;995;918;918;853;853;853;757;737;737;714;714;714;714;714","PELLEGRINO MUSTO;MICHELE AIETA;CARMELA MAZZOCCOLI;ROBERTO MINA;VITTORIO SIMEON;P. PEDICINI;GIOVANNI STORTO;ROCCO GALASSO;VITALBA RUGGIERI;LORENZA SISINNI;VINCENZO FUSCO;C. CHIUMENTO;DANIELA CAPACCHIONE;GIOVANNA MANSUETO;ROBERTO GUARIGLIA;ROSJ GALLICCHIO;FRANCESCA MADDALENA;R. CAIVANO;FRANCESCA AGRIESTI;T. TATARANNI","1571;442;219;204;169;166;165;160;149;125;87;81;76;76;76;76;75;73;72;66","PELLEGRINO MUSTO;MICHELE AIETA;GIOVANNI D’ARENA;VITTORIO SIMEON;GIOVANNI STORTO;P. PEDICINI;VINCENZO FUSCO;ALDO CAMMAROTA;R. CAIVANO;C. CHIUMENTO;CARMELA MAZZOCCOLI;GIULIA VITA;ILARIA LAURENZANA;KATIA TODOERTI;ROCCO GALASSO;SILVIA LEPORE;STEFANIA TRINO;VITALBA RUGGIERI;ANTONELLA CAIVANO;ALBA FIORENTINO","21;12;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;BUSINESS;ENGINEERING;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","60;32;16;5;4;3;1;1;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GENETICS;BIOCHEMISTRY;CANCER RESEARCH;IMMUNOLOGY;PATHOLOGY;GASTROENTEROLOGY;CELL BIOLOGY;NUCLEAR MEDICINE;RADIOLOGY;MOLECULAR BIOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;PHARMACOLOGY;UROLOGY;ARTIFICIAL INTELLIGENCE;ENDOCRINOLOGY;GYNECOLOGY;OPTICS","46;24;21;18;17;16;13;13;12;10;10;9;8;6;4;4;4;3;3;3;3","CANCER;GENE;CHEMOTHERAPY;BONE MARROW;CONFIDENCE INTERVAL;MULTIPLE MYELOMA;LYMPHOMA;RADIATION THERAPY;STEM CELL;ANTIBODY;CLINICAL TRIAL;LEUKEMIA;MULTIVARIATE ANALYSIS;POPULATION;RECEPTOR;SIGNAL TRANSDUCTION;COHORT;ADVERSE EFFECT;CELL;CONTEXT (ARCHAEOLOGY);POSITRON EMISSION TOMOGRAPHY;PREDNISONE;PROPORTIONAL HAZARDS MODEL;TRANSPLANTATION","19;17;12;9;8;8;7;6;6;5;5;5;5;5;5;5;4;3;3;3;3;3;3;3","DOCETAXEL;GENE EXPRESSION;CLINICAL ENDPOINT;HAEMATOPOIESIS;PROSTATE CANCER;BORTEZOMIB;CHRONIC LYMPHOCYTIC LEUKEMIA;HAZARD RATIO;LENALIDOMIDE;PROGRESSION-FREE SURVIVAL;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BREAST CANCER;COLORECTAL CANCER;MAINTENANCE THERAPY;MELPHALAN;METASTASIS;MONOCLONAL ANTIBODY;THALIDOMIDE;ADENOCARCINOMA;AUTOCRINE SIGNALLING;CD34;CELL CYCLE;CHROMOSOME;CISPLATIN;CYCLOPHOSPHAMIDE;DIFFUSE LARGE B-CELL LYMPHOMA;DOUBLING TIME;FOLLICULAR LYMPHOMA;HEPATOCYTE GROWTH FACTOR;IMMUNOPHENOTYPING;INTERIM ANALYSIS;MAPK/ERK PATHWAY;MESSENGER RNA;METABOLIC SYNDROME;MICRORNA;NEUTROPENIA;OCTREOTIDE;PACLITAXEL;PET-CT;PROGENITOR CELL;QUALITY ASSURANCE;RADIATION TREATMENT PLANNING;RADIOBIOLOGY;RITUXIMAB;UNIVARIATE ANALYSIS","6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANDROGEN DEPRIVATION THERAPY;MONOCLONAL;BENDAMUSTINE;DNA METHYLATION;KARYOTYPE;MICROVESICLES;REPOPULATION;ABDOMINAL OBESITY;ACRYLAMIDE;ANAEROBIC GLYCOLYSIS;ANDROGEN RECEPTOR;BETA-CATENIN;BONE METASTASIS;BOVINE PAPILLOMAVIRUS;CAPECITABINE;CARBOPLATIN;CARFILZOMIB;CATENIN;CD117;CHEMOIMMUNOTHERAPY;CUTANEOUS MASTOCYTOSIS;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA GLYCOSYLASE;DOSE-VOLUME HISTOGRAM;ERLOTINIB;EXTERNAL BEAM RADIOTHERAPY;EXTRACELLULAR SIGNAL-REGULATED KINASES;FLUDARABINE;FOURNIER GANGRENE;FRAMESHIFT MUTATION;HOUSEKEEPING GENE;IGHV@;IL-2 RECEPTOR;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KEARNS–SAYRE SYNDROME;KRAS;METASTATIC BREAST CANCER;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MITOCHONDRIAL MYOPATHY;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;NAB-PACLITAXEL;NEUROGLOBIN;PEMETREXED;PROGENITOR;RANKL;RNA EXTRACTION;STEATOHEPATITIS;TAXANE;TRANSLATION (BIOLOGY);TRIPLE NEGATIVE;TRIPLE-NEGATIVE BREAST CANCER","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MULTIPLE MYELOMA;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;;MIDDLE AGED;ADULT;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;TREATMENT OUTCOME;DISEASE-FREE SURVIVAL;BIOMARKERS, TUMOR;COLORECTAL NEOPLASMS;PROGNOSIS;ANIMALS;CYSTIC FIBROSIS;HEPATOCYTE GROWTH FACTOR;KAPLAN-MEIER ESTIMATE","47;26;25;25;23;22;21;19;15;11;11;11;10;9;9;9;8;8;8;8","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR CHAPERONES IN PROTEIN FOLDING AND DISEASE;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ACUTE MYELOID LEUKEMIA;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;RENAL CELL CARCINOMA;THERAPEUTIC ADVANCES IN CYSTIC FIBROSIS RESEARCH;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS;EFFICACY AND RESISTANCE IN CML TREATMENT","9;5;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","TREATMENT;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;INTERNATIONAL MYELOMA WORKING GROUP;MAINTENANCE THERAPY;MANTLE CELL LYMPHOMA;MELPHALAN;PROSTATE CANCER;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AZACITIDINE;BENDAMUSTINE;BIOMARKER ANALYSIS;CABAZITAXEL;CONCOMITANT;DIAGNOSTIC IMAGING;DISCONTINUATION;DOUBLING TIME;EVEROLIMUS;EXTRACELLULAR VESICLES;FOLLICULAR LYMPHOMA","8;6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE MYELOMA;PROSTATE CANCER;CASTRATION-RESISTANT PROSTATE;ELDERLY PATIENTS;PATIENTS PTS;BONE MARROW;BREAST CANCER;CLINICAL OUTCOMES;ADVANCED BREAST;B-CELL LYMPHOMA;CANCER CRPC;CANCER PATIENTS;CELL CARCINOMA;CELL-CYCLE PROGRESSION;CHRONIC LYMPHOCYTIC;CLINICAL RADIOBIOLOGY;CLINICALLY RELEVANT;COLORECTAL TUMORS;CRPC RESULTS;DIAGNOSED MULTIPLE;DOCETAXEL DOC;DVH-BASED EVALUATION;FIRST-LINE CHEMOTHERAPY;FOLL TRIAL;FOLLICULAR LYMPHOMA;FONDAZIONE ITALIANA;GAMMA MAPS;HEMATOPOIETIC STEMPROGENITOR;INTERNATIONAL PATHOLOGY;ITALIAN MULTICENTER","9;5;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE MYELOMA;MEC- CELLS;BONE MARROW;NOTCH MUTATIONS;NICD MUTATED;ACRYLAMIDE INTAKE;CD EXPRESSION;MUTATED MEC-;BONE METASTASIS;CD CD;CELL LINES;EC RISK;FLOW CYTOMETRY;RNA EXPRESSION;TEST CLASSIFICATION;AL BLOOD;CELLS TRANSFECTED;MULTIVARIATE ANALYSIS;NEWLY DIAGNOSED;NOTCH MUTATED;PROTEIN EXPRESSION;PROTEIN LEVELS;BETA-CATENIN EXPRESSION;CF PATIENTS;CLL CELLS;CONTROL VECTOR;DIAGNOSED MULTIPLE;GENE EXPRESSION;MUTATED DNA;MYELOMA ECS","16;14;13;10;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4",29,0.41,2.1,19.04,3.95,76.41,8.12,1,28,4,4,4,2,1,3,0,0,0,2.2,1,6,3,3,3,0,0,0,1.5,1,2,8.75,1,31,0,0,0,1,1,1,5.67,1,11,0,0,0,0,0,0,2,1,3,1,1,1,4.33,1,9,1,1,1,0,0,0,0,0,0,127,32,480,127,32,480,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2015,90,16.1555555555556,2.38888888888889,0.418604651162791,0.233333333333333,0.144444444444444,0.211111111111111,0.5,2,41,24,15,4,0.46,0.27,0.17,0.04,27.81,0.746242244978421,0.322222222222222,0.988888888888889,5.31005586592179,0.48810581975364,0.440972222222222,0.465909090909091,0.410774410774411,"PELLEGRINO MUSTO;VITTORIO SIMEON;KATIA TODOERTI;ANTONINO NERI;MICHELE AIETA;GIOVANNI D’ARENA;ILARIA LAURENZANA;FORTUNATO MORABITO;LUCA MAURILLO;ANTONELLA CAIVANO;GIANLUCA GAÏDANO;GIOVANNA MANSUETO;GIUSEPPE DI LORENZO;SONIA FABRIS;AGOSTINO CORTELEZZI;MASSIMO BRECCIA;GIOVANNI STORTO;ROBERTO LATAGLIATA;ALDO CAMMAROTA;GIUSEPPE PIETRANTUONO","23;14;12;12;9;8;8;6;5;5;5;5;5;5;5;5;5;4;4;4","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;VITTORIO SIMEON;T. FABRIZIO;MICHELE AIETA;KATIA TODOERTI;ANTONINO NERI;GIOVANNI D’ARENA;GIOVANNI STORTO;ILARIA LAURENZANA;ROSJ GALLICCHIO;ROCCHINA CAIVANO;GIUSEPPINA GALLUCCI;ALDO CAMMAROTA;MATILDE GIOIOSO;ANTONELLA CAIVANO;ALFREDO TARTARONE;FRANCESCA MADDALENA;PANTALEO BUFO;VINCENZO FUSCO","1.65;1.16;1.1;1.06;0.91;0.79;0.79;0.6;0.59;0.56;0.48;0.45;0.39;0.39;0.39;0.37;0.35;0.33;0.3;0.3","PELLEGRINO MUSTO;VITTORIO SIMEON;KATIA TODOERTI;MICHELE AIETA;GIOVANNI D’ARENA;ILARIA LAURENZANA;ANTONELLA CAIVANO;GIOVANNA MANSUETO;AGOSTINO CORTELEZZI;GIOVANNI STORTO;ALDO CAMMAROTA;GIUSEPPE PIETRANTUONO;STEFANIA TRINO;LUCIANA DE LUCA;FRANCESCO LA ROCCA;STEFANIA CLEMENTE;MATILDE GIOIOSO;ROCCHINA CAIVANO;ANTONIO VILLONIO;ANTONIO TRAFICANTE","23;14;12;9;8;8;5;5;5;5;4;4;4;4;4;4;4;4;3;3","PELLEGRINO MUSTO;GIUSEPPE PIETRANTUONO;VITTORIO SIMEON;T. FABRIZIO;MICHELE AIETA;KATIA TODOERTI;GIOVANNI D’ARENA;GIOVANNI STORTO;ILARIA LAURENZANA;ROSJ GALLICCHIO;ROCCHINA CAIVANO;GIUSEPPINA GALLUCCI;ALDO CAMMAROTA;MATILDE GIOIOSO;ANTONELLA CAIVANO;ALFREDO TARTARONE;FRANCESCA MADDALENA;PANTALEO BUFO;VINCENZO FUSCO;GIULIA VITA","1.65;1.16;1.1;1.06;0.91;0.79;0.6;0.59;0.56;0.48;0.45;0.39;0.39;0.39;0.37;0.35;0.33;0.3;0.3;0.29","PELLEGRINO MUSTO;VITTORIO SIMEON;ANTONIO PALUMBO;FRANCESCA GAY;MICHÈLE CAVO;FORTUNATO MORABITO;ILARIA LAURENZANA;ALESSANDRA LAROCCA;GIOVANNI D’ARENA;ANNEMIEK BROIJL;BENEDETTO BRUNO;EFSTATHIOS KASTRITIS;EVANGELOS TERPOS;H. EINSELE;HANS ERIK JOHNSEN;HEINZ LUDWIG;MARTINA KLEBER;MELETIOS Α. DIMOPOULOS;MERAL BEKSAÇ;MONIKA ENGELHARDT","1115;552;543;485;485;422;365;357;356;331;331;331;331;331;331;331;331;331;331;331","PELLEGRINO MUSTO;VITTORIO SIMEON;ILARIA LAURENZANA;GIOVANNI D’ARENA;KATIA TODOERTI;GIOVANNA MANSUETO;ANTONELLA CAIVANO;FRANCESCO LA ROCCA;LUCIANA DE LUCA;STEFANIA TRINO;FIORELLA D′AURIA;GIUSEPPE PIETRANTUONO;GIOVANNI STORTO;ANTONIO TRAFICANTE;MADDALENA MAIETTI;T. IZZO;ANNALISA MORANO;CARLO BUONERBA;GIOVANNI CALICE;STEFANIA CLEMENTE","1115;552;365;356;315;304;280;261;261;261;200;194;188;167;166;166;119;114;92;92","PELLEGRINO MUSTO;VITTORIO SIMEON;KATIA TODOERTI;MICHELE AIETA;ILARIA LAURENZANA;GIOVANNI D’ARENA;ANTONELLA CAIVANO;GIOVANNA MANSUETO;GIOVANNI STORTO;ALDO CAMMAROTA;FRANCESCO LA ROCCA;LUCIANA DE LUCA;MATILDE GIOIOSO;ROCCHINA CAIVANO;STEFANIA CLEMENTE;STEFANIA TRINO;GIUSEPPE PIETRANTUONO;ANNALISA MORANO;ANTONELLA LOTUMOLO;ANTONIO VILLONIO","23;14;12;9;8;8;5;5;5;4;4;4;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;PHYSICS;COMPUTER SCIENCE;BUSINESS;ENGINEERING;POLITICAL SCIENCE;ART;ECONOMICS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;PSYCHOLOGY","73;40;15;4;4;3;2;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;GENETICS;BIOCHEMISTRY;GASTROENTEROLOGY;IMMUNOLOGY;SURGERY;CELL BIOLOGY;PATHOLOGY;RADIOLOGY;NUCLEAR MEDICINE;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;PALEONTOLOGY;MEDICAL PHYSICS;PHARMACOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE;GEOMETRY;LAW;MEDICAL EDUCATION;NURSING;PHYSIOLOGY;UROLOGY","61;26;24;20;19;17;17;17;13;13;11;9;8;5;5;4;4;3;2;2;2;2;2;2;2","CANCER;GENE;CHEMOTHERAPY;RADIATION THERAPY;LEUKEMIA;MULTIPLE MYELOMA;MYELOID LEUKEMIA;SIGNAL TRANSDUCTION;BONE MARROW;POPULATION;CELL;CELL GROWTH;CONCOMITANT;IMMUNE SYSTEM;IMMUNOHISTOCHEMISTRY;LYMPHOMA;MAGNETIC RESONANCE IMAGING;CLINICAL TRIAL;COHORT;DISEASE;LUNG CANCER;MYELOID;PHOSPHORYLATION;RECEPTOR;STAGE (STRATIGRAPHY);TOXICITY","34;25;15;12;10;10;10;8;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","GENE EXPRESSION;COLORECTAL CANCER;PROSTATE CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;BREAST CANCER;CLINICAL ENDPOINT;DIFFUSION MRI;EFFECTIVE DIFFUSION COEFFICIENT;ENDOMETRIAL CANCER;GENOTYPE;IMATINIB;MUTATION;MYELODYSPLASTIC SYNDROMES;RITUXIMAB;BORTEZOMIB;CD20;CD34;CELL CYCLE;CHEMOKINE;CHEMOTHERAPY REGIMEN;CYCLOPHOSPHAMIDE;CYTOKERATIN;DOCETAXEL;DOWNREGULATION AND UPREGULATION;GENE SILENCING;LENALIDOMIDE;METASTASIS;MICRORNA;NOTCH SIGNALING PATHWAY;PLASMA CELL LEUKEMIA;PROGRESSION-FREE SURVIVAL;RADIATION TREATMENT PLANNING;RADIOSURGERY;T CELL","8;7;7;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","DNA METHYLATION;IMATINIB MESYLATE;KRAS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;BENDAMUSTINE;CIRCULATING TUMOR CELL;CXCR4;CYBERKNIFE;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;FLUDARABINE;GASTROINTESTINAL CANCER;JAG1;JURKAT CELLS;MOLECULAR MEDICINE;MONOCLONAL;NILOTINIB;PROMOTER;TAXANE;TRANSLATION (BIOLOGY)","5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;MIDDLE AGED;FEMALE;;AGED;MALE;ADULT;BREAST NEOPLASMS;ITALY;MULTIPLE MYELOMA;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;NEOPLASMS;LEUKEMIA, MYELOID, ACUTE;PROSTATIC NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADENOCARCINOMA;BIOMARKERS, TUMOR;TREATMENT OUTCOME","61;32;31;29;27;27;17;17;17;15;15;14;14;14;13;13;12;11;11;11","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ACUTE MYELOID LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;RADIOTHERAPY PHYSICS AND TECHNOLOGY;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;LYMPHOID NEOPLASMS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ROLE OF PIM ONCOGENES IN TUMORIGENESIS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;CANCER STEM CELLS AND TUMOR METASTASIS;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;COLORECTAL CANCER RESEARCH AND TREATMENT;CRANIOFACIAL RECONSTRUCTION TECHNIQUES","9;7;6;4;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CONCOMITANT;INTERNATIONAL MYELOMA WORKING GROUP;ACUTE MYELOID LEUKEMIA;AZACITIDINE;CLINICAL ENDPOINT;DIFFUSION-WEIGHTED IMAGING;IMATINIB MESYLATE;BREAST MRI;CANCER TREATMENT;CHEMOTHERAPY REGIMEN;INTENSITY-MODULATED RADIOTHERAPY;PERFUSION IMAGING;PLASMA CELL LEUKEMIA;PROGRESSION-FREE SURVIVAL;RADIOTHERAPY;REGIMEN;ABIRATERONE ACETATE;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BARRETT'S ESOPHAGUS;BENDAMUSTINE","5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","MYELOID LEUKEMIA;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PROSTATE CANCER;ACUTE MYELOID;CANCER PATIENTS;ELDERLY PATIENTS;MAGNETIC RESONANCE;MULTIPLE MYELOMA;ENDOMETRIAL CANCER;II STUDY;LEUKEMIA PATIENTS;PHASE II;PLASMA CELL;RESONANCE IMAGING;BONE MARROW;BREAST CANCER;CELL DYSCRASIAS;CELL LUNG;CHRONIC MYELOID;CIRCULATING TUMOR;CONCOMITANT DRUGS;DIFFUSION WEIGHTED;EXTRACELLULAR VESICLES;ITALIAN CANCER;ITALIAN MULTICENTER;ITMO STUDY;LEUKEMIA CELLS;LINE SETTING;LOCALLY ADVANCED","7;6;6;6;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MILAN ITALY;RESEARCH FUNDING;HONORARIA RESEARCH;ITALY DEPARTMENT;MULTIPLE MYELOMA;GENE EXPRESSION;CONSULTANCY HONORARIA;PLASMA CELL;RS POLYMORPHISM;TRANSLATIONAL RESEARCH;ANTONINO NERI;BASILICATA RIONERO;CANCER CENTER;PROMOTER METHYLATION;REFERRAL CANCER;SEPT PROMOTER;STEM CELLS;EC PATIENTS;FONDAZIONE IRCCS;ITALY HEMATOLOGY;MULTIVARIATE ANALYSIS;CANCER PATIENTS;HEMATOLOGY UNIT;IRCCS-CROB REFERRAL;ITALY LABORATORY;ABNORMAL ACT;CELL CYCLE;CELL MOTILITY;CLINICAL SCIENCES;COMMUNITY HEALTH","18;17;12;12;11;10;9;9;9;9;8;8;8;8;8;8;8;7;7;7;7;6;6;6;6;5;5;5;5;5",38,0.42,2.25,14.5,5.5,47.1,7.2,1,20,2,1,4,0,0,0,1,1,1,2.6,1,5,2,1,3,0,0,0,1,1,1,8.7,1,27,0,0,0,0,0,0,5.86,1,16,0,0,0,2,2,2,1.5,1,2,1.67,1,3,3.57,1,6,2.67,1,5,0,0,0,0,0,0,89.8,35,364,89.8,35,364,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2016,87,18.5172413793103,2.45977011494253,0.406542056074766,0.206896551724138,0.149425287356322,0.114942528735632,0.517241379310345,0,51,27,7,0,0.59,0.31,0.08,0,24.38,0.750524974465173,0.298850574712644,1,5.29972752043597,0.493855802556859,0.471111111111111,0.55,0.327380952380952,"PELLEGRINO MUSTO;VITTORIO SIMEON;GIOVANNI D’ARENA;MICHELE AIETA;KATIA TODOERTI;ILARIA LAURENZANA;STEFANIA TRINO;CONCETTA CONTICELLO;FRANCESCO DI RAIMONDO;ANTONINO NERI;ANNA MARINA LIBERATI;LUCIANA DE LUCA;MATTEO LANDRISCINA;ANTONIO PALUMBO;STEFANO MOLICA;ORESTE VILLANI;LUIGI DEL VECCHIO;FRANCA ESPOSITO;ROBERTO RIA;ANGELO MICHELE CARELLA","25;16;11;9;9;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5","PELLEGRINO MUSTO;VITTORIO SIMEON;KATIA TODOERTI;MICHELANGELO VESTITA;ANGELA FILONI;DOMENICO BONAMONTE;MICHELE AIETA;ANTONINO NERI;GIOVANNI D’ARENA;MATTEO LANDRISCINA;ILARIA LAURENZANA;STEFANIA TRINO;FRANCA ESPOSITO;CARMELA MAZZOCCOLI;LUIGI DEL VECCHIO;MARTINA MANZONI;LUCA AGNELLI;LUCIANA DE LUCA;FRANCESCO DI RAIMONDO;GIUSEPPINA IMPROTA","1.42;1.2;0.9;0.87;0.87;0.87;0.7;0.68;0.65;0.58;0.55;0.48;0.45;0.43;0.41;0.4;0.4;0.38;0.38;0.34","PELLEGRINO MUSTO;VITTORIO SIMEON;GIOVANNI D’ARENA;MICHELE AIETA;KATIA TODOERTI;ILARIA LAURENZANA;STEFANIA TRINO;LUCIANA DE LUCA;MATTEO LANDRISCINA;ORESTE VILLANI;GIUSEPPE PIETRANTUONO;CARMELA MAZZOCCOLI;ANTONELLA CAIVANO;FRANCESCO LA ROCCA;GIOVANNA MANSUETO;ANNA MARIA BOCHICCHIO;STEFANO CORDIO;LORENZA SISINNI;MICHELANGELO VESTITA;FRANCESCA MADDALENA","25;16;11;9;9;8;8;6;6;6;5;5;5;5;5;5;4;4;3;3","PELLEGRINO MUSTO;VITTORIO SIMEON;KATIA TODOERTI;MICHELANGELO VESTITA;MICHELE AIETA;GIOVANNI D’ARENA;MATTEO LANDRISCINA;ILARIA LAURENZANA;STEFANIA TRINO;CARMELA MAZZOCCOLI;LUCIANA DE LUCA;GIUSEPPINA IMPROTA;LORENZA SISINNI;ANTONELLA CAIVANO;FRANCESCO LA ROCCA;ANNA MARIA BOCHICCHIO;FRANCESCA MADDALENA;GIOVANNI STORTO;ORESTE VILLANI;GIUSEPPE PIETRANTUONO","1.42;1.2;0.9;0.87;0.7;0.65;0.58;0.55;0.48;0.43;0.38;0.34;0.34;0.33;0.33;0.31;0.28;0.27;0.27;0.25","PELLEGRINO MUSTO;VITTORIO SIMEON;MICHELE AIETA;MATTEO LANDRISCINA;KATIA TODOERTI;FRANCESCO MASSARI;UGO DE GIORGI;CRISTIAN LOLLI;EMANUELA SCARPI;VINCENZA CONTEDUCA;LUCA AGNELLI;NICOLA GIULIANI;FRANCA ESPOSITO;DANILO SWANN MATASSA;ANTONINO NERI;ANTONIO PALUMBO;CARMELA MAZZOCCOLI;GIUSEPPE PIETRANTUONO;ANNA MARINA LIBERATI;CONCETTA CONTICELLO","572;431;396;382;376;289;289;281;281;280;276;276;270;245;231;230;220;204;201;201","PELLEGRINO MUSTO;VITTORIO SIMEON;MICHELE AIETA;KATIA TODOERTI;MATTEO LANDRISCINA;CARMELA MAZZOCCOLI;GIUSEPPE PIETRANTUONO;FRANCESCA MADDALENA;ILARIA LAURENZANA;STEFANIA TRINO;LUCIANA DE LUCA;ORESTE VILLANI;GIOVANNA MANSUETO;LORENZA SISINNI;ANTONELLA CAIVANO;FRANCESCO LA ROCCA;GIOVANNI D’ARENA;ANTONIO TRAFICANTE;GIACOMO LETTINI;ANNALISA MORANO","572;431;385;376;338;220;204;201;198;198;178;159;151;148;147;147;147;90;88;72","PELLEGRINO MUSTO;VITTORIO SIMEON;GIOVANNI D’ARENA;KATIA TODOERTI;MICHELE AIETA;ILARIA LAURENZANA;STEFANIA TRINO;LUCIANA DE LUCA;ORESTE VILLANI;ANTONELLA CAIVANO;FRANCESCO LA ROCCA;CARMELA MAZZOCCOLI;GIOVANNA MANSUETO;GIUSEPPE PIETRANTUONO;ANNA MARIA BOCHICCHIO;LORENZA SISINNI;MATTEO LANDRISCINA;FRANCESCA MADDALENA;GIOVANNI STORTO;MICHELANGELO VESTITA","25;16;11;9;8;8;8;6;6;5;5;5;5;5;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATERIALS SCIENCE;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;PSYCHOLOGY;ART","74;41;7;5;4;3;3;2;2;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;GENETICS;IMMUNOLOGY;SURGERY;BIOCHEMISTRY;GASTROENTEROLOGY;CELL BIOLOGY;PATHOLOGY;PALEONTOLOGY;NUCLEAR MEDICINE;PHARMACOLOGY;RADIOLOGY;MEDICAL PHYSICS;MOLECULAR BIOLOGY;OPTICS;ARTIFICIAL INTELLIGENCE;DERMATOLOGY;UROLOGY","59;28;28;24;22;20;16;15;13;11;7;6;6;5;4;4;4;3;3;3","CANCER;GENE;MULTIPLE MYELOMA;LEUKEMIA;CHEMOTHERAPY;BONE MARROW;RADIATION THERAPY;APOPTOSIS;CLINICAL TRIAL;IMMUNE SYSTEM;LYMPHOMA;RECEPTOR;ANTIBODY;COHORT;REGIMEN;CONCOMITANT;HEMATOLOGY;IN VITRO;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);STEM CELL;TOXICITY","27;21;18;11;10;8;7;6;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4","CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;COLORECTAL CANCER;BORTEZOMIB;CELL CYCLE;LENALIDOMIDE;BREAST CANCER;CYCLOPHOSPHAMIDE;DOWNREGULATION AND UPREGULATION;MICRORNA;DOCETAXEL;GENE EXPRESSION;GENOTYPE;GIST;MELPHALAN;METASTASIS;MONOCLONAL ANTIBODY;MUTATION;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;RITUXIMAB;SALVAGE THERAPY;SUNITINIB","9;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","IGHV@;GENE EXPRESSION PROFILING;OXALIPLATIN;BRENTUXIMAB VEDOTIN;CD38;CHLORAMBUCIL;FRAMESHIFT MUTATION;FYN;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;KRAS;MASTECTOMY;MICROVESICLES;MISSENSE MUTATION;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;PHARMACOGENETICS;ABDOMINOPERINEAL RESECTION;ALLELE FREQUENCY;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ARGINASE;AUTOPHAGOSOME;BENDAMUSTINE;BREAST RECONSTRUCTION;CAPECITABINE;CARBOPLATIN;CATENIN;CELL CYCLE CHECKPOINT;CIRCULATING TUMOR CELL;CRIZOTINIB;CXCR4;CYBERKNIFE;CYCLIN D1;CYCLIN-DEPENDENT KINASE 1;CYTOGENETICS;DNA MISMATCH REPAIR;EPITHELIAL–MESENCHYMAL TRANSITION;FLUDARABINE;GERMLINE MUTATION;GLUTAMINASE;GLUTAMINE SYNTHETASE;GRANZYME B;HPV INFECTION;IN SITU HYBRIDIZATION;INDOLEAMINE 2,3-DIOXYGENASE;JURKAT CELLS;LONG NON-CODING RNA;MAMMOGRAPHY;METAPHASE;METASTASECTOMY;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;MITOPHAGY;MMP9;MYELOID-DERIVED SUPPRESSOR CELL;NON-CODING RNA;OFATUMUMAB;OSTEONECROSIS OF THE JAW;PDGFRA;PERFORIN;PLASMA CELL DYSCRASIA;POMALIDOMIDE;PSEUDOGENE;SABR VOLATILITY MODEL;SH-SY5Y;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL HAIRPIN RNA;SOX2;STEM CELL FACTOR;TAXANE;TRAMETINIB;UNTRANSLATED REGION;VEMURAFENIB","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MULTIPLE MYELOMA;;FEMALE;MALE;AGED;ANTINEOPLASTIC AGENTS;MIDDLE AGED;ADULT;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;THALIDOMIDE;HSP90 HEAT-SHOCK PROTEINS;OVARIAN NEOPLASMS;BIOMARKERS, TUMOR;GASTROINTESTINAL STROMAL TUMORS;BORTEZOMIB;CELL LINE, TUMOR;CELL PROLIFERATION;TREATMENT OUTCOME","48;45;39;31;29;28;26;26;21;20;20;17;13;11;10;10;9;9;9;9","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER RESEARCH AND TREATMENT;MOLECULAR CHAPERONES IN PROTEIN FOLDING AND DISEASE;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ROLE OF LONG NONCODING RNAS IN CANCER AND DEVELOPMENT;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;MACROPHAGE ACTIVATION AND POLARIZATION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER","12;9;4;4;4;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1","CLINICAL ENDPOINT;REGIMEN;CONCOMITANT;HEMATOLOGY;IGHV@;INTERNATIONAL MYELOMA WORKING GROUP;CANCER THERAPY;EXTRACELLULAR VESICLES;MELPHALAN;PROGRESSION-FREE SURVIVAL;RADIOTHERAPY;REFRACTORY (PLANETARY SCIENCE);SALVAGE THERAPY;TREATMENT;ADJUVANT THERAPY;ANAPLASTIC LARGE-CELL LYMPHOMA;B CELL ABNORMALITIES;BRENTUXIMAB VEDOTIN;CANCER TREATMENT;CHEMOTHERAPY REGIMEN","6;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2","MULTIPLE MYELOMA;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;CLINICAL OUTCOME;GENE EXPRESSION;MYELOMA PATIENTS;REAL LIFE;RECTAL CANCER;ADVANCED RECTAL;BREAST CANCER;EXPRESSION PROFILING;GASTROINTESTINAL STROMAL;IMMUNE-INFLAMMATION INDEX;LOCALLY ADVANCED;NEWLY DIAGNOSED;OBSERVATIONAL STUDY;PHASE III;SYSTEMIC IMMUNE-INFLAMMATION;ANTICANCER THERAPY;BONE MARROW;BRENTUXIMAB VEDOTIN;CANCER PATIENTS;CANCER TREATED;CARE NURSING;CELL CANCER;CELL CARCINOMA;CIRCULATING MICROVESICLES;CLINICAL OUTCOMES;CLINICAL UTILITY;COHORT STUDY","11;7;7;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","NOTCH MUTATIONS;ITALY HEMATOLOGY;ITALY DEPARTMENT;HEMATOLOGY UNIT;GENE EXPRESSION;UTR NOTCH-MUT;VULTURE PZ;CODING NOTCH-MUT;CELL LINES;MULTIPLE MYELOMA;PZ ITALY;SURVIVAL OS;CANCER CENTER;CELL CYCLE;IRCCS REFERRAL;NOTCH SIGNALING;PATIENTS RECEIVING;REFERRAL CANCER;ROME ITALY;CLL PATIENTS;CONSULTANCY HONORARIA;DISTANT METASTASES;DISTANT SITES;HUMAN ONCOLOGY;MEDICAL ONCOLOGY;MICHELANGELO VESTITA;MM PATIENTS;MYELOMA MM;NOTCH MUTATION;PATIENTS TREATED","24;20;18;17;14;10;10;9;8;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6",36,0.41,1.125,13.31,7,23.95,7.44,1,17,0,0,0,1,1,1,0,0,0,1.14,1,2,3,3,3,0,0,0,1.5,1,2,7.67,1,17,0,0,0,1,1,1,7.29,1,13,0,0,0,0,0,0,2,1,5,1.67,1,3,3.86,1,10,2.2,1,4,0.22,0,1,0,0,0,65.89,21,120,64.78,16,121,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2017,61,16.9016393442623,2.52459016393443,0.396103896103896,0.295081967213115,0.19672131147541,0.229508196721311,0.622950819672131,1,32,18,7,1,0.52,0.3,0.11,0.02,16.2,0.549506579145693,0.344262295081967,1,5.23471882640587,0.49274327800304,0.467261904761905,0.46474358974359,0.426716141001855,"PELLEGRINO MUSTO;VITTORIO SIMEON;MATTEO LANDRISCINA;MICHELE AIETA;KATIA TODOERTI;ANTONINO NERI;GIOVANNI D’ARENA;ILARIA LAURENZANA;FRANCA ESPOSITO;FRANCESCO DI RAIMONDO;FRANCESCO LA ROCCA;FRANCESCA MADDALENA;GIORGINA SPECCHIA;ORESTE VILLANI;VITALBA RUGGIERI;GIOVANNI STORTO;ALESSANDRA ROMANO;GIUSEPPE SAGLIO;GIULIA VITA;STEFANIA TRINO","17;11;7;6;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3","PELLEGRINO MUSTO;ALFREDO TARTARONE;MATTEO LANDRISCINA;VITTORIO SIMEON;GIOVANNI D’ARENA;FRANCA ESPOSITO;FRANCESCA MADDALENA;GIOVANNI STORTO;MICHELE AIETA;GIACOMO LETTINI;VALENTINA CONDELLI;LORENZA SISINNI;GIULIA VITA;MICHELE KLAIN;LEONARDO PACE;ILARIA LAURENZANA;KATIA TODOERTI;ANTONINO NERI;VITALBA RUGGIERI;TIZIANA NOTARANGELO","1.23;1;0.98;0.8;0.73;0.5;0.5;0.49;0.4;0.38;0.38;0.38;0.35;0.34;0.34;0.34;0.33;0.33;0.27;0.25","PELLEGRINO MUSTO;VITTORIO SIMEON;MATTEO LANDRISCINA;MICHELE AIETA;KATIA TODOERTI;GIOVANNI D’ARENA;ILARIA LAURENZANA;FRANCESCO LA ROCCA;FRANCESCA MADDALENA;ORESTE VILLANI;VITALBA RUGGIERI;GIOVANNI STORTO;GIULIA VITA;STEFANIA TRINO;CARMELA MAZZOCCOLI;LUCIANA DE LUCA;ANTONELLA CAIVANO;GIACOMO LETTINI;CLÁUDIA PICCOLI;FRANCESCA AGRIESTI","17;11;7;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","PELLEGRINO MUSTO;ALFREDO TARTARONE;MATTEO LANDRISCINA;VITTORIO SIMEON;GIOVANNI D’ARENA;FRANCESCA MADDALENA;GIOVANNI STORTO;MICHELE AIETA;GIACOMO LETTINI;VALENTINA CONDELLI;LORENZA SISINNI;GIULIA VITA;ILARIA LAURENZANA;KATIA TODOERTI;VITALBA RUGGIERI;TIZIANA NOTARANGELO;CLÁUDIA PICCOLI;FRANCESCA AGRIESTI;FRANCESCO LA ROCCA;LUCIANA POSSIDENTE","1.23;1;0.98;0.8;0.73;0.5;0.49;0.4;0.38;0.38;0.38;0.35;0.34;0.33;0.27;0.25;0.23;0.23;0.23;0.23","PELLEGRINO MUSTO;VITTORIO SIMEON;ANTONINO NERI;KATIA TODOERTI;MATTEO LANDRISCINA;ILARIA LAURENZANA;ANNA MARINA LIBERATI;ORESTE VILLANI;ANTONIO PALUMBO;SARA BRINGHEN;PIETER SONNEVELD;STELVIO BALLANTI;VITTORIO MONTEFUSCO;FRANCESCO LA ROCCA;GIOVANNI D’ARENA;LORENZA SISINNI;VALENTINA CONDELLI;GIANLUCA GAÏDANO;ANTONELLA CAIVANO;DANIELA CILLONI","373;189;125;125;124;118;111;104;102;102;99;99;99;97;97;87;87;86;81;81","PELLEGRINO MUSTO;VITTORIO SIMEON;KATIA TODOERTI;ILARIA LAURENZANA;ORESTE VILLANI;FRANCESCO LA ROCCA;GIOVANNI D’ARENA;MATTEO LANDRISCINA;LORENZA SISINNI;VALENTINA CONDELLI;ANTONELLA CAIVANO;LUCIANA DE LUCA;STEFANIA TRINO;FILOMENA NOZZA;MICHELE AIETA;CARMELA MAZZOCCOLI;VITALBA RUGGIERI;FRANCESCA MADDALENA;GIACOMO LETTINI;GIOVANNI STORTO","373;189;125;118;104;97;97;95;87;87;81;81;81;75;75;63;62;58;58;45","PELLEGRINO MUSTO;VITTORIO SIMEON;MICHELE AIETA;KATIA TODOERTI;GIOVANNI D’ARENA;ILARIA LAURENZANA;MATTEO LANDRISCINA;FRANCESCA MADDALENA;GIOVANNI STORTO;ORESTE VILLANI;VITALBA RUGGIERI;FRANCESCO LA ROCCA;FRANCESCA AGRIESTI;ANNA MARIA BOCHICCHIO;ANTONELLA CAIVANO;GIACOMO LETTINI;GIULIA VITA;LORENZA SISINNI;LUCIANA DE LUCA;STEFANIA TRINO","17;11;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATHEMATICS;BUSINESS;COMPUTER SCIENCE;MATERIALS SCIENCE","53;27;8;4;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;BIOCHEMISTRY;GENETICS;GASTROENTEROLOGY;CELL BIOLOGY;IMMUNOLOGY;RADIOLOGY;PALEONTOLOGY;PATHOLOGY;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;PEDIATRICS;PHARMACOLOGY;ASTROBIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;FOOD SCIENCE;STATISTICS;UROLOGY","49;31;20;14;13;12;10;9;9;7;6;6;5;5;3;3;2;2;2;2;2;2","CANCER;GENE;CHEMOTHERAPY;MYELOID LEUKEMIA;CLINICAL TRIAL;MULTIPLE MYELOMA;RETROSPECTIVE COHORT STUDY;BONE MARROW;CONCOMITANT;LEUKEMIA;RADIATION THERAPY;STAGE (STRATIGRAPHY);ADVERSE EFFECT;CONFIDENCE INTERVAL;FLOW CYTOMETRY;POSITRON EMISSION TOMOGRAPHY;THYROID;APOPTOSIS;CELL CULTURE;COHORT;DISCONTINUATION;DISEASE;HEMATOLOGY;LYMPHOMA;MULTIVARIATE ANALYSIS;OBSERVATIONAL STUDY;REGIMEN","23;17;14;9;7;7;7;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;THYROID CARCINOMA;ADENOCARCINOMA;CHRONIC LYMPHOCYTIC LEUKEMIA;DOWNREGULATION AND UPREGULATION;GENE EXPRESSION;IMATINIB;LENALIDOMIDE;PET-CT;PHASES OF CLINICAL RESEARCH;RNA;THYROID CANCER;UNIVARIATE ANALYSIS;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AUTOPHAGY;CELL CYCLE;CHROMOSOME;DOCETAXEL;GENE SILENCING;GENOTYPE;GLYCOLYSIS;MELPHALAN;METASTASIS;MYELODYSPLASTIC SYNDROMES;NUCLEOPHOSMIN;OVARIAN CANCER;PROSTATE CANCER;TEMOZOLOMIDE;TRANSFECTION;VIABILITY ASSAY","6;5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","DASATINIB;DNA METHYLATION;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;NILOTINIB;OXALIPLATIN;TRASTUZUMAB;ACUTE PROMYELOCYTIC LEUKEMIA;ADENOCARCINOMA OF THE LUNG;BARRETT'S ESOPHAGUS;BARRETT'S OESOPHAGUS;BONE METASTASIS;BRACONIDAE;BRENTUXIMAB VEDOTIN;CARFILZOMIB;CELL CYCLE CHECKPOINT;CIRCULATING TUMOR CELL;CYCLIN;CYCLIN-DEPENDENT KINASE 1;ELECTROCHEMOTHERAPY;EPITHELIAL OVARIAN CANCER;ESOPHAGITIS;ESTROGEN RECEPTOR;ETHAMBUTOL;GENOME INSTABILITY;HELIOTHIS VIRESCENS;IGHV@;LATENT TUBERCULOSIS;METASTATIC BREAST CANCER;MONOCLONAL;ONCOGENE;PAZOPANIB;POLYMORPHISM (COMPUTER SCIENCE);PROSTATE-SPECIFIC ANTIGEN;REFLUX ESOPHAGITIS;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBOSOME;RNA INTERFERENCE;RNA SPLICING;SINGLE-NUCLEOTIDE POLYMORPHISM;UBIQUITIN LIGASE;VEMURAFENIB;VISMODEGIB","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;AGED;MIDDLE AGED;ADULT;AGED, 80 AND OVER;MULTIPLE MYELOMA;LEUKEMIA, MYELOID, ACUTE;RETROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROGNOSIS;TREATMENT OUTCOME;ADENOCARCINOMA;ESOPHAGITIS;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;BARRETT ESOPHAGUS;BRAIN NEOPLASMS","33;27;24;23;22;21;15;14;14;13;11;10;9;9;9;8;8;8;7;7","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ACUTE MYELOID LEUKEMIA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;EFFICACY AND RESISTANCE IN CML TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CHOLANGIOCARCINOMA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;LYMPHOID NEOPLASMS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MOLECULAR MECHANISMS OF AXON GUIDANCE;MOLECULAR RESEARCH ON BREAST CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES","6;5;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;CONCOMITANT;INTERNATIONAL MYELOMA WORKING GROUP;PROGRESSION-FREE SURVIVAL;BARRETT'S ESOPHAGUS;CANCER IMAGING;DIFFERENTIATED THYROID CANCER;DISCONTINUATION;HEMATOLOGY;PET-CT;REGIMEN;UNIVARIATE ANALYSIS;AML;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AUTOLOGOUS TRANSPLANTATION;AUTOPHAGY;AZACITIDINE;BREAST CANCER;IMATINIB MESYLATE;LAPATINIB","5;5;5;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MULTIPLE MYELOMA;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;ACUTE MYELOID;BREAST CANCER;CELL CARCINOMA;CHRONIC LYMPHOCYTIC;ITALIAN STUDY;LEUKEMIA CELLS;METASTATIC COLORECTAL;NEWLY DIAGNOSED;PATIENTS TREATED;PROGNOSTIC ROLE;REAL LIFE;STEM CELL;ADJUVANT TRASTUZUMAB;ARGININE DEPRIVATION;AUTOLOGOUS STEM;CANCER TREATED;CD SUPSUP;CELL TRANSPLANTATION;CHRONIC MYELOID;COLORECTAL CARCINOMA;CONCOMITANT RADIO-CHEMOTHERAPY;DIAGNOSED MULTIPLE;DIFFERENTIATED THYROID;FDG PETCT;GLIOBLASTOMA PATIENTS;HUMAN METASTATIC;II STUDY","6;5;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BONE MARROW;THYROID CARCINOMA;CELL LINES;CLIENT PROTEINS;MULTIPLE MYELOMA;COLORECTAL CARCINOMAS;COLORECTAL TUMORS;IMMUNE RESPONSE;METASTATIC COLORECTAL;PROGRESSION-FREE SURVIVAL;CD CELLS;CELL LINE;DE GRAMONT;GENE EXPRESSION;MARROW CD;NOTCH-MUT CLL;PATIENTS RECEIVED;PROTEIN NETWORK;TG NORMALIZATION;TRAP PROTEIN;BARRETTS OESOPHAGUS;BRAF VE;BRENTUXIMAB VEDOTIN;CARCINOMA CELLS;CELL CYCLE;CELL GROWTH;CELL PROLIFERATION;CLINICAL PRACTICE;CLINICAL TRIAL;EPHAMAB TREATMENT","14;8;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4",30,0.49,0.875,6.92,4,10.55,9.12,1,19,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,12.25,1,38,0,0,0,0,0,0,9.71,2,19,0,0,0,0,0,0,1,1,1,2.6,1,6,5.14,1,7,3,1,7,0,0,0,0,0,0,43.75,21,68,43.75,21,68,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2018,73,14.5753424657534,2.35616438356164,0.424418604651163,0.342465753424658,0.26027397260274,0.26027397260274,0.589041095890411,2,39,8,12,0,0.53,0.11,0.16,0,9.71,0.318350852824538,0.178082191780822,0.972602739726027,4.99765807962529,0.485920711032762,0.435714285714286,0.524074074074074,0.39030612244898,"PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;CARMELA MAZZOCCOLI;FRANCESCO DI RAIMONDO;GIANDOMENICO ROVIELLO;CLÁUDIA PICCOLI;CONSIGLIA PACELLI;ANTONELLA ZUCCHETTO;STEFANIA TRINO;GIOVANNI DEL POETA;ANNALISA CHIARENZA;FRANCESCO ZAJA;NAZZARENO CAPITANIO;GIANLUCA GAÏDANO;ANTONINO NERI;MATTEO LANDRISCINA;FRANCESCA AGRIESTI;VALTER GATTEI;GIUSEPPE GUGLIELMI","14;12;11;7;7;7;6;5;5;5;5;5;5;5;5;5;5;5;5;5","GIANDOMENICO ROVIELLO;ALFREDO TARTARONE;MICHELE AIETA;PELLEGRINO MUSTO;GIOVANNI D’ARENA;CARMELA MAZZOCCOLI;GIUSEPPE PIETRANTUONO;CLÁUDIA PICCOLI;GIUSEPPE GUGLIELMI;CONSIGLIA PACELLI;NAZZARENO CAPITANIO;FRANCESCA AGRIESTI;RAFFAELE ARDITO;GIOVANNI STORTO;MATTEO LANDRISCINA;STEFANIA TRINO;ANTONINO NERI;ROSA LEROSE;FIORELLA RESTAINO MARINO;RAFFAELE CONCA","1.93;1.55;1.22;1.18;1.12;0.75;0.71;0.7;0.63;0.55;0.55;0.55;0.55;0.53;0.52;0.51;0.51;0.5;0.5;0.46","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;CARMELA MAZZOCCOLI;GIANDOMENICO ROVIELLO;CONSIGLIA PACELLI;STEFANIA TRINO;MATTEO LANDRISCINA;FRANCESCA AGRIESTI;ROCCHINA CAIVANO;RAFFAELE CONCA;GIUSEPPE PIETRANTUONO;VITTORIO SIMEON;LORENZA SISINNI;GIOVANNI STORTO;TIZIANA TATARANNI;ALDO CAMMAROTA;KATIA TODOERTI;GIOVANNI CALICE;VINCENZO FUSCO","14;12;11;7;7;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3","GIANDOMENICO ROVIELLO;ALFREDO TARTARONE;MICHELE AIETA;PELLEGRINO MUSTO;GIOVANNI D’ARENA;CARMELA MAZZOCCOLI;GIUSEPPE PIETRANTUONO;CONSIGLIA PACELLI;FRANCESCA AGRIESTI;RAFFAELE ARDITO;GIOVANNI STORTO;MATTEO LANDRISCINA;STEFANIA TRINO;ROSA LEROSE;FIORELLA RESTAINO MARINO;RAFFAELE CONCA;TIZIANA TATARANNI;LORENZA SISINNI;ROCCHINA CAIVANO;ROSJ GALLICCHIO","1.93;1.55;1.22;1.18;1.12;0.75;0.71;0.55;0.55;0.55;0.53;0.52;0.51;0.5;0.5;0.46;0.45;0.45;0.38;0.37","MICHELE AIETA;PELLEGRINO MUSTO;ALBA A. BRANDES;ANITA RIMANTI;ANTONINO MUSOLINO;ANTONIO FRASSOLDATI;FEDERICO PIACENTINI;FRANCESCO GIOTTA;GIANCARLO BISAGNI;LUIGI CAVANNA;ORNELLA GARRONE;PIERFRANCO CONTÉ;ROBERTO D’AMICO;ROBERTO VICINI;SARA BALDUZZI;VALENTINA GUARNERI;VITTORIO GEBBIA;A. MOLINO;ALESSANDRA BEANO;ALESSIO SCHIRONE","225;156;145;145;145;145;145;145;145;145;145;145;145;145;145;145;145;139;139;139","MICHELE AIETA;PELLEGRINO MUSTO;STEFANIA TRINO;MATTEO LANDRISCINA;GIANDOMENICO ROVIELLO;LORENZA SISINNI;GIOVANNI CALICE;ROCCHINA CAIVANO;VITTORIO SIMEON;PIETRO ZOPPOLI;CARMELA MAZZOCCOLI;DANIELA LAMORTE;ILARIA LAURENZANA;KATIA TODOERTI;GIOVANNI STORTO;VALENTINA CONDELLI;GIOVANNI D’ARENA;FIORELLA D′AURIA;LUCIANA VALVANO;TEODORA STATUTO","213;156;101;80;73;71;69;50;43;41;35;35;35;35;34;34;33;28;28;28","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;GIANDOMENICO ROVIELLO;CARMELA MAZZOCCOLI;STEFANIA TRINO;ROCCHINA CAIVANO;GIOVANNI STORTO;GIUSEPPE PIETRANTUONO;LORENZA SISINNI;MATTEO LANDRISCINA;ALDO CAMMAROTA;ALFREDO TARTARONE;GIOVANNI CALICE;KATIA TODOERTI;RAFFAELE CONCA;VINCENZO FUSCO;ANTONIO VILLONIO;DANIELA LAMORTE;GIANCARLO IANNELLI","14;12;10;7;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;ENGINEERING;MATERIALS SCIENCE;HISTORY;POLITICAL SCIENCE;PSYCHOLOGY","58;37;12;9;5;4;3;3;3;1;1;1","INTERNAL MEDICINE;ONCOLOGY;GENETICS;CANCER RESEARCH;SURGERY;CELL BIOLOGY;PATHOLOGY;BIOCHEMISTRY;RADIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;PALEONTOLOGY;ENVIRONMENTAL HEALTH;OPTICS;ENDOCRINOLOGY;MOLECULAR BIOLOGY;MICROBIOLOGY;NUCLEAR MAGNETIC RESONANCE;STATISTICS;STEREOCHEMISTRY;UROLOGY","48;30;21;16;14;13;13;12;10;9;7;7;6;5;5;4;4;3;3;3;3;3","CANCER;GENE;CHEMOTHERAPY;LEUKEMIA;ANTIBODY;CELL CULTURE;HEMATOLOGY;MULTIPLE MYELOMA;POPULATION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;CELL;DISEASE;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;APOPTOSIS;BONE MARROW;CELL GROWTH;COHORT;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);EXTERNAL QUALITY ASSESSMENT;FLOW CYTOMETRY;IN VITRO;MALIGNANCY;SCANNER;THYROID","30;17;10;8;6;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;CLINICAL ENDPOINT;DOCETAXEL;PROSTATE CANCER;CANCER CELL;MUTATION;PHASES OF CLINICAL RESEARCH;QUALITY ASSURANCE;THYROID CANCER;TOLERABILITY;BIOSYNTHESIS;BORTEZOMIB;BREAKPOINT CLUSTER REGION;CANCER STEM CELL;CELL CYCLE;EPIDERMAL GROWTH FACTOR RECEPTOR;GENE EXPRESSION;GENE SILENCING;HAZARD RATIO;HUMAN GENETICS;MAINTENANCE THERAPY;METHYLATION;MONOCLONAL ANTIBODY;PANCREATIC CANCER;PET-CT;PHENOTYPE;PLASMA CELL LEUKEMIA;SALVAGE THERAPY;SOLITARY PULMONARY NODULE;SOMATIC EVOLUTION IN CANCER;TRANSFECTION;TUMOR MICROENVIRONMENT","7;7;6;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TRASTUZUMAB;ANDROGEN DEPRIVATION THERAPY;IGHV@;KRAS;OXALIPLATIN;ANDROGEN RECEPTOR;CAPECITABINE;DNA METHYLATION;METASTATIC BREAST CANCER;AMPLICON;ANTHRACYCLINE;BENDAMUSTINE;BONE METASTASIS;CANCER CELL LINES;CD23;CETUXIMAB;CILIOPATHIES;DEEP SEQUENCING;GASTROESOPHAGEAL JUNCTION;GEFITINIB;GERMLINE MUTATION;HEMATOPOIETIC STEM CELL;HSP90;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IONIZATION CHAMBER;METHYLTRANSFERASE;MONOCLONAL;MYELOPROLIFERATIVE NEOPLASM;NIVOLUMAB;ONCOGENE;PEMBROLIZUMAB;PLASMA CELL DYSCRASIA;POLYKETIDE;PSEUDOMEMBRANOUS COLITIS;RIBOSOME;RNA-BINDING PROTEIN;SINGLE-NUCLEOTIDE POLYMORPHISM;SMALL INTERFERING RNA;SOMATIC HYPERMUTATION;TAXANE;TRANSLATION (BIOLOGY);TRIPLE-NEGATIVE BREAST CANCER","4;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MULTIPLE MYELOMA;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MIDDLE AGED;ANTINEOPLASTIC AGENTS;ADULT;CELL PROLIFERATION;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL;DISEASE-FREE SURVIVAL;HSP90 HEAT-SHOCK PROTEINS;ORGANOPHOSPHORUS COMPOUNDS;PROTO-ONCOGENE PROTEINS B-RAF;TAXOIDS;TRASTUZUMAB;ANEMIA, HEMOLYTIC, AUTOIMMUNE","43;27;17;17;17;16;15;15;13;9;8;6;6;6;6;6;6;6;6;5","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;HER2 SIGNALING IN BREAST CANCER TREATMENT;ACUTE MYELOID LEUKEMIA;COLORECTAL CANCER RESEARCH AND TREATMENT;GASTRIC CANCER RESEARCH AND TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;RADIOTHERAPY PHYSICS AND TECHNOLOGY;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANALYSIS OF GENE INTERACTION NETWORKS;BIOACTIVE LIMONOIDS IN MEDICINAL PLANTS;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA","9;4;4;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","HEMATOLOGY;CLINICAL ENDPOINT;BREAST CANCER;TRASTUZUMAB;ABIRATERONE ACETATE;CANCER CELL METABOLISM;CANCER THERAPY;IGHV@;IMAGE-GUIDED RADIOTHERAPY;PROSTATE CANCER;TOLERABILITY;BREAKPOINT CLUSTER REGION;CABAZITAXEL;CANCER;CANCER TREATMENT;ENZALUTAMIDE;HISTOPATHOLOGY;HUMAN GENETICS;INTERNATIONAL MYELOMA WORKING GROUP;MAGNETIC RESONANCE IMAGING","6;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CHRONIC LYMPHOCYTIC;PHASE II;PROSTATE CANCER;BREAST CANCER;CANCER CELL;CASTRATION-RESISTANT PROSTATE;LYMPHOCYTIC LEUKEMIA;MULTIPLE MYELOMA;FINAL RESULTS;METASTATIC CASTRATION-RESISTANT;THYROID TUMOR;ABIRATERONE ACETATE;ADJUVANT TRASTUZUMAB;CANCER MCRPC;CANCER PATIENTS;CARCINOMA CELLS;CELL GROWTH;CELL LEUKEMIA;CELL LINE;CLINICAL SCANNER;COMPLETE RESPONSE;GRUPPO ONCOLOGICO;II STUDY;II TRIAL;MAGNETIC RESONANCE;MULTICENTER TRIAL;MYELOMA CELLS;PANCREATIC CANCER;PLASMA CELL;PRIMARY PLASMA","5;5;5;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;HONORARIA RESEARCH;BREAST CANCER;CD EXPRESSION;SPEAKERS BUREAU;ACCEPTABLE DIRS;HYPOCELLULAR MDS;LOW INTERMEDIATE;NORMOCELLULAR MDS;SFB MUTATIONS;ABBVIE HONORARIA;CI TTFT;CONSULTANCY SPEAKERS;CR PATIENTS;CYCLIN-DEPENDENT KINASE;HONORARIA ABBVIE;JANSSEN HONORARIA;LOWER RISK;MEDIAN CI;MONTHS CI;NOTCH PATHWAY;SHORT ARM;SURVIVAL OS;THYROID TUMOR;TUMOR CELLS;VLA- ACTIVATION;CARDIAC EVENTS;CELGENE HONORARIA","18;14;14;12;9;9;9;8;8;8;8;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;5;5",25,0.34,1,15.11,3,69.65,17.57,1,76,1,1,1,0,0,0,0,0,0,2,1,3,1,1,1,0,0,0,1,1,1,20,1,87,0,0,0,0,0,0,22.6,5,71,0,0,0,0,0,0,1.67,1,2,10,4,16,14.8,5,43,3.5,1,10,0,0,0,0,0,0,61.86,19,172,61.86,19,172,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2019,76,17.578947368421,2.42105263157895,0.41304347826087,0.25,0.223684210526316,0.171052631578947,0.723684210526316,0,42,13,5,2,0.55,0.17,0.07,0.03,11.22,0.461559248603248,0.342105263157895,1,4.61324786324786,0.438764647657394,0.447521865889213,0.467857142857143,0.411924119241192,"PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;FRANCESCO DI RAIMONDO;ILARIA LAURENZANA;GIOVANNI CALICE;GIOVANNI DEL POETA;VINCENZO FUSCO;LUCIANA DE LUCA;CLÁUDIA PICCOLI;GERARDO DELLA SALA;PIETRO ZOPPOLI;CARMELA MAZZOCCOLI;MARTA COSCIA;FRANCESCO ZAJA;FRANCESCO LA ROCCA;IDANNA INNOCENTI;MASSIMO OFFIDANI;VITALBA RUGGIERI;CONSIGLIA PACELLI","20;15;9;8;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;GERARDO DELLA SALA;CLÁUDIA PICCOLI;ILARIA LAURENZANA;LUCIANA DE LUCA;GIOVANNI CALICE;VINCENZO FUSCO;LUCIANA POSSIDENTE;GIANDOMENICO ROVIELLO;ROBERTO PETRIOLI;PIETRO ROSELLINI;CARMELA MAZZOCCOLI;VITALBA RUGGIERI;FRANCESCO LA ROCCA;FRANCESCO DI RAIMONDO;PIETRO ZOPPOLI;FIORELLA D′AURIA;CONSIGLIA PACELLI","1.55;1.32;0.73;0.64;0.57;0.57;0.53;0.52;0.51;0.48;0.43;0.43;0.43;0.43;0.41;0.4;0.4;0.39;0.33;0.33","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;ILARIA LAURENZANA;GIOVANNI CALICE;VINCENZO FUSCO;LUCIANA DE LUCA;CLÁUDIA PICCOLI;GERARDO DELLA SALA;PIETRO ZOPPOLI;CARMELA MAZZOCCOLI;FRANCESCO LA ROCCA;VITALBA RUGGIERI;LUCIANA POSSIDENTE;FIORELLA D′AURIA;GIOVANNA MANSUETO;VITTORIO SIMEON;TEODORA STATUTO;STEFANIA TRINO;GIANDOMENICO ROVIELLO","20;15;9;6;6;6;6;6;6;5;5;5;5;4;4;4;4;3;3;3","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;GERARDO DELLA SALA;CLÁUDIA PICCOLI;ILARIA LAURENZANA;LUCIANA DE LUCA;GIOVANNI CALICE;VINCENZO FUSCO;LUCIANA POSSIDENTE;GIANDOMENICO ROVIELLO;CARMELA MAZZOCCOLI;VITALBA RUGGIERI;FRANCESCO LA ROCCA;PIETRO ZOPPOLI;FIORELLA D′AURIA;GIOVANNA GALDO;GIOVANNA MANSUETO;VITTORIO SIMEON;SABINO RUSSI","1.55;1.32;0.73;0.64;0.57;0.57;0.53;0.52;0.51;0.48;0.43;0.43;0.41;0.4;0.39;0.33;0.33;0.31;0.3;0.3","PELLEGRINO MUSTO;CLÁUDIA PICCOLI;VITALBA RUGGIERI;GERARDO DELLA SALA;PIETRO ZOPPOLI;GIOVANNI D’ARENA;CARMELA MAZZOCCOLI;FRANCESCO LA ROCCA;ILARIA LAURENZANA;GIOVANNI CALICE;CONSIGLIA PACELLI;NAZZARENO CAPITANIO;VINCENZO FUSCO;MASSIMO OFFIDANI;GEPPINO FALCO;LUCIANO LEVATO;BRUNO MARTINO;SABINO RUSSI;DARIO FERRERO;ELENA AMENDOLA","260;138;131;125;108;101;98;98;96;95;94;94;94;89;85;79;73;72;71;71","PELLEGRINO MUSTO;VITALBA RUGGIERI;CLÁUDIA PICCOLI;GERARDO DELLA SALA;PIETRO ZOPPOLI;GIOVANNI D’ARENA;CARMELA MAZZOCCOLI;FRANCESCO LA ROCCA;ILARIA LAURENZANA;GIOVANNI CALICE;VINCENZO FUSCO;SABINO RUSSI;SIMONA LAURINO;FRANCESCA AGRIESTI;TIZIANA TATARANNI;GIUSEPPE LA TORRE;MICHELE AIETA;CINZIA LAPADULA;LUCIANA DE LUCA;GIULIANO LO BIANCO","260;131;130;125;108;101;98;98;96;95;94;72;71;63;63;58;57;41;40;27","PELLEGRINO MUSTO;GIOVANNI D’ARENA;MICHELE AIETA;VINCENZO FUSCO;GIOVANNI CALICE;ILARIA LAURENZANA;LUCIANA DE LUCA;GERARDO DELLA SALA;CLÁUDIA PICCOLI;FRANCESCO LA ROCCA;PIETRO ZOPPOLI;VITALBA RUGGIERI;CARMELA MAZZOCCOLI;FIORELLA D′AURIA;GIOVANNA MANSUETO;LUCIANA POSSIDENTE;FRANCESCA AGRIESTI;GIANDOMENICO ROVIELLO;STEFANIA TRINO;TEODORA STATUTO","20;15;8;7;6;6;6;6;5;5;5;5;5;4;4;4;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;BUSINESS;POLITICAL SCIENCE;ENGINEERING;HISTORY","60;31;9;9;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;IMMUNOLOGY;CELL BIOLOGY;BIOCHEMISTRY;PATHOLOGY;PALEONTOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;OPTICS;UROLOGY;MEDICAL PHYSICS;MOLECULAR BIOLOGY;COMPUTATIONAL BIOLOGY;FAMILY MEDICINE;PEDIATRICS;STEREOCHEMISTRY","52;26;22;21;18;14;13;12;9;9;7;6;5;5;5;5;4;4;3;3;3;3","CANCER;LEUKEMIA;GENE;CHEMOTHERAPY;RANDOMIZED CONTROLLED TRIAL;MULTIPLE MYELOMA;BONE MARROW;STEM CELL;MYELOID LEUKEMIA;RADIATION THERAPY;CLINICAL TRIAL;CONTEXT (ARCHAEOLOGY);ANTIBODY;APOPTOSIS;CLINICAL SIGNIFICANCE;COHORT;POPULATION;RECEPTOR;REGIMEN;SIGNAL TRANSDUCTION","24;16;15;12;11;9;7;7;6;6;5;5;4;4;4;4;4;4;4;4","CHRONIC LYMPHOCYTIC LEUKEMIA;GENE EXPRESSION;HAEMATOPOIESIS;LENALIDOMIDE;PROSTATE CANCER;BREAST CANCER;CLINICAL ENDPOINT;DOCETAXEL;PROGENITOR CELL;RANDOMIZATION;BREAKPOINT CLUSTER REGION;COLORECTAL CANCER;DOWNREGULATION AND UPREGULATION;EMBRYONIC STEM CELL;IMATINIB;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;TYROSINE KINASE;AUTOPHAGY;B CELL;CANCER CELL;CD20;CELLULAR DIFFERENTIATION;DEFERASIROX;EPIGENETICS;HAZARD RATIO;MONOCLONAL ANTIBODY;MYELODYSPLASTIC SYNDROMES;RAMUCIRUMAB;RETINOIC ACID;RITUXIMAB;SALVAGE THERAPY;SUNITINIB;TOLERABILITY;UNIVARIATE ANALYSIS","11;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANDROGEN RECEPTOR;DNA METHYLATION;IBRUTINIB;B-CELL RECEPTOR;BRUTON'S TYROSINE KINASE;CARFILZOMIB;MITOPHAGY;MONOCLONAL;NILOTINIB;TRASTUZUMAB;VENETOCLAX;ACUTE PROMYELOCYTIC LEUKEMIA;ANDROGEN DEPRIVATION THERAPY;AXITINIB;BENDAMUSTINE;BONE MARROW FAILURE;CANCER CELL LINES;CELL CYCLE CHECKPOINT;CHEMOIMMUNOTHERAPY;CLOCK;CORONAVIRUS DISEASE 2019 (COVID-19);CRYOGLOBULINEMIA;CYTOGENETICS;DASATINIB;FOLINIC ACID;GASTRULATION;GENE EXPRESSION PROFILING;GENE SIGNATURE;GLI1;GLI2;HISTONE H3;HSP90;IGHV@;IMATINIB MESYLATE;IN SITU HYBRIDIZATION;INDUCED PLURIPOTENT STEM CELL;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;KRAS;LASER CAPTURE MICRODISSECTION;LYN;METASTATIC BREAST CANCER;PARKIN;POMALIDOMIDE;RNA SPLICING;ROS1;SEROUS CARCINOMA;SYK;TARGET LESION;TAXANE;TIGIT;TRANSCRIPTOME;VERSICAN;VINORELBINE","4;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MULTIPLE MYELOMA;ADULT;PROGNOSIS;AGED, 80 AND OVER;ANIMALS;BREAST NEOPLASMS;CELL PROLIFERATION;LYMPHOMA, B-CELL;PANCREATIC NEOPLASMS;RETROSPECTIVE STUDIES;SIGNAL TRANSDUCTION;BRAIN NEOPLASMS","40;34;22;22;20;18;17;17;16;12;9;8;8;8;8;8;8;8;8;7","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;SPONGE-ASSOCIATED MICROORGANISMS AND BIOTECHNOLOGICAL POTENTIAL;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;CALCIUM SIGNALING AND ION CHANNELS IN SENSATION;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CARDIOTOXICITY OF CANCER TREATMENTS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;COLORECTAL CANCER RESEARCH AND TREATMENT;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION","10;7;5;4;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1","INTERNATIONAL MYELOMA WORKING GROUP;CLINICAL ENDPOINT;ENZALUTAMIDE;REGIMEN;B-CELL RECEPTOR SIGNALING;BREAKPOINT CLUSTER REGION;CANCER TREATMENT;CLINICAL SIGNIFICANCE;METASTATIC GASTRIC CANCER;PROGRESSION-FREE SURVIVAL;TREATMENT;CANCER IMAGING;CONCORDANCE;DEFERASIROX;DISCONTINUATION;GASTRIC CANCER;HEMATOLOGY;IGHV@;INTERQUARTILE RANGE;MANTLE CELL LYMPHOMA","5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","MULTIPLE MYELOMA;CHRONIC LYMPHOCYTIC;LYMPHOCYTIC LEUKEMIA;PROSTATE CANCER;PHASE II;RANDOMIZED TRIAL;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;CHEIRON STUDY;FINAL RESULTS;FIRST-LINE CHEMOTHERAPY;GASTRIC CANCER;II RANDOMIZED;ITALIAN EXPERIENCE;MCRPC CHEIRON;METASTATIC CASTRATION-RESISTANT;MULTICENTRIC PHASE;MYELOID LEUKEMIA;PANCREATIC CANCER;PATIENTS PTS;VERSUS DOCETAXEL;ACUTE MYELOID;BONE MARROW;CLL PATIENTS;DEFERASIROX DRIVES;DIAGNOSED MULTIPLE;GENE EXPRESSION;GROSS TUMOR;INTERIM ANALYSIS;INTERVENTIONAL RADIOTHERAPY","7;6;6;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;RESEARCH FUNDING;HONORARIA MEMBERSHIP;SPEAKERS BUREAU;ADVISORY CONSULTANCY;PATIENTS TREATED;CLL CELLS;CELL LINES;COMMITTEES SPEAKERS;ARTERIAL HYPERTENSION;CLL PATIENTS;NEWLY DIAGNOSED;PULMONARY ARTERIAL;VLA- ACTIVATION;COMMITTEES RESEARCH;MONTHS CI;ADVERSE EVENTS;BCRI TREATMENT;BCRI TREATMENTS;CELGENE HONORARIA;CONSULTANCY MEMBERSHIP;CONTENT HTTPSLINKSLWWCOMHSA;DIGITAL CONTENT;GENE EXPRESSION;PROGRESSION-FREE SURVIVAL;SUPPLEMENTAL DIGITAL;HONORARIA RESEARCH;MULTIPLE MYELOMA;ACCOMMODATION EXPENSES","77;77;34;27;27;26;25;18;15;14;13;13;13;13;13;12;12;11;11;11;11;11;11;11;11;11;11;10;10;9",32,0.42,1.625,12.49,4.45,24.65,12.75,1,27,1,1,1,2,2,2,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,14.25,1,34,0,0,0,0,0,0,13.57,1,27,0,0,0,0,0,0,2,1,4,3.5,2,7,9.17,3,18,2.86,1,7,0,0,0,0,0,0,40.25,6,76,40.25,6,76,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2020,60,19.0666666666667,2.48333333333333,0.402684563758389,0.2,0.2,0.2,0.766666666666667,0,34,13,4,0,0.57,0.22,0.07,0,18.53,0.735491572610003,0.233333333333333,1,4.80459770114943,0.39157404488561,0.25,0.403508771929825,0.331896551724138,"MICHELE AIETA;ALESSANDRO SGAMBATO;PELLEGRINO MUSTO;RAFFAELE CONCA;FRANCESCO DI RAIMONDO;ROBERTO PETRIOLI;CONSIGLIA PACELLI;ROSELLA SCRIMA;ILARIA LAURENZANA;PIETRO ZOPPOLI;GIOVANNI CALICE;GIANDOMENICO ROVIELLO;NAZZARENO CAPITANIO;MATTEO LANDRISCINA;VITALBA RUGGIERI;GEPPINO FALCO;GIOVANNI D’ARENA;MONICA RAMELLO;MARTINA CATALANO;FRANCA ESPOSITO","11;9;7;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3","ALESSANDRO SGAMBATO;MICHELE AIETA;ROBERTO PETRIOLI;RAFFAELE CONCA;GIANDOMENICO ROVIELLO;ROBERTA TETA;ALFONSO MANGONI;VALERIA COSTANTINO;GERARDO DELLA SALA;GIOVANNA GALDO;MONICA RAMELLO;MARTINA CATALANO;ILARIA LAURENZANA;SIMONA LAURINO;PIETRO ZOPPOLI;MATTEO LANDRISCINA;EMANUELE CEREDA;PAOLA MOLETTIERI;LUCA RASTRELLI;CLAUDIO RICCIARDI TENORE","0.89;0.61;0.53;0.48;0.47;0.42;0.42;0.42;0.42;0.38;0.37;0.37;0.37;0.35;0.35;0.34;0.33;0.33;0.33;0.33","MICHELE AIETA;ALESSANDRO SGAMBATO;PELLEGRINO MUSTO;RAFFAELE CONCA;ILARIA LAURENZANA;PIETRO ZOPPOLI;GIOVANNI CALICE;GIANDOMENICO ROVIELLO;MATTEO LANDRISCINA;VITALBA RUGGIERI;GEPPINO FALCO;GIOVANNI D’ARENA;MICHELE PIETRAFESA;GIACOMO LETTINI;FRANCESCA MADDALENA;FRANCESCA AGRIESTI;ORESTE VILLANI;SABINO RUSSI;GIOVANNA GALDO;SIMONA LAURINO","11;9;7;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","ALESSANDRO SGAMBATO;MICHELE AIETA;RAFFAELE CONCA;GIANDOMENICO ROVIELLO;GERARDO DELLA SALA;GIOVANNA GALDO;ILARIA LAURENZANA;SIMONA LAURINO;PIETRO ZOPPOLI;MATTEO LANDRISCINA;GRAZIELLA MARINO;GIUSEPPINA GALLUCCI;PELLEGRINO MUSTO;GEPPINO FALCO;GIOVANNI CALICE;MICHELE PIETRAFESA;GIACOMO LETTINI;VALENTINA CONDELLI;VITALBA RUGGIERI;GIOVANNI STORTO","0.89;0.61;0.48;0.47;0.42;0.38;0.37;0.35;0.35;0.34;0.33;0.33;0.28;0.27;0.27;0.26;0.26;0.26;0.26;0.25","MICHELE AIETA;ALESSANDRO SGAMBATO;PELLEGRINO MUSTO;FRANCESCO DI RAIMONDO;DANIELE SANTINI;ALAIN GELIBTER;ALESSANDRO RUSSO;ALFREDO BERRUTI;ALFREDO FALCONE;ANTONIO GALVANO;ANTONIO RUSSO;DANIELA IACONO;ELISA ROCA;ENRICO VASILE;FAUSTO PETRELLI;FRANCESCO PANTANO;G. PASQUINI;GIOVANNI MANSUETO;GIUSEPPE APRILE;GIUSEPPE TONINI","206;201;193;184;144;143;143;143;143;143;143;143;143;143;143;143;143;143;143;143","MICHELE AIETA;ALESSANDRO SGAMBATO;PELLEGRINO MUSTO;MARCO IMPERATORI;GIOVANNI CALICE;MATTEO LANDRISCINA;GIOVANNA GALDO;FABIANA CRISPO;FRANCESCA MADDALENA;VITALBA RUGGIERI;VINCENZO FUSCO;FRANCESCO LA ROCCA;VITINA GRIECO;ILARIA LAURENZANA;FRANCESCA AGRIESTI;VITTORIO SIMEON;SABINO RUSSI;GIOVANNI D’ARENA;RAFFAELE CONCA;FIORELLA D′AURIA","206;201;176;143;93;87;85;80;80;78;66;62;62;57;56;52;51;50;50;47","MICHELE AIETA;ALESSANDRO SGAMBATO;RAFFAELE CONCA;PELLEGRINO MUSTO;GIOVANNI CALICE;ILARIA LAURENZANA;MATTEO LANDRISCINA;PIETRO ZOPPOLI;VITALBA RUGGIERI;FABIANA CRISPO;FRANCESCA MADDALENA;GIACOMO LETTINI;GIOVANNA GALDO;GIOVANNI D’ARENA;MICHELE PIETRAFESA;ORESTE VILLANI;VALENTINA CONDELLI;FRANCESCA AGRIESTI;GIOVANNI STORTO;SABINO RUSSI","11;9;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;BUSINESS;ART;MATHEMATICS;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;ENVIRONMENTAL SCIENCE;GEOGRAPHY;GEOLOGY;PHILOSOPHY;SOCIOLOGY","47;30;11;4;4;3;2;2;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;BIOCHEMISTRY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;CELL BIOLOGY;SURGERY;IMMUNOLOGY;PALEONTOLOGY;COMPUTATIONAL BIOLOGY;ENDOCRINOLOGY;PATHOLOGY;PHARMACOLOGY;DERMATOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;PSYCHIATRY;RADIOLOGY","38;21;14;14;13;12;11;9;6;6;4;4;4;4;3;3;3;3;3;3","CANCER;GENE;CHEMOTHERAPY;DISEASE;RANDOMIZED CONTROLLED TRIAL;CELL;CONFIDENCE INTERVAL;CLINICAL TRIAL;STAGE (STRATIGRAPHY);LEUKEMIA;REGIMEN;STEM CELL;TRANSPLANTATION;APOPTOSIS;FLOW CYTOMETRY;MITOCHONDRION;POPULATION;RECEPTOR;ADVERSE EFFECT;ANTIOXIDANT;COHORT;COHORT STUDY;ENZYME;EPILEPSY;LUNG CANCER;MESENCHYMAL STEM CELL;METABOLISM;MOTILITY;MULTIPLE MYELOMA;MYELOID LEUKEMIA;NAUSEA;OBESITY;OUTBREAK;PSORIASIS;RETROSPECTIVE COHORT STUDY;SIGNAL TRANSDUCTION","28;12;9;7;7;6;6;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;HAZARD RATIO;NEUTROPENIA;DOWNREGULATION AND UPREGULATION;GEMCITABINE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MUTATION;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;ADENOCARCINOMA;CANCER CELL;CARCINOGENESIS;CELLULAR DIFFERENTIATION;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;DOCETAXEL;GENE SILENCING;GLYCOLYSIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;KETOGENIC DIET;METASTASIS;MICRORNA;MULTICENTER STUDY;TOLERABILITY;VIABILITY ASSAY;WEIGHT LOSS;WNT SIGNALING PATHWAY","9;5;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NIVOLUMAB;CAPECITABINE;CORONAVIRUS DISEASE 2019 (COVID-19);METASTATIC BREAST CANCER;OXALIPLATIN;CATENIN;ABTS;ACTIN CYTOSKELETON;ADENOSINE RECEPTOR;ADENYLYLATION;AMINO ACID RESIDUE;ANAEROBIC GLYCOLYSIS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ASPARAGINASE;AXIN2;BARRETT'S ESOPHAGUS;BETA-CATENIN;BLASTOCYST;CARFILZOMIB;CATECHIN;CETUXIMAB;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CYCLIN D1;DASATINIB;DIGITAL POLYMERASE CHAIN REACTION;EGFR INHIBITORS;EPITHELIAL–MESENCHYMAL TRANSITION;ESOPHAGITIS;EXTERNAL BEAM RADIOTHERAPY;FIBROBLAST GROWTH FACTOR RECEPTOR;FOLINIC ACID;FRIZZLED;GASTRULATION;GENE EXPRESSION PROFILING;GERMLINE MUTATION;GLUT1;GLUTATHIONE PEROXIDASE;IMATINIB MESYLATE;IRINOTECAN;JAK2 V617F;LONG NON-CODING RNA;LOW-INTENSITY PULSED ULTRASOUND;LRP5;LRP6;MULTICENTER TRIAL;NILOTINIB;NON-SMALL CELL LUNG CANCER (NSCLC);OPERON;PDGFRA;POLYKETIDE;RADIOIODINE THERAPY;REFLUX ESOPHAGITIS;TAXANE;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES;UROTHELIAL CANCER;UROTHELIAL CARCINOMA;VINORELBINE;WARBURG EFFECT","4;3;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;MALE;MIDDLE AGED;AGED;NEUTROPENIA;COLORECTAL NEOPLASMS;GENE EXPRESSION REGULATION, NEOPLASTIC;MITOCHONDRIA;MULTIPLE MYELOMA;ADULT;BREAST NEOPLASMS;CAPECITABINE;CARCINOMA, NON-SMALL-CELL LUNG;HSP90 HEAT-SHOCK PROTEINS;ITALY;LUNG NEOPLASMS;NAUSEA","30;28;22;18;15;14;12;12;11;10;10;9;8;8;7;7;7;7;7;7","CANCER IMMUNOTHERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PANCREATIC CANCER RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;WNT SIGNALING IN DEVELOPMENT AND DISEASE;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS AND CRISPR-ASSOCIATED PROTEINS;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EFFECTS OF KETOGENIC DIET ON HEALTH;EFFICACY AND RESISTANCE IN CML TREATMENT;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS","3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;REGIMEN;BREAST CANCER;METASTATIC PANCREATIC CANCER;PANDEMIC;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;CANCER THERAPY;CANCER TREATMENT;EXTRACELLULAR VESICLES;FOLFOX;KETOGENIC DIET;METABOLISM;TOLERABILITY;TRASTUZUMAB;VIABILITY ASSAY;2019-20 CORONAVIRUS OUTBREAK;ABTS;ACUTE MYELOBLASTIC LEUKEMIA;ADENYLYLATION","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","PHASE II;II TRIAL;BREAST CANCER;COLON CANCER;GASTRIC CANCER;METASTATIC PANCREATIC;STEM CELLS;ADVANCED BREAST;CANCER CELLS;CANCER PATIENTS;CELL CARCINOMA;CELL TRANSPLANTATION;CHRONIC LYMPHOCYTIC;CHRONIC PLAQUE;COLORECTAL CANCER;EMBRYONIC STEM;EXTRACELLULAR VESICLES;GRUPPO ONCOLOGICO;II COLON;INDUCTION PHASE;KETOGENIC INDUCTION;LEUKEMIA PATIENTS;LUNG CANCER;LYMPHOCYTIC LEUKEMIA;MERIDIONALE GOIM;MOLECULAR NETWORKING;MULTIPLE MYELOMA;MYELOID LEUKEMIA;PANCREATIC CANCER;PATIENTS PTS","5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ITALY SEARCH;MEDICAL ONCOLOGY;II NAPLES;ZSCAN CELLS;MD DIVISION;SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;UNIT OSPEDALE;BIOLOGY UNIVERSITY;BREAST UNIT;CELL LINES;ONCOLOGY BREAST;ORCIDORG--- DEPARTMENT;CONSULTANCY HONORARIA;EXPERIMENTAL MEDICINE;FOGGIA FOGGIA;FOGGIA ITALY;MEDICINE UNIVERSITY;STEM CELLS;MD MEDICAL;MONTHS CI;INDEPENDENT BIOLOGICAL;BIOLOGICAL REPLICATES;BIOTECHNOLOGY UNIVERSITY;MEDICAL BIOTECHNOLOGY;MOLECULAR MEDICINE;RESEARCH FUNDING;BRINDISI ITALYSEARCH;FAZZI LECCE","40;37;24;24;18;18;16;16;16;15;14;14;14;14;13;13;13;13;13;13;12;12;10;9;9;9;9;9;8;8",31,0.52,1.25,17.13,5,47,10.25,1,35,1,1,1,1,1,1,0,0,0,2.25,1,6,0,0,0,0,0,0,0,0,0,11.62,1,42,0,0,0,0,0,0,11.33,1,33,0,0,0,0,0,0,1,1,1,5.25,1,12,6,1,15,2.25,1,5,0,0,0,0,0,0,42.88,3,96,42.88,3,96,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2021,56,20.3035714285714,2.76785714285714,0.361290322580645,0.25,0.214285714285714,0.375,0.803571428571429,0,28,10,4,2,0.5,0.18,0.07,0.04,11.23,0.72838032697086,0.196428571428571,0.982142857142857,4.81362007168459,0.441761873856935,0.282828282828283,0.402777777777778,0.287545787545788,"ALESSANDRO SGAMBATO;MICHELE AIETA;GIUSEPPE PIETRANTUONO;ILARIA LAURENZANA;PELLEGRINO MUSTO;ALESSANDRO PULSONI;SARA GALIMBERTI;RAFFAELE CONCA;STEFANO LUMINARI;GIOVANNI CALICE;GIANDOMENICO ROVIELLO;GEPPINO FALCO;GIOVANNI STORTO;AGOSTINO TAFURI;PIETRO ZOPPOLI;GIULIA VITA;GRAZIELLA MARINO;ROSJ GALLICCHIO;GUIDO GINI;MONICA GIORDANO","12;8;8;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3","ALESSANDRO SGAMBATO;MICHELE AIETA;ILARIA LAURENZANA;RAFFAELE CONCA;GIANDOMENICO ROVIELLO;GIOVANNI CALICE;GIOVANNI STORTO;GEPPINO FALCO;ROSJ GALLICCHIO;GRAZIELLA MARINO;GIUSEPPE PIETRANTUONO;GIUSEPPE LA TORRE;ALFREDO TARTARONE;ANNA PASSARELLI;GIOVANNA GALDO;TERESA PELLEGRINO;ANNA NARDELLI;MARIA VALERIA DE BONIS;GIANPAOLO RUOCCO;PIETRO ZOPPOLI","1.29;0.68;0.57;0.53;0.53;0.39;0.38;0.38;0.37;0.37;0.35;0.34;0.32;0.31;0.31;0.31;0.29;0.27;0.27;0.25","ALESSANDRO SGAMBATO;MICHELE AIETA;GIUSEPPE PIETRANTUONO;ILARIA LAURENZANA;PELLEGRINO MUSTO;RAFFAELE CONCA;GIOVANNI CALICE;GEPPINO FALCO;GIOVANNI STORTO;PIETRO ZOPPOLI;GIULIA VITA;GRAZIELLA MARINO;ROSJ GALLICCHIO;SABINO RUSSI;SIMONA LAURINO;ALFREDO TARTARONE;DANIELA LAMORTE;TEODORA STATUTO;ANNA PASSARELLI;STEFANIA TRINO","12;8;8;6;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2","ALESSANDRO SGAMBATO;MICHELE AIETA;ILARIA LAURENZANA;RAFFAELE CONCA;GIOVANNI CALICE;GIOVANNI STORTO;GEPPINO FALCO;ROSJ GALLICCHIO;GRAZIELLA MARINO;GIUSEPPE PIETRANTUONO;GIUSEPPE LA TORRE;ALFREDO TARTARONE;ANNA PASSARELLI;GIOVANNA GALDO;TERESA PELLEGRINO;PIETRO ZOPPOLI;SABINO RUSSI;SIMONA LAURINO;DANIELA LAMORTE;TOMMASO FABRIZIO","1.29;0.68;0.57;0.53;0.39;0.38;0.38;0.37;0.37;0.35;0.34;0.32;0.31;0.31;0.31;0.25;0.25;0.25;0.24;0.23","ALESSANDRO SGAMBATO;PELLEGRINO MUSTO;MICHELE AIETA;ASHRAF BADROS;BALDEEP WIRK;BRIAN G.M. DURIE;BRUNO PAIVA;CARLOS FERNÁNDEZ DE LARREA;ENRIQUE M. OCIO;FREDRIK SCHJESVOLD;GIAMPAOLO MERLINI;GÖSTA GAHRTON;HARTMUT GOLDSCHMIDT;HERMANN EINSELE;JESÚS F. SAN MIGUEL;JO CAERS;JOAN BLADÉ;LAURA ROSIÑOL;LAURENT GARDERET;MARTIN KAISER","131;127;98;94;94;94;94;94;94;94;94;94;94;94;94;94;94;94;94;94","ALESSANDRO SGAMBATO;PELLEGRINO MUSTO;MICHELE AIETA;ILARIA LAURENZANA;GIOVANNI CALICE;ALFREDO TARTARONE;PIETRO ZOPPOLI;SABINO RUSSI;SIMONA LAURINO;GRAZIELLA MARINO;MATTEO LANDRISCINA;VINCENZO FUSCO;DANIELA LAMORTE;GIUSEPPE PIETRANTUONO;GERARDO DELLA SALA;GIOVANNI STORTO;ANTONELLA CAIVANO;LUCIANA DE LUCA;STEFANIA TRINO;VITALBA RUGGIERI","131;115;98;87;54;53;47;45;45;37;34;34;32;32;27;27;26;26;26;26","ALESSANDRO SGAMBATO;GIUSEPPE PIETRANTUONO;MICHELE AIETA;ILARIA LAURENZANA;GIOVANNI CALICE;GIOVANNI STORTO;GIULIA VITA;RAFFAELE CONCA;GRAZIELLA MARINO;DANIELA LAMORTE;PELLEGRINO MUSTO;PIETRO ZOPPOLI;ROSJ GALLICCHIO;SABINO RUSSI;SIMONA LAURINO;ALFREDO TARTARONE;ANNA PASSARELLI;ANTONELLA CAIVANO;GERARDO DELLA SALA;GIOVANNA GALDO","12;8;8;6;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;ECONOMICS;PSYCHOLOGY;BUSINESS;MATHEMATICS;POLITICAL SCIENCE","50;21;5;4;4;3;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;BIOCHEMISTRY;CANCER RESEARCH;GENETICS;PATHOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;IMMUNOLOGY;PALEONTOLOGY;INTENSIVE CARE MEDICINE;NURSING;RADIOLOGY;FAMILY MEDICINE;NUCLEAR MEDICINE;OPTICS;PEDIATRICS;COMPUTATIONAL BIOLOGY;DERMATOLOGY;ECONOMIC GROWTH;EMERGENCY MEDICINE;MEDICAL EMERGENCY;MEDICAL PHYSICS;ORGANIC CHEMISTRY;PSYCHIATRY;VIROLOGY","40;23;12;10;10;10;10;8;8;8;8;7;5;5;5;4;4;3;3;2;2;2;2;2;2;2;2;2","CANCER;DISEASE;GENE;CHEMOTHERAPY;POPULATION;CONFIDENCE INTERVAL;COHORT;LYMPHOMA;STAGE (STRATIGRAPHY);APOPTOSIS;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;STEM CELL;TRANSPLANTATION;ADVERSE EFFECT;BONE MARROW;HEALTH CARE;INCIDENCE (GEOMETRY);LEUKEMIA;LUNG CANCER;MULTIPLE MYELOMA;POSITRON EMISSION TOMOGRAPHY;PROPORTIONAL HAZARDS MODEL;RANDOMIZED CONTROLLED TRIAL;REGIMEN;SARCOMA","26;9;9;8;8;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);BREAST CANCER;COLORECTAL CANCER;METASTASIS;CLINICAL ENDPOINT;CELL CYCLE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;ADJUVANT THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AUTOPHAGY;CANCER CELL;CISPLATIN;GENE EXPRESSION;HODGKIN LYMPHOMA;HUMAN HERPESVIRUS;IMMUNOTHERAPY;MICRORNA;NEUTROPENIA;PET-CT;POLYMERASE CHAIN REACTION;PROGENITOR CELL;PROSTATE CANCER;SUNITINIB;TELEMEDICINE","6;6;5;5;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);CIRCULATING TUMOR CELL;BRENTUXIMAB VEDOTIN;DNA METHYLATION;KAPOSI'S SARCOMA;KRAS;MICROVESICLES;NIVOLUMAB;PRIMARY TUMOR;ACCESSION NUMBER (LIBRARY SCIENCE);AMPLICON;ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;AXITINIB;BIOMARKER DISCOVERY;BONE METASTASIS;BREAST CARCINOMA;BREAST RECONSTRUCTION;CASPASE;CHLORAMBUCIL;CHROMATIN REMODELING;DIGITAL POLYMERASE CHAIN REACTION;EXTRAVERSION AND INTROVERSION;FEBRILE NEUTROPENIA;GENE SIGNATURE;GONADOTROPIN-RELEASING HORMONE;INTERFERON Α;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IPILIMUMAB;MASTECTOMY;METASTATIC BREAST CANCER;MICROSATELLITE;NON-SMALL CELL LUNG CANCER (NSCLC);ONCOGENE;OXALIPLATIN;PAPANICOLAOU STAIN;PAZOPANIB;PEMBROLIZUMAB;PLASMA CELL NEOPLASM;PROGENITOR;PURINE ANALOGUE;TRASTUZUMAB","6;4;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;COVID-19;FEMALE;MALE;AGED;ADULT;MIDDLE AGED;PROGNOSIS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS, TUMOR;FOLLOW-UP STUDIES;NEOPLASMS;RETROSPECTIVE STUDIES;SARS-COV-2;ANTINEOPLASTIC AGENTS;AUTOPHAGY;CELL SURVIVAL;COLONIC NEOPLASMS;HODGKIN DISEASE","35;19;10;10;9;8;6;6;6;5;5;5;5;5;5;4;4;4;4;4","LYMPHOID NEOPLASMS;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;BREAST RECONSTRUCTION TECHNIQUES AND OUTCOMES;CALCIUM SIGNALING AND ION CHANNELS IN SENSATION;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHROMATIN REMODELING IN CANCER AND DEVELOPMENT;CORONAVIRUS DISEASE 2019;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER","5;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CIRCULATING TUMOR CELL;CLINICAL ENDPOINT;KAPOSI'S SARCOMA;MANTLE CELL LYMPHOMA;PANDEMIC;REGIMEN;2019-20 CORONAVIRUS OUTBREAK;ADJUVANT THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BREAST CANCER;BRENTUXIMAB VEDOTIN;CANCER GROWTH;ETIOLOGY;EXTRACELLULAR VESICLES;MATHEMATICAL MODELING;MULTISCALE MODEL;NEOADJUVANT THERAPY;PET IMAGING;PET-CT;PRIMARY TUMOR","4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CELL LUNG;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LUNG CANCER;METASTATIC COLORECTAL;ANMCO POSITION;AUTOLOGOUS STEM;BRENTUXIMAB VEDOTIN;CELL CARCINOMA;CIRCULATING TUMOR;EXTRACELLULAR VESICLES;FAILURE UNDERGOING;HODGKIN LYMPHOMA;HUMAN METASTATIC;II TRIAL;KAPOSIS SARCOMA;LINFOMI FIL;MASS TRANSFER;METASTATIC RENAL;MULTIPLE MYELOMA;NON-SMALL CELL;PAPER CARDIO-ONCOLOGY;PHASE II;PLASMA CELL;POSITION PAPER;PREDICTS OUTCOME;PROSTATE CANCER;REALLIFE EXPERIENCE;RENAL CELL","3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HR CI;ADVISORY COMMITTEES;ENTITYS BOARD;ADVISORY ROLE;COVID- PANDEMIC;ROLE ROCHE;MEDIAN OS;CELL LINES;CTC CONCENTRATION;INTERSTITIAL PNEUMONIA;MCRC PATIENTS;PERIPHERAL NEUROPATHY;RESEARCH FUNDING;MATH XMLNSHTTPWWWWORGMATHMATHML;NSCLC PATIENTS;POOR PROGNOSIS;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;XMLNSHTTPWWWWORGMATHMATHML IDM;ADC VALUES;BREAST CANCER;CELL LINE;LOCAL THERAPY;MEDIAN AGE;METASTATIC RCC;MULTIVARIATE ANALYSIS;OS MONTHS;PLASMA CELLS;SPEAKERS BUREAU;SURVIVAL PFS","19;14;14;12;11;10;8;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5",27,0.48,1.25,23.29,4,114.65,33.43,1,168,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,42.86,1,212,0,0,0,0,0,0,46.2,8,167,0,0,0,0,0,0,1,1,1,9.33,2,21,31.2,7,113,14.33,1,32,0,0,0,0,0,0,32.29,2,72,32.29,2,72,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2022,62,19.7741935483871,2.12903225806452,0.46969696969697,0.112903225806452,0.0806451612903226,0.0806451612903226,0.758064516129032,0,15,20,6,4,0.24,0.32,0.1,0.06,5.82,0.652257821797601,0.32258064516129,1,4.45166959578207,0.359158463864561,0.138888888888889,0.290909090909091,0.15,"CARMEN GRAVINA;ANDREA TUBARO;ANTONIO NACCHIA;BEATRICE TURCHI;RICCARDO LOMBARDO;COSIMO DE NUNZIO;ANTONIO CICIONE;GIUSEPPE PIETRANTUONO;OLIVIA ALESSANDRA VOGLINO;GIACOMO GALLO;MICHELE AIETA;RAFFAELE CONCA;FERDINANDO DI GIACOMO;JORDI STIRA;ELISA MANCINI;SARA RIOLO;GIANDOMENICO ROVIELLO;LORENZO MARIA ROVESTI;ANTONIO FRANCO;ALESSANDRO GUERCIO","8;8;8;8;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6","RAFFAELE CONCA;GIANDOMENICO ROVIELLO;MARTINA CATALANO;ROBERTO PETRIOLI;ALESSANDRO SGAMBATO;CARMEN GRAVINA;ANDREA TUBARO;ANTONIO NACCHIA;BEATRICE TURCHI;RICCARDO LOMBARDO;COSIMO DE NUNZIO;MONICA RAMELLO;GIUSEPPE APRILE;FERDINANDO DI GIACOMO;GRAZIA LAZZARI;GIOVANNI SILVANO;OLIVIA ALESSANDRA VOGLINO;ANTONIO CICIONE;ANTONIO FRANCO;GIOVANNI CALICE","0.68;0.68;0.64;0.54;0.53;0.51;0.51;0.51;0.51;0.51;0.51;0.5;0.5;0.47;0.45;0.45;0.44;0.39;0.38;0.34","ANTONIO NACCHIA;GIUSEPPE PIETRANTUONO;MICHELE AIETA;RAFFAELE CONCA;FERDINANDO DI GIACOMO;ALESSANDRO SGAMBATO;GIOVANNI CALICE;VINCENZO FUSCO;GRAZIELLA MARINO;G DISABATO;PIETRO ZOPPOLI;GRAZIA LAZZARI;TEODORA STATUTO;MATTEO LANDRISCINA;GIOVANNI SILVANO;VALENTINA CONDELLI;GIOVANNI CASTALDO;LUCIANA RAGO;ANTONIETTA MONTAGNA;GIOVANNI D’ARENA","8;7;6;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2","RAFFAELE CONCA;ALESSANDRO SGAMBATO;ANTONIO NACCHIA;FERDINANDO DI GIACOMO;GRAZIA LAZZARI;GIOVANNI SILVANO;GIOVANNI CALICE;GIOVANNI CASTALDO;ANTONIETTA MONTAGNA;GIUSEPPE PIETRANTUONO;MATTEO LANDRISCINA;VALENTINA CONDELLI;GRAZIELLA MARINO;ALDO CAMMAROTA;MICHELE AIETA;G DISABATO;DANIELA LAMORTE;TEODORA STATUTO;LUCIANA RAGO;ANGELA PIA SOLAZZO","0.68;0.53;0.51;0.47;0.45;0.45;0.34;0.33;0.33;0.28;0.28;0.28;0.28;0.25;0.23;0.23;0.22;0.22;0.22;0.21","GIUSEPPE PIETRANTUONO;MARIO BOCCADORO;PELLEGRINO MUSTO;ANGELO BELOTTI;MASSIMO GENTILE;PAOLA CURCI;RENATO ZAMBELLO;SALVATORE PALMIERI;ANDRÉA CAPRA;FRANCESCA GAY;A LEDDA;ANNA MARINA LIBERATI;ANNA PASCARELLA;DELIA ROTA‐SCALABRINI;FEDERICO MONACO;FRANCESCA FAZIO;FRANCESCO PISANI;GIOVANNI DE SABBATA;LAURA PARÍS;LUCA BERTAMINI","60;60;60;58;58;58;58;58;49;48;47;47;47;47;47;47;47;47;47;47","GIUSEPPE PIETRANTUONO;ALESSANDRO SGAMBATO;VINCENZO FUSCO;RAFFAELE CONCA;GIUSEPPINA GALLUCCI;MICHELE AIETA;PIETRO ZOPPOLI;GIOVANNI CALICE;GRAZIELLA MARINO;CONCETTA SAPONARO;DONATELLO SALVATORE;VALENTINA CONDELLI;MARIO CIUFFI;ORAZIO IGNOMIRELLI;R. TUCCIARIELLO;FERDINANDO DI GIACOMO;ANTONELLA BIANCULLI;SABINO RUSSI;SIMONA LAURINO;LUCIANA RAGO","60;43;39;33;30;27;27;22;22;18;18;15;14;14;14;13;12;12;12;11","ANTONIO NACCHIA;GIUSEPPE PIETRANTUONO;MICHELE AIETA;RAFFAELE CONCA;ALESSANDRO SGAMBATO;VINCENZO FUSCO;FERDINANDO DI GIACOMO;GIOVANNI CALICE;GRAZIELLA MARINO;LUCIANA RAGO;ANTONIETTA MONTAGNA;GIOVANNI CASTALDO;TEODORA STATUTO;VALENTINA CONDELLI;G DISABATO;ANGELA PIA SOLAZZO;ANTONELLA BIANCULLI;DANIELA LAMORTE;FABIANA CRISPO;FIORELLA D′AURIA","8;7;6;6;5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;SOCIOLOGY;CHEMISTRY;ECONOMICS;PSYCHOLOGY;ENGINEERING;POLITICAL SCIENCE","53;18;5;3;3;3;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;UROLOGY;CANCER RESEARCH;IMMUNOLOGY;GENETICS;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PALEONTOLOGY;INTENSIVE CARE MEDICINE;CELL BIOLOGY;BIOCHEMISTRY;FAMILY MEDICINE;NUCLEAR MEDICINE;PSYCHIATRY;QUANTUM MECHANICS;SOCIAL SCIENCE;ARTIFICIAL INTELLIGENCE;BOTANY;CARDIOLOGY;CLINICAL PSYCHOLOGY;COMPUTATIONAL BIOLOGY;DATABASE;MEDICAL PHYSICS;PHARMACOLOGY;RADIOLOGY","48;25;13;11;9;8;7;7;6;6;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;RADIATION THERAPY;CHEMOTHERAPY;POPULATION;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;DISEASE;MULTIPLE MYELOMA;RECEPTOR;ADVERSE EFFECT;CELL;GENE;PROPORTIONAL HAZARDS MODEL;URINARY SYSTEM;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);LEUKEMIA;MULTIDISCIPLINARY APPROACH;MULTIVARIATE ANALYSIS;RENAL CELL CARCINOMA;STAGE (STRATIGRAPHY);TOXICITY","31;9;7;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","BREAST CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;PROSTATE;COLORECTAL CANCER;LENALIDOMIDE;BLADDER CANCER;GENE EXPRESSION;HAZARD RATIO;IMMUNOTHERAPY;PANCREATIC CANCER;PHASES OF CLINICAL RESEARCH;PROSTATE CANCER;UNIVARIATE ANALYSIS;ADJUVANT THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CELL CYCLE;CHEMOKINE;CHRONIC LYMPHOCYTIC LEUKEMIA;FIBRONECTIN;GASTRITIS;GEMCITABINE;HAEMATOPOIESIS;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MULTICENTER STUDY;NEUTROPENIA;PACLITAXEL;PERFORMANCE STATUS;PHARMACOVIGILANCE;PLASMA CELL LEUKEMIA;PROGENITOR CELL;PROGRESSIVE DISEASE;REPROGRAMMING;SUNITINIB;TYROSINE KINASE","6;5;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CARFILZOMIB;CORONAVIRUS DISEASE 2019 (COVID-19);CYSTECTOMY;FEBRILE NEUTROPENIA;NAB-PACLITAXEL;NIVOLUMAB;PROSTATECTOMY;RESIDUAL URINE;ADENOMATOUS POLYPOSIS COLI;ADJUVANT CHEMOTHERAPY;ADULT STEM CELL;ATROPHIC GASTRITIS;BIOLOGICAL PATHWAY;BLADDER OUTLET OBSTRUCTION;CAPECITABINE;CARBOPLATIN;CAREGIVER BURDEN;CATENIN;CHEMOIMMUNOTHERAPY;CYCLIN D1;DEOXYCYTIDINE;DIFFUSE ALVEOLAR DAMAGE;DNA METHYLATION;FOXM1;GENE EXPRESSION PROFILING;GENE REGULATORY NETWORK;HYPERFRACTIONATION;IBRUTINIB;IGHV@;INDUCED PLURIPOTENT STEM CELL;MAMMOGRAPHY;MASTECTOMY;MHC CLASS II;MIRABEGRON;NEOADJUVANT THERAPY;NON-SMALL CELL LUNG CANCER (NSCLC);PEMBROLIZUMAB;RADIOIMMUNOTHERAPY;REGULON;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SOLIFENACIN;SPIRILLACEAE;SYSTEMIC THERAPY;TOLTERODINE;TRPV1;UROTHELIAL CARCINOMA","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MALE;TREATMENT OUTCOME;AGED;FEMALE;NEOPLASM RECURRENCE, LOCAL;PANCREATIC NEOPLASMS;RETROSPECTIVE STUDIES;ANTINEOPLASTIC AGENTS;COVID-19;URINARY BLADDER NEOPLASMS;ANTIMICROBIAL CATIONIC PEPTIDES;BREAST NEOPLASMS;CARDIOVASCULAR DISEASES;COLORECTAL NEOPLASMS;DEOXYCYTIDINE;GASTRITIS, ATROPHIC;HELICOBACTER INFECTIONS","41;21;9;6;6;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3","DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR RESEARCH ON BREAST CANCER;STANDARDISATION OF LOWER URINARY TRACT FUNCTION;CANCER IMMUNOTHERAPY;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;PROSTATE CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;ANTIMICROBIAL PEPTIDES IN HOST DEFENSE AND THERAPY;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;BODY COMPOSITION ASSESSMENT AND ANALYSIS;BREAST CANCER SCREENING TECHNOLOGY;CALCIUM SIGNALING AND ION CHANNELS IN SENSATION;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHEMOTHERAPY-INDUCED DERMATOLOGICAL TOXICITY","4;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;NEOADJUVANT THERAPY;PROGRESSION-FREE SURVIVAL;CANCER TREATMENT;PEPTIDE RECEPTOR RADIONUCLIDE THERAPY;RADIOTHERAPY;UNIVARIATE ANALYSIS;ADJUVANT THERAPY;ALPHA PARTICLE THERAPY;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CANCER IMAGING;DIAGNOSIS CRITERIA;EVEROLIMUS;GOLD STANDARD (TEST);LOWER URINARY TRACT SYMPTOMS;METASTATIC PANCREATIC CANCER;METASTATIC PROSTATE CANCER;MINIMAL RESIDUAL DISEASE;MYOCARDIAL FIBROSIS;NAB-PACLITAXEL","5;5;5;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CELL CARCINOMA;CELL LEUKEMIA;COLORECTAL CANCER;METASTATIC RENAL;MULTIPLE MYELOMA;PANCREATIC CANCER;PROSTATE CANCER;RENAL CELL;SUPPORTIVE CARE;URINARY TRACT;ADMINISTRATION FDA;ADVANCED UROTHELIAL;CARDIAC DAMPS;CHRONIC LYMPHOCYTIC;CLINICAL NOMOGRAM;CLINICAL TRIALS;CONTINENT URINARY;CONTROLLED CLINICAL;DIVERSION INITIAL;DRUG ADMINISTRATION;EMNHOVON- STUDY;EUDRAVIGILANCE EV;FDA PHARMACOVIGILANCE;FIRST-LINE PLATINUM-BASED;FIRST-LINE TREATMENT;GASTRIC JUICE;INCREASES SYSTEMIC;INITIAL EXPERIENCE;ITALIAN MULTICENTER","4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;STAGE III;MONTHS CI;MEDIAN PFS;PATIENTS TREATED;III NSCLC;PERFORMANCE STATUS;PLASMA CELL;RADIATION THERAPY;RISK FACTORS;SURVIVAL OS;CANCER PATIENTS;CLINICAL PRACTICE;GENE EXPRESSION;MEDIAN FOLLOW-UP;RELATIONSHIP RECIPROCITY;SURVIVAL PFS;ADVERSE EVENTS;ICIS THERAPY;LU-DOTATATE EVEROLIMUS;PEA CELLS;PROGRESSION-FREE SURVIVAL;BLOCKING AGENTS;FLOW CYTOMETRY;PTS AGED;RESPONSE RATE;SDF- IL-Β;ACTIVATED VLA-;ISS STAGE;LONG-TERM RESPONSES","18;14;12;10;10;9;9;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;5;5;5",21,0.34,1.25,11.19,2.95,38.38,10.83,3,34,0,0,0,1,1,1,0,0,0,2,2,2,0,0,0,1,1,1,0,0,0,13.83,3,42,0,0,0,0,0,0,9.83,2,31,0,0,0,0,0,0,1.25,1,2,1.5,1,2,6.8,2,17,4.25,1,13,0,0,0,0,0,0,13.67,3,35,13.67,3,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2023,59,21.8983050847458,3.32203389830508,0.301020408163265,0.338983050847458,0.254237288135593,0.186440677966102,0.830508474576271,0,16,17,6,1,0.27,0.29,0.1,0.02,3.39,0.773388396910483,0.372881355932203,1,4.09342560553633,0.397891353218509,0.291005291005291,0.294372294372294,0.37037037037037,"GIUSEPPE PIETRANTUONO;GIOVANNI CALICE;ALFREDO TARTARONE;ANTONELLA BIANCULLI;MICHELE AIETA;RAFFAELE CONCA;PELLEGRINO MUSTO;GIOVANNI STORTO;MARIELLA GRASSO;GRAZIA LAZZARI;ILARIA BENEVENTO;MARIO BOCCADORO;RAFFAELE TUCCIARIELLO;ROSJ GALLICCHIO;BARBARA D’ANDREA;GIOVANNI CASTALDO;GIOVANNI D’ARENA;PIETER SONNEVELD;ALESSANDRO SGAMBATO;JO CAERS","8;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3","TOMMASO FABRIZIO;ALFREDO TARTARONE;GIUSEPPE GUARRO;GIOVANNI CALICE;ROSA LEROSE;GIUSEPPE PIETRANTUONO;ANTONELLA BIANCULLI;RAFFAELE CONCA;GIOVANNI STORTO;GRAZIA LAZZARI;ILARIA BENEVENTO;RAFFAELE TUCCIARIELLO;GIOVANNI CASTALDO;MARINA TARTARONE;BARBARA D’ANDREA;ANDREA TUBARO;ANTONIO NACCHIA;RICCARDO LOMBARDO;ANTONIETTA MONTAGNA;ALESSANDRO SGAMBATO","0.68;0.67;0.62;0.6;0.47;0.46;0.44;0.42;0.35;0.35;0.35;0.35;0.35;0.33;0.31;0.31;0.31;0.31;0.29;0.26","GIUSEPPE PIETRANTUONO;GIOVANNI CALICE;ALFREDO TARTARONE;ANTONELLA BIANCULLI;MICHELE AIETA;RAFFAELE CONCA;PELLEGRINO MUSTO;GIOVANNI STORTO;GRAZIA LAZZARI;ILARIA BENEVENTO;RAFFAELE TUCCIARIELLO;ROSJ GALLICCHIO;BARBARA D’ANDREA;GIOVANNI CASTALDO;GIOVANNI D’ARENA;ALESSANDRO SGAMBATO;ILARIA LAURENZANA;ROSA LEROSE;ROCCO GALASSO;DANIELA LAMORTE","8;7;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3","TOMMASO FABRIZIO;ALFREDO TARTARONE;GIUSEPPE GUARRO;GIOVANNI CALICE;ROSA LEROSE;GIUSEPPE PIETRANTUONO;ANTONELLA BIANCULLI;RAFFAELE CONCA;GIOVANNI STORTO;GRAZIA LAZZARI;ILARIA BENEVENTO;RAFFAELE TUCCIARIELLO;GIOVANNI CASTALDO;BARBARA D’ANDREA;ANDREA TUBARO;ANTONIO NACCHIA;RICCARDO LOMBARDO;ANTONIETTA MONTAGNA;ALESSANDRO SGAMBATO;ROSJ GALLICCHIO","0.68;0.67;0.62;0.6;0.47;0.46;0.44;0.42;0.35;0.35;0.35;0.35;0.35;0.31;0.31;0.31;0.31;0.29;0.26;0.26","MICHELE AIETA;ALESSANDRA BOLOGNA;ANDREA DECENSI;ANGIOLO GADDUCCI;CLAUDIO ZAMAGNI;CRISTINA CHURRUCA GALAZ;ELENA BIAGIOLI;ELIANA RULLI;GERMANA TOGNON;GIULIA TASCA;GIUSEPPE FUNARI;MARIA PILAR BARRETINA-GINESTA;MASSIMO AGLIETTA;NICOLETTA COLOMBO;PAOLO ZOLA;ROLDANO FOSSATI;UGO DE GIORGI;VALENTINA ARCANGELI;ALFREDO TARTARONE;BINIAM KIDANE","43;32;32;32;32;32;32;32;32;32;32;32;32;32;32;32;32;32;31;24","MICHELE AIETA;ALFREDO TARTARONE;GIOVANNI CALICE;ROCCO GALASSO;RAFFAELE CONCA;GIUSEPPE PIETRANTUONO;GIOVANNI STORTO;ROSJ GALLICCHIO;CONCETTA SAPONARO;DANIELA LAMORTE;GABRIELLA BIANCHINO;SABINO RUSSI;SIMONA LAURINO;TIZIANA NOTARANGELO;VITINA GRIECO;LUCIANA DEL RICCIO;RICCARDO AMODIO;ANTONIO NACCHIA;TERESA D’AMORE;ALESSANDRO SGAMBATO","43;31;20;20;18;16;14;14;11;8;8;8;8;8;8;7;7;6;6;5","GIUSEPPE PIETRANTUONO;GIOVANNI CALICE;MICHELE AIETA;ANTONELLA BIANCULLI;GIOVANNI STORTO;ALFREDO TARTARONE;RAFFAELE CONCA;BARBARA D’ANDREA;ROSJ GALLICCHIO;DANIELA LAMORTE;ROCCO GALASSO;TOMMASO FABRIZIO;ROSA LEROSE;A. CAPOBIANCO;ALESSANDRO SGAMBATO;ALESSIA GIORDANO;ANNA NARDELLI;ANTONIO NACCHIA;ANTONIO NAPPI;CARMELA MAZZOCCOLI","8;7;5;5;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;ENGINEERING;BUSINESS;ECONOMICS;HISTORY;MATERIALS SCIENCE;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE","55;21;4;4;3;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;PATHOLOGY;GENETICS;RADIOLOGY;BIOCHEMISTRY;CELL BIOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;NUCLEAR MEDICINE;NURSING;PALEONTOLOGY;BIOINFORMATICS;MACHINE LEARNING;PHARMACOLOGY;UROLOGY;ANESTHESIA;COMPUTATIONAL BIOLOGY;DEMOGRAPHY;DERMATOLOGY;FAMILY MEDICINE;FISHERY;GENERAL SURGERY;INTENSIVE CARE MEDICINE;MEDICAL PHYSICS;MOLECULAR BIOLOGY;PHYSICAL THERAPY","48;26;15;12;10;9;8;7;7;7;6;6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;GENE;RANDOMIZED CONTROLLED TRIAL;LYMPHOMA;DISEASE;LUNG CANCER;MULTIPLE MYELOMA;POPULATION;RADIATION THERAPY;RETROSPECTIVE COHORT STUDY;STEM CELL;CLINICAL TRIAL;CONFIDENCE INTERVAL;IN VITRO;POSITRON EMISSION TOMOGRAPHY;IMMUNE SYSTEM;LEUKEMIA;MELANOMA;MULTIVARIATE ANALYSIS;QUALITY OF LIFE (HEALTHCARE)","28;10;7;7;6;5;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3","BREAST CANCER;CLINICAL ENDPOINT;IMMUNOTHERAPY;LENALIDOMIDE;FOLLICULAR LYMPHOMA;PHASES OF CLINICAL RESEARCH;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;HAZARD RATIO;CANCER CELL;CANCER REGISTRY;CD8;CISPLATIN;CYTOTOXIC T CELL;DOXORUBICIN;EPIDERMAL GROWTH FACTOR RECEPTOR;GEMCITABINE;GENE EXPRESSION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);LIVER CANCER;METASTASIS;NEUTROPENIA;PANCREATIC CANCER;PLASMA CELL LEUKEMIA;PROGENITOR CELL;RITUXIMAB;STANDARDIZED UPTAKE VALUE;T CELL;UNIVARIATE ANALYSIS","7;6;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CARFILZOMIB;CORONAVIRUS DISEASE 2019 (COVID-19);IGHV@;NIVOLUMAB;TRASTUZUMAB;AXILLARY LYMPH NODES;BENDAMUSTINE;BRAIN METASTASIS;CARBOPLATIN;CD3;CD38;CETUXIMAB;COLONOSCOPY;DABIGATRAN;DARATUMUMAB;DNA EXTRACTION;DNA METHYLATION;ELECTROCHEMOTHERAPY;ELEVATED ALKALINE PHOSPHATASE;EXTERNAL BEAM RADIOTHERAPY;GERMINAL CENTER;HERPESVIRIDAE;HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2;IMMUNE CHECKPOINT;INTERNATIONAL PROGNOSTIC INDEX;IRINOTECAN;MULTICENTER TRIAL;NATURAL KILLER T CELL;OESTROGEN RECEPTOR;OXALIPLATIN;PEMBROLIZUMAB;RADIOIMMUNOTHERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBOSOME;RIVAROXABAN;RUNX2;SOX2;STAT PROTEIN;TRABECTEDIN;TRANSCRIPTOME;TRANSLATION (BIOLOGY);TRIPLE-NEGATIVE BREAST CANCER","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;FEMALE;RETROSPECTIVE STUDIES;NEOPLASM RECURRENCE, LOCAL;ADULT;BREAST NEOPLASMS;LUNG NEOPLASMS;MELANOMA;POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY;ANTINEOPLASTIC AGENTS;DOXORUBICIN;LEIOMYOSARCOMA;NEOPLASMS;PACLITAXEL;PANCREATIC NEOPLASMS;POSTOPERATIVE COMPLICATIONS;VASCULAR NEOPLASMS;ALKALINE PHOSPHATASE","30;29;10;8;8;7;5;5;5;5;5;4;4;4;4;4;4;4;4;3","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;PANCREATIC CANCER RESEARCH AND TREATMENT;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DEEP LEARNING IN MEDICAL IMAGE ANALYSIS;DNA BARCODING FOR FOOD AUTHENTICATION AND FRAUD DETECTION;DNA TOPOISOMERASES: STRUCTURE, FUNCTION, AND INHIBITION","6;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;FOLLICULAR LYMPHOMA;BREAST CANCER;CANCER;CANCER IMAGING;CANCER THERAPY;SKIN CANCERS;CONCORDANCE;DIAGNOSIS CRITERIA;DISCONTINUATION;EXTRAMAMMARY PAGET'S DISEASE;IGHV@;LIVER CANCER;LUNG CANCER;METASTATIC PANCREATIC CANCER;NEOADJUVANT THERAPY;PET/CT;PLASMA CELL LEUKEMIA;PROSTATE CANCER;RADIOTHERAPY","6;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER PATIENTS;RETROSPECTIVE STUDY;CELL CARCINOMA;FOLL TRIAL;FOLLICULAR LYMPHOMA;LUNG CANCER;PHASE III;PLASMA CELL;PRIMARY PLASMA;RANDOMIZED TRIAL;SQUAMOUS CELL;TUMOR VOLUME;CANCER -YEAR;CELL LEUKEMIA;CHRONIC LYMPHOCYTIC;EMNHOVON- STUDY;FINAL ANALYSIS;III RANDOMIZED;LENALIDOMIDE-BASED THERAPY;LOCALLY ADVANCED;LYMPHOCYTIC LEUKEMIA;METABOLIC TUMOR;METASTATIC PANCREATIC;MULTIPLE MYELOMA;ONE-YEAR TRASTUZUMAB;PANCREATIC CANCER;PATIENTS AGED;PATIENTS TREATED;PHASE EMNHOVON-","7;6;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PLASMA CELL;PAIN MANAGEMENT;PROGRESSION-FREE SURVIVAL;BREAST CANCER;MEDIAN FOLLOW-UP;CANCER PATIENTS;PRIMARY ENDPOINT;FOLLICULAR LYMPHOMA;MEDIAN NA;PERFORMANCE STATUS;PRIMARY PLASMA;SURVIVAL OS;DISEASE PROGRESSION;EGFR MUTATION;FOLL TRIAL;MEDIAN AGE;MEDIAN PFS;MONTHS CI;PATIENTS UNDERGOING;PERIPHERAL BLOOD;POOR PROGNOSIS;SURVIVAL PFS;TIDAL VOLUME;TUMOR BURDEN;ADEQUATE PAIN;CELL COUNT;CELL LEUKAEMIA;CELL LINES;CLINICAL PRACTICE;FLOW CYTOMETRY","14;11;11;10;9;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5",23,0.39,1.25,70.9,14.15,274.279999999999,96.67,23,363,1,1,1,1.33,1,2,0,0,0,2,1,3,0,0,0,1,1,1,0,0,0,105.5,26,385,0,0,0,0,0,0,94.83,23,358,0,0,0,0,0,0,2.75,1,5,11.17,2,39,71.17,13,289,10.67,4,26,0,0,0,0,0,0,17.83,7,31,17.83,7,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_CROB",2024,60,22.65,2.96666666666667,0.337078651685393,0.35,0.233333333333333,0.183333333333333,0.65,1,29,13,3,3,0.48,0.22,0.05,0.05,1.75,1.83110987282026,0.25,1,3.42987249544627,0.445661156378831,0.378516624040921,0.229674796747967,0.264957264957265,"ROCCO GALASSO;CINZIA GASPAROTTI;LUIGINO DAL MASO;MARISABEL MECCA;PAOLA BALLOTARI;TEODORA STATUTO;ANNA CLARA FANETTI;GIUSEPPE PIETRANTUONO;LAURA BOTTA;CLAUDIA CASELLA;STEFANO FERRETTI;MARGHERITA FERRANTE;DIEGO SERRAINO;WALTER MAZZUCCO;STEFANO GUZZINATI;LUCIANA RAGO;ADELE CALDARELLA;ROSSELLA CAVALLO;GIUSEPPE SAMPIETRO;MARIA LETIZIA GAMBINO","9;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5","TOMMASO FABRIZIO;MARISABEL MECCA;MARTINA GIUSEFFI;EUGENIA GIGLIO;ROCCO GALASSO;ALESSIO VAGLIASINDI;GRETA DI STEFANO;BATTISTINO PUPPIO;FRANCESCA SANSEVERINO;FRANCESCO CASTELLANETA;SANTOLO D’ANTONIO;GEPPINO FALCO;ANNA MARIA BOCHICCHIO;SALVATORE CORTELLINO;MARZIA SICHETTI;SABINO RUSSI;LUIGI TODARO;ANTONIO PROSPERO COLASURDO;SIMONA PICERNO;LUCIAN DEL RICCIO","1.45;1.31;0.64;0.64;0.53;0.52;0.52;0.52;0.43;0.42;0.42;0.41;0.4;0.4;0.39;0.35;0.33;0.33;0.33;0.33","ROCCO GALASSO;MARISABEL MECCA;TEODORA STATUTO;GIUSEPPE PIETRANTUONO;LUCIANA RAGO;ANNA MARIA BOCHICCHIO;SABINO RUSSI;FRANCESCA SANSEVERINO;GIOVANNI STORTO;ANTONELLA BIANCULLI;TOMMASO FABRIZIO;GIOVANNI D’ARENA;MICHELE AIETA;GRAZIELLA MARINO;FIORELLA D′AURIA;GIOVANNA MANSUETO;ALESSIO VAGLIASINDI;GRETA DI STEFANO;SIMONA LAURINO;LUCIANA VALVANO","9;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","TOMMASO FABRIZIO;MARISABEL MECCA;MARTINA GIUSEFFI;EUGENIA GIGLIO;ROCCO GALASSO;ALESSIO VAGLIASINDI;GRETA DI STEFANO;BATTISTINO PUPPIO;FRANCESCA SANSEVERINO;FRANCESCO CASTELLANETA;SANTOLO D’ANTONIO;ANNA MARIA BOCHICCHIO;SALVATORE CORTELLINO;MARZIA SICHETTI;SABINO RUSSI;SIMONA PICERNO;GIOVANNI STORTO;GRAZIELLA MARINO;TEODORA STATUTO;SIMONA LAURINO","1.45;1.31;0.64;0.64;0.53;0.52;0.52;0.52;0.43;0.42;0.42;0.4;0.4;0.39;0.35;0.33;0.31;0.31;0.29;0.28","ROCCO GALASSO;LAURA BOTTA;ALEXANDER KATALINIC;KAIRE INNOS;PAOLO BAILI;XAVIER TROUSSARD;ADELE CALDARELLA;CINZIA GASPAROTTI;GIUSEPPE SAMPIETRO;LUIGINO DAL MASO;MARGHERITA FERRANTE;MARIA LETIZIA GAMBINO;PAOLA BALLOTARI;STEFANO FERRETTI;STEFANO GUZZINATI;FRANCESCO CUCCARO;GEMMA GATTA;ROBERTA DE ANGELIS;SILVIA ROSSI;ELENA DEMURU","54;52;48;48;48;48;30;30;30;30;30;30;30;30;30;29;29;28;28;27","ROCCO GALASSO;FRANCESCA SANSEVERINO;GRAZIELLA MARINO;ALDA GIULIANO;ALESSANDRO ROCCO LETTINI;GIOVANNI DEIANA;ILARIA BOCHICCHIO;PASQUALE MARINO;STEFANIA LAPADULA;OTTAVIA BARTOLO;MARISABEL MECCA;GIUSEPPINA GALLUCCI;SIMONA PICERNO;GIOVANNI D’ARENA;RAFFAELE CONCA;GIUSEPPE PIETRANTUONO;PELLEGRINO MUSTO;ROSA LEROSE;TEODORA STATUTO;CLAUDIA SABATO","54;24;24;22;22;22;22;22;22;14;8;6;6;5;4;3;3;3;3;2","ROCCO GALASSO;MARISABEL MECCA;GIUSEPPE PIETRANTUONO;LUCIANA RAGO;TEODORA STATUTO;ANNA MARIA BOCHICCHIO;ANTONELLA BIANCULLI;FRANCESCA SANSEVERINO;SABINO RUSSI;TOMMASO FABRIZIO;GRAZIELLA MARINO;EUGENIA GIGLIO;FIORELLA D′AURIA;GIOVANNA MANSUETO;LUCIANA VALVANO;MARTINA GIUSEFFI;SIMONA LAURINO;GIOVANNI DEIANA;GIUSEPPINA GALLUCCI;GRAZIA LAZZARI","9;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;PHYSICS;SOCIOLOGY;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY;MATERIALS SCIENCE;POLITICAL SCIENCE","55;15;8;6;5;4;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;CELL BIOLOGY;DEMOGRAPHY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;STATISTICS;ANATOMY;BIOINFORMATICS;GYNECOLOGY;MEDICAL PHYSICS;NUCLEAR MEDICINE;OPTICS","45;22;14;12;10;10;9;9;7;6;5;4;4;4;4;4;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;POPULATION;RADIATION THERAPY;GENE;CLINICAL TRIAL;IMMUNE SYSTEM;LEUKEMIA;RETROSPECTIVE COHORT STUDY;APOPTOSIS;COHORT;LYMPHOMA;MULTIPLE MYELOMA;ADVERSE EFFECT;BONE MARROW;CELL;DISEASE;DNA;MELANOMA;ANTIBODY;DELPHI METHOD;DISCONTINUATION;ENZYME;FLOW CYTOMETRY;GRADING (ENGINEERING);GUIDELINE;INCIDENCE (GEOMETRY);INFLAMMATION;NATURAL HISTORY;OBSERVATIONAL STUDY;STAGE (STRATIGRAPHY);SURGICAL RESECTION;TOXICITY","35;10;8;8;7;5;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;IMMUNOTHERAPY;CHRONIC LYMPHOCYTIC LEUKEMIA;CANCER REGISTRY;GENE EXPRESSION;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;B CELL;BLEOMYCIN;CLINICAL ENDPOINT;EOSINOPHILIC ESOPHAGITIS;EPIGENETICS;IMMUNOPHENOTYPING;METASTASIS;PACLITAXEL;PANCREATIC CANCER;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PROSTATE;PROTEASES;T CELL;THYROID CANCER","9;7;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PEMBROLIZUMAB;ELECTROCHEMOTHERAPY;GENE SIGNATURE;ABSCOPAL EFFECT;ACTIN CYTOSKELETON;ADJUVANT CHEMOTHERAPY;ANTHRACYCLINE;BRUTON'S TYROSINE KINASE;CASPASE;CD38;CHLORAMBUCIL;CTLA-4;DAPAGLIFLOZIN;DEOXYCYTIDINE;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;EPITHELIAL–MESENCHYMAL TRANSITION;ESTROGEN RECEPTOR;EZH2;GASTROESOPHAGEAL JUNCTION;GENOME INSTABILITY;GERD;GERMINAL CENTER;IBRUTINIB;INHIBITOR OF APOPTOSIS;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IPILIMUMAB;IRINOTECAN;LUTETIUM;MOLECULAR MEDICINE;PAZOPANIB;PD-L1;PEMETREXED;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TFAM;TRANSCRIPTOME;VERSICAN","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;ADULT;AGED, 80 AND OVER;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;PREVALENCE;PROSTATIC NEOPLASMS;REGISTRIES;RETROSPECTIVE STUDIES;PROGNOSIS;QUALITY OF LIFE;RADIOTHERAPY, INTENSITY-MODULATED;TREATMENT OUTCOME;ADOLESCENT","36;24;14;14;13;12;11;9;7;5;5;5;5;4;4;3;3;3;3;2","GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;CANCER IMMUNOTHERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;DIAGNOSIS AND MANAGEMENT OF EOSINOPHILIC ESOPHAGITIS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;GASTRIC CANCER RESEARCH AND TREATMENT;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;PROSTATE CANCER RESEARCH AND TREATMENT;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN BIOMEDICAL SCIENCE AND HEALTH RESEARCH;ANTIOXIDANTS AND FREE RADICALS IN HEALTH AND DISEASE;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;CANCER STEM CELLS AND TUMOR METASTASIS;CATALYTIC VALORIZATION OF LIGNIN FOR RENEWABLE CHEMICALS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","4;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;BREAST CANCER SCREENING;CANCER EPIGENETICS;CANCER INCIDENCE;IMAGE-GUIDED RADIOTHERAPY;RADIOTHERAPY;RADIOTHERAPY PHYSICS;BREAST CANCER;CANCER CELL METABOLISM;CLINICAL ENDPOINT;CONCOMITANT;DELPHI METHOD;DISCONTINUATION;ELECTROCHEMOTHERAPY;EOSINOPHILIC DISORDERS;EOSINOPHILIC ESOPHAGITIS;GASTRIC CANCER;GENE SIGNATURE;GRADING (ENGINEERING);GUIDELINE","6;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER PATIENTS;LYMPHOCYTIC LEUKEMIA;PROSTATE CANCER;CHRONIC LYMPHOCYTIC;PHASE II;POPULATION-BASED STUDY;CANCER CHEMOPREVENTION;CELL CARCINOMA;CELL LINES;COLORECTAL CANCER;EOETALY CONSENSUS;FIRST-LINE PEMBROLIZUMAB;GASTRIC CANCER;GENE SIGNATURE;HIV- PROTEASES;HYPOFRACTIONATED RADIOTHERAPY;II RANDOMIZED;LOCALIZED PROSTATE;MULTIPLE MYELOMA;PROTEASES INHIBITORS;ST EOETALY;A-MANTRA STUDY;ABDOMINAL WALL;ACQUISITION PLAN;ADDITIONAL COPIES;ADIPOSE TISSUE;ADJUVANT RADIOTHERAPY;ADVANCED BREAST;ADVANCED CUTANEOUS","4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","BREAST CANCER;CURE PREVALENCE;MITOCHONDRIAL RESPIRATION;LYMPHOCYTIC LEUKEMIA;PAIN MANAGEMENT;CELL LINES;CHRONIC LYMPHOCYTIC;COMPLETE PREVALENCE;CRC CELLS;CANCER CELL;CANCER DIAGNOSIS;DISEASE CONTROL;GYNECOLOGICAL CANCERS;MEDIAN PFS;NON-CANCER PAIN;PD-L EXPRESSION;PROGNOSTIC FACTORS;PROGRESSION-FREE SURVIVAL;STAGE IV;SURVIVAL PFS;AGILENT SEAHORSE;BONE MARROW;CANCER CELLS;CANCER REGISTRIES;CRC CELL;DISEASE PROGRESSION;HIV- PROTEASE;HYPOFRACTIONATED RADIOTHERAPY;IL- IL-;INHIBITOR PRECURSOR","13;11;9;7;7;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
